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This thesis studies different aspects of enuresis and nocturia, in order to provide a more united 
view of these two related conditions. To understand current insights and treatment modalities, 
history may be helpful. This introduction starts with subsections on enuresis and on nocturia and 
moves on to the underlying pathophysiological concepts of both conditions: nocturnal polyuria (NP), 
small bladder capacity and sleep problems. Finally, the general aims and outline of this thesis are 
described.
Enuresis
More than 3000 years of history
Enuresis is derived from the Greek word ἐνούρησις, meaning to urinate in the night (nocturna), 
or in plain English: bedwetting. Enuresis has been referred to on the earliest papyrus documents 
found (1550 BC). It is clear that is has always been a shameful symptom, which led to lower assumed 
physical and intellectual abilities, accuse of laziness and lack of hygiene [1], and sorrow in parents [2]. 
The problem of enuresis was treated with physical punishment and magical or religious treatments 
and ceremonies [1, 2]. Salmon described a very compact and compelling history of treatment for 
bedwetting, from the earliest days of mankind onwards [2]. Treatments are vividly described; like the 
following in the first (1545) British textbook of Thomas Phair: “Take the wesande of a cocke and pluck 
it, tha brenne it in pouder and vse it twyse or thryse a daye. The stones of a hedgehogge poudred is 
of the same vertue. Item the clawes of a goate...” [2].  Or, in modern English: ‘take the esophagus of 
a rooster and harvest it. Burn it to powder and use it twice or three times a day. The powder of an 
hedgehogs insides works as well. Collect the claws of a goat’.
  
Several doctors, like Bagellardus and Rhazes followed the dogma of humors [2, 3]. Enuresis was 
often seen as a sign of the devil or as laziness. However, mainly in rural areas, it was accepted to 
wait for puberty to stop the problem, as the dirty bed straw was easily disposed with the animal 
excrements [1]. Towards the nineteenth century, urbanization with its associated increased hygiene 
requirements and few washing facilities - the crisis of filth - [4], made the enuretic an easy outcast [1]. 
Therefore, in the eighteenth century, different hypotheses were formed, like extreme irritable, weak 
or small bladder, or a meatus that was insensitive [1]. Several chemical and mechanical treatments 
were tried [2].
In the second half of the nineteenth century (the Victorian era), mother and child received better 
medical care, especially due to the aforementioned urbanization. Also, enuresis was a problem 
in the army. Enuresis patients were subjected to a combination of the following treatments: 
“fluid restriction, enemata, the use of an alarm clock, cold baths, warm baths, cold dashes to the 
perineum, douches to the lower spine” and all kind of mixtures of drugs, applied orally, rectally or 
as an ointment, injected in the perineum, into the meatus or the whole urethra [2]. Mechanical 
treatments were used to try to stop the urine from flowing, by compressing the urethra or closing 
the meatus, like a tape or iron device around the penis [1, 2]. 
Remarkably, in 2013 a case report was published about an eight year old boy suffering from penile 
Tourniquet syndrome, due to applying a thread around his penis for 15 days to try to stop his enuresis 
[5], expressing the same rationale as these mechanical devices, and showing the possible damage. 
This was noticed by several physicians in those days as well [2].
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The current frequently applied alarm therapy has two interesting predecessors in the Victorian 
civilized and in the tribal world. The first is an electrical apparatus that was used at night with a 
moist sponge between the shoulders and a dry one over the meatus. When wetting occurred, the 
electrical circuit was completed and the patient arose. The second is a frog, tied to the belly of the 
patient, which croaked when wetting occurred, waking the patient as well [2]. 
In the twentieth century, discussion arose whether or not enuresis was a psychosocial problem 
alone, and the MacDonald triad of enuresis, fire setting and animal abuse was described [6, 7]. 
Since the last decades of the twentieth century, enuresis is thought to have a multifactorial origin 
[8], and several treatment modalities became available.  
Terminology
When searching Pubmed for enuresis, the results encountered show that the definition has changed 
over time [8, 9]. The first three quarters of the twentieth century, enuresis was not only intermittent 
incontinence (at night) [8, 10]. Enuresis could mean ‘enuresis risoria (giggle incontinence)’, ‘enuresis 
ureterica’ (ectopic ureter causing continuous incontinence), diurnal enuresis or nocturnal enuresis. 
The last change in terminology was made in 2006 by the International Children’s Continence Society 
(ICCS) [11]. This report was updated in 2014 [8]. Enuresis currently is defined as nighttime intermittent 
incontinence (Figure 1). The addition of the term ‘nocturna’ is optional. Daytime incontinence is 
the term for incontinence during the day, and the term diurnal enuresis should be avoided [12]. 
In this thesis, this current definition of enuresis is used: nighttime intermittent incontinence of ≥ 1 
episode per month. Enuresis is subdivided in monosymptomatic (MNE) and non-monosymptomatic 
enuresis (NMNE), the latter including daytime Lower Urinary Tract Symptoms (LUTS). Individuals 
with secondary enuresis have experienced a dry period of at least six months, those with primary 
enuresis have not. 
Incontinence
Continuous
incontinence
Intermittent
incontinence
Day-time
incontinence Enuresis
Monosymptomatic Non-monosymptomatic
Primary Secondary Primary Secondary
Figure 1. Definition of enuresis. Adapted from Austin 2014 [8]. 
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Pathophysiology and etiology
Enuresis has a multifactorial origin and has been found to be related with several genetic, physiologic 
and psychologic factors [13]. A genetic and clinical heterogeneity is apparent: several loci on different 
chromosomes are involved in enuresis: chromosome 8, 12, 13 and 22 [14-19]. Enuresis is associated 
with several diseases, like sickle cell disease [20], constipation [21], sleep apnea and upper airway 
obstructive symptoms [22] and prior cardiac [23] and renal [24] transplantation. It can also arise 
in patients with an orthotopic neobladder after radical cystoprostatectomy [25]. Psychological and 
behavioral disorders are present in 20-40% of children with enuresis. This includes both internalizing 
psychological disorders like depressive and anxiety disorders, and externalizing disorders like 
Attention Deficit (Hyperactivity) Disorder (AD(H)D and Oppositional Defiant Disorder (ODD) [26]. 
Behavioral problems do more frequently occur in secondary enuresis [8]. Treating the behavioral 
disorder can result in decrease of bedwetting as well. Psychopathology in enuresis seems to be 
associated with older age, male gender, low socio-economic status and admission to specialized 
clinics [27]. Additionally, enuresis can be medically induced, due to valproate [28], risperidone [29, 
30] or lithium [31].  
Current consensus is that enuresis results as an interaction of three causal factors: nocturnal 
polyuria, small bladder capacity and arousal disorders [32].  Enuresis patients were found to excrete 
less vasopressin at night than during the day, in contrast to children without enuresis [33], resulting 
in a larger nocturnal urine output. Age affects bladder storage, also in incontinent children [34]. Even 
in healthy children without enuresis undergoing fluid challenge, if the nocturnal urine production 
exceeds the bladder capacity, incidental wetting of the bed will be provoked [35]. The three causal 
factors are more extensively discussed later in this chapter.
Epidemiology
Since the late nineties, in several countries epidemiological surveys have been carried out. Most 
of them used parental questionnaires for school-aged children. Prevalence of nocturnal enuresis is 
lower in females and decreases with age. It is less prevalent in Asian countries (7-12 yrs. 8% [36], 
5-15 yrs. 3.9’% [37], 16-40 yrs. 2.3% [38], whereas the numbers for Western countries and Africa 
seem comparable - Africa 6-16 yrs. 8-17.6% [39-41], North America: 5yr olds: 33%, 8 yr. olds: 18%, 11 
yr. olds 7%, 17 yr. olds 0.7% [42], Australia 5-12 yr. olds: 18.9% [43]. In the Netherlands enuresis was 
found in 15% of 5-6 yr. olds and 1% of 13-15 yr. olds [44]. In a cross-sectional sample of 18-64 year 
old adults, enuresis prevalence was 0.5%. There were no significant differences between age groups 
nor gender [45]. The spontaneous remission rate in 1129 enuretic patients was 15% per year [46].
Effects on quality of life
Enuresis can cause stress and social problems [1, 47, 48], like bullying [49]. It affects self-
esteem [45, 50, 51], and complicates holidays and relationships [45]. Constant poor-quality 
sleep can cause daytime sleepiness, depression and immune problems [52]. When properly 
treated, self-esteem may be normalized [51] and psychosocial damage can be prevented [53]. In 
contrast, those patients who remain wet if they grow older, have more severe complaints [54]. 
Enuresis also negatively affects the health related quality of life of patients and parents [55]. Still 
in the beginning of the twenty-first century, many parents in the US did not know that primary 
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nocturnal enuresis is a physical problem, and many healthcare providers never or rarely discussed 
enuresis, according to parents’ responses [56]. Parental punishment for enuresis is now known to 
have a detrimental effect on depression and quality of life of children [57].
Treatment
Recent standardization documents on the treatment of enuresis state the following evaluation 
and treatment options for MNE [10] and NMNE [58]. Primary evaluation and treatment of MNE 
can be carried out by a primary care doctor or by an educated nurse, and should include a good 
history and a frequency volume chart (FVC). Treatment includes bladder advice (urotherapy), 
alarm therapy and/or desmopressin. Alarm therapy is in favor in case of small bladder capacity, 
desmopressin in case of nocturnal polyuria. If therapy-resistance is present, patients should be 
referred to a specialist, where anticholinergics or in specific cases, imipramine can be prescribed [10]. 
For NMNE, it is important to treat constipation, fecal incontinence and underlying lower 
urinary tract diseases symptoms (overactive bladder, postponement, dysfunctional voiding) 
first. Accompanying behavioral disorders should also be treated. If enuresis still persists 
afterwards, then the standard treatment, as described for MNE can be started  [58]. 
Underneath, a short description of the different treatment modalities is given.
Alarm therapy has been introduced in 1938 by Mohrer and Mohrer, two psychologists, as 
a conditioning method [59, 60]. It works by achieving arousal to the sensation of a full bladder, 
and inhibit voiding. Most probably, it works by operant conditioning [60, 61]. Throughout 
the years, several different forms of alarm treatment have been investigated, like the pad 
and bell, the body sensor and alarm, and the body worn alarm. Overall, they all work by 
the rationale that, when the material between two electrodes or sensors will turn wet, 
and the circuit is closed, this leads to an alarm going off, making a sound or vibrating [60]. 
Alarm therapy has a high success rate (65%), although studies are heterogeneous in terms of 
inclusion and outcome parameters [62, 63].  It has a lower relapse rate (46%) than desmopressin 
(65%) [64]. Additionally, it has a positive effect on bladder storage in MNE [65]. 
Imipramin is a tricyclic antidepressant drug. The working mechanism is thought to be via the 
brainstem through noradrenergic action [66-68]. However, it had some unexpected adverse effects, 
like cardiac problems, personality changes, insomnia, anorexia and anxiety [68, 69], which made it a 
less favorable treatment option. Recently, it undergoes a slight comeback, as it has been propagated 
to be of use in therapy-resistant cases [10].
Another important current treatment is desmopressin, a synthetic vasopressin analogue. The 
working mechanism of arginine vasopressin peptide (AVP), which is formed in the pituitary gland, is 
discussed in the subsection on nocturnal polyuria. Desmopressin acts on the renal collecting duct 
and distal tubules to enlarge reabsorption of water and is a stronger antidiuretic than AVP itself [66]. 
Being introduced as a nasal spray, later and current routes of administration are oral tablets and 
an oral lyophylysate (sublingual melting) [70].  Efficacy was similar [71], or even better (probability 
improvement bedwetting odds ratio 2.0 (95%CI 1.07–3.73) of melt vs tablet) [70] In this mainly 
pharmacy-driven study, melt and tablet were given in a cross-over design to patients that were 
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already treated by desmopressin in advance. The overall prevalence of success (full response) 
was 19%. Therefore, the relative risk that this OR represents is lower - as explained in Chapter 2 
– and is 1.68 (1.06-2.46). Desmopressin seems to increase patient compliance [70], although not 
significantly [71]. Response rates of desmopressin were reported to be similar to imipramine, 
but desmopressin gave fewer side-effects [72]. The most recent, 2009 Cochrane review shows 
that desmopressin, during treatment effectively reduced bed-wetting compared with placebo: 
relative risk (RR) for failure to achieve 14 dry nights with 20 µg was 0.84 (95%CI 0.79-0.91), mean 
difference in wet nights per week was -1.34 (95%CI -1.57- -1.11) [64]. However, desmopressin 
has a high relapse rate after stopping treatment, resulting in no difference after treatment has 
finished [64]. Structured withdrawal was recently reported to give lower relapse rates [73, 74]. 
Main side effects are anorexia, bad taste, headache, nasal discomfort, nosebleeds, rash, dermatitis, 
edema, sight problems and vomiting. The nasal problems are mainly noted for the nasal spray [64, 
75]. For all administration routes, severe hyponatremia, with convulsions and coma, is a rare but 
serious complication [76, 77]. Predictive factors for severe hyponatremia to occur are excessive 
intake of fluids, younger age, start of therapy and prodromal symptoms like nausea, vomiting and 
headache [76, 78]. 
Urotherapy has a standard and a specific intervention component and is described in detail in the 
standardization document of the ICCS [8]. In short, it consists of LUT rehabilitation; a conservative 
therapy, including information and demystification, behavioral modification, life style advice on fluid 
intake and diet, registration of symptoms and voiding habits, and support and encouragement. 
Specific interventions include pelvic floor muscle training, neuromodulation, intermittent 
catheterization and cognitive behavioral therapy [8]. 
Dry Bed Training (DBT) has been developed by Azrin, Sneed and Fox in 1973 for retarded adults, 
and has been adjusted for non-retarded children with enuresis in 1974 [79]. It consists of alarm 
training, with several additional training components to obtain a faster result: hourly awakenings, 
large fluid intake to increase the desire to urinate, positive practice and cleanliness training, 
and positive reinforcement for correct urinations at the toilet. Positive practice involves getting 
out of bed to go to the toilet 20 times before sleeping, and after every wet episode. Cleanliness 
training involves changing bed sheets and night clothes in case of a wet bed, by the child itself. 
The training was performed by parents, at home, except for the first intensive training night, in 
which an outsider did the training at home. The first night included all elements described above. 
During the following nights, only positive practice and cleanliness training were performed, and 
children were woken at their parents’ bedtime to go to the toilet; every day this was half an hour 
earlier. After seven consecutive dry nights, the training was stopped. This method appeared to be 
rapid and effective. Bollard adjusted the training by teaching the parents to administer the whole 
procedure, including the first training night; lowering expenses and inconvenience of an outside 
trainer at home [80]. To reduce expenses even more, training parents in groups was performed, 
which was shown to be as effective as individual parent training [81]. Two-year follow-up of 60 
children treated by DBT showed that after achieving dryness during a fortnight, 39% of the group 
relapsed during the two years of follow-up. After re-treatment with DBT, 14 out of 15 cases were dry 
[82]. Evidence suggested that the alarm could be left out as well, although results were not as good 
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[83]. In Butlers Modified DBT (DBT-M), the positive practice and the reprimands were left out [83]. 
The 2008 Cochrane review on complex behavioral interventions for enuresis stated that a complex 
intervention like DBT including an alarm was better than no treatment and than alarm treatment 
alone. The effect of only DBT without an alarm was not better than an alarm on its own. Direct 
contact and support from a therapist might increase the effect of the intervention [84]. 
Several other treatments have been reported, like furosemide [85], bladder transection [86], 
acupuncture [87] and hypnotherapy [88], although reports are of low quality [87].
Nocturia
History
Nocturia is derived from the Greek word νυκτουρία, merging the words for night and for urine. 
Although mankind has probably experienced nocturia as a symptom since ancient history, 
historical reports on nocturia are not easily found. In contrast to the history of enuresis, until the 
beginning of the twenty-first century, nocturia has mainly been described as one of the Lower 
Urinary Tract Symptoms (LUTS), as part of or associated with different disease entities. Nocturia 
is only investigated as a sole symptom or condition since the last decades. It gains more and more 
attention by urologists and general practitioners and is discussed in focus groups of the ICS [89, 90]. 
Nocturia was initially thought to be mainly a condition in men. However, we now know that it is as 
prevalent in women [91, 92]. 
Terminology and effects on quality of life
The most recent terminology report of nocturia was published by the ICS in 2002 [93]. Nocturia is 
defined as the number of voids during a night sleep; each void is preceded and followed by sleep 
[93]. It is distinct from night-time frequency, which is defined as the number of voids recorded from 
the moment an individual goes to bed with the intention of sleeping until the moment an individual 
wakes with the intention of rising [93]. In general, nocturia is known to be clinically bothersome if a 
person experiences two or more voids during sleep. However, some people experience one void to 
be bothersome and others are not bothered by three, or even more, nocturnal voids. Nocturia may 
affect health and well-being [94] and is associated with several morbidities like falling and fractures 
[95]. Nevertheless, in 2007, there was still a lack of knowledge on nocturia in patients [96].
Pathophysiology and etiology
Just like enuresis, nocturia is known to be multifactorial. Several symptoms and conditions are 
assumed to be associated with nocturia, although some are just co-occurring with increasing age. 
Examples are:   body mass index, Hispanic and Black race, diabetes, hypertension, anxiety and 
depression, a history of enuresis, arthritis, asthma, heart disease, inflammatory bowel disease, 
cystitis, uterine prolapse, hysterectomy, menopausal status, prostatitis and prostate cancer [97], as 
well as obstructive sleep apnea syndrome (OSAS) [98]. Additionally, nocturia may be part of the Over 
Active Bladder (OAB) syndrome. 
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Causal factors of nocturia are nocturnal polyuria, global polyuria, bladder storage problems, sleep 
problems and circadian clock problems [93, 99], which all have their own causes [100]. Global 
polyuria, which represents the condition in which the 24-hour urine production exceeds 40 ml/kg 
bodyweight, is found in conditions like diabetes mellitus, diabetes insipidus, behavioral excessive 
fluid intake or it can be a side effect of medication [99]. The other factors will be described more 
extensively further on, as they are causal factors in enuresis as well.
Epidemiology
The prevalence of nocturia in the general population is high. In a large cross-sectional survey 
in 30,000 men and women of the general population with a 59% response rate, nocturia 
(≥1x) was present in 69% of men and 76% of women. Clinically relevant nocturia (≥2x) was 
present in 28% and 34% [97]. Other studies give comparable, or slightly lower, numbers [91]. 
In the Netherlands, in men aged 50-78 years from the general population, nocturia (≥2x) prevalence 
was 27.1% [101]. Important to note is that the prevalence of nocturia may differ depending on the 
assessment method used; questionnaires like the International Prostate Symptom Score, or FVCs 
[102, 103]. Most often, prevalence of nocturia is described, which is the proportion of cases in a 
population on a specific moment in time. The incidence rate – the number of new cases in the 
population that is at risk, in a given time period – is rarely investigated, but was found to be 23.9% in 
a Dutch longitudinal study in men aged 50 to 78 years [102]. 
Treatment
Treatment of nocturia depends on its main cause [89, 100]. Therefore, a thorough evaluation by 
means of an FVC is necessary [99]. The optimal length of an FVC seems to be 3 days, at the optimal 
balance of patient compliance and reliability [104]. The European Association of Urology (EAU) 2015 
guideline on non-neurogenic male LUTS reports a flow chart in which treatment is described in 
a stepwise manner [105]. A recent report on the proceedings of specific nocturia sessions of the 
International Consultation on Incontinence - Research Society (ICI-RS) recently also proposed an 
algorithm for the treatment of nocturia [89].
 
In general, the following treatments are advised for the separate causes. In case of 24-hour 
polyuria, Diabetes Mellitus should be treated, intake should be reduced, and desmopressin could be 
considered according to the ICI-RS. In case of NP, the EAU states that education and lifestyle advice 
should be given, with or without desmopressin. The ICI-RS additionally mentions furosemide and 
treatment of OSAS. Additionally, drugs possibly causing nocturia or NP should be assessed first. 
In case of predominant bladder storage problems, the EAU propagates education and lifestyle 
advice, with or without a muscarinic receptor antagonist, although the effectivity of this drug is 
questionable. If storage problems are not predominant and prostate volume is larger than 40 ml, 
education, life-style advice, 5 α-reductase inhibitor and α-blocker or PDE5 inhibitor can be prescribed, 
drugs of which the effectivity is not certain either. The ICI-RS is quite in line and reports that in case 
of bladder storage problems due to Bladder Outlet Obstruction (BOO), α-blockers, 5-α-reductase 
inhibitors, pelvic floor muscle exercises or desobstruction are treatments of choice. For bladder 
storage problems due to overactive bladder (OAB) or detrusor over activity (DO), treatment consists 
of an anticholinergic, pelvic floor muscle exercises, β-3 agonist, sacral neuromodulation or botulinum 
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toxin injection submucosally in the bladder [89]. 
As discussed, both nocturia and enuresis are thought to share the causes of 24-hour polyuria, 
nocturnal polyuria, small bladder capacity and sleep problems, and circadian clock problems. The 
following paragraphs will focus on these.
Nocturnal polyuria
Nocturnal polyuria is the condition of overproduction of urine at night.. Physiologically, several renal 
mechanisms regulate urine production. In specific, atrial vasopressin (AVP) – or antidiuretic hormone 
(ADH) - changes renal excretion of water and regulates plasma osmolality and sodium concentration. 
This hormone is formed in the paraventricular and supraoptic nuclei of the hypothalamus and is 
released from the pituitary gland, in response to increased plasma osmolality or low blood pressure 
and blood volume. The vasopressin-2 (V2) receptor subtype is most important for antidiuresis and is 
located in the epithelial cells of the renal collecting duct. The other less important subtypes (V1a and 
V1b) are located in the vascular and central nervous system. When AVP is absent, the thin epithelial 
membrane between urine and blood in the renal collecting duct is almost impermeable to water. In 
the presence of AVP, this binds to the V2-receptor, activating aquaporin channels in the membrane, 
resulting in high permeability and reabsorption of most water. By this process, small changes in AVP 
level can have a large effect on the amount of water excreted by the kidneys [106]. 
In normal physiologic conditions, AVP secretion and consequently urine production expresses 
a circadian rhythm, resulting in an increased secretion of AVP and a decreased urine production 
during sleeping hours [33, 107, 108]. The circadian, or peripheral, clock generates this circadian 
rhythm. This is a molecular genetic feedback mechanism, present in most peripheral organs and 
cells, which is centrally regulated by the central clock, located in the suprachiasmatic nucleus of the 
brain [109]. The central clock generates the central circadian rhythm of the body by synchronizing 
the environment by receiving light cycle signals from the retina. The peripheral clocks are adjusted by 
neural and hormonal signals and by indirect behavioral controls via feeding and sleep-wake pattern 
[110]. Genetic defects in the circadian clock system resulted in adjusted rhythms in both urine 
production and bladder storage function in mice [110]. Similarly, both in nocturia and in enuresis, 
this circadian rhythm of AVP secretion and the production of urine seems to be disturbed [33, 107], 
resulting in increased nocturnal urine production. 
AVP secretion is not only influenced by diurnal patterns, but also by aging and gender. Changes in 
water metabolism due to age are multifold: the composition of body fluid decreases and body fat 
increases, plasma volume lowers, thirst perception lessens, and renal function decreases. This results 
in a higher susceptibility for mismatches like dehydration or overhydration and hyperosmolality and 
hypo-osmolality like hyponatremia [106]. 
In brief, nocturnal polyuria can manifest itself when the circadian pattern of AVP secretion 
is disturbed. Other causes of nocturnal polyuria can be extreme high evening fluid intake, a 
defect in AVP action or solute diuresis caused by congestive heart failure, sleep apnea and 
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renal insufficiency. Nocturnal polyuria often is idiopathic, due to changes according to age 
[99]. In general, NP causes can be divided in water diuresis and solute diuresis. To distinguish 
between these two, renal function profiles have recently been proposed to be helpful [111]. 
Presented like this, nocturnal polyuria presence or absence seems quite straightforward. 
Unfortunately however, quantifying the presence of nocturnal polyuria is more difficult than it 
seems, as many different definitions for nocturnal polyuria are available, and the association 
between nocturnal polyuria and nocturnal voiding frequency was not clear yet. 
Definitions of nocturnal polyuria – Pediatric and adult definitions
Both continence societies have published a definition on NP, which are used for enuresis (ICCS) 
and nocturia (ICS) respectively. The adult, International Continence Society (ICS) definition is: an 
age-dependent nocturnal urine output exceeding 20-33% of 24-hour urine output; the nocturnal 
polyuria index [93]. It is therefore a ratio between night-time and 24-hour urine production, in which 
the first morning void is regarded as night-time urine production. In contrast to the ICS definition, 
the pediatric continence society, the ICCS, defines nocturnal polyuria as a nocturnal urine production 
exceeding 130% of the expected bladder capacity for age (EBC), which itself is defined as (age+1)*30 
[8, 112]. This definition thus uses the relation between night-time urine production (including the 
first morning void) and the bladder capacity; a completely different strategy than the ratio of the ICS 
definition. Alongside these two definitions, more definitions of NP are used in literature, resulting 
in confusion. 
In conclusion, nocturnal polyuria is an important pathophysiologic factor both in nocturia and 
nocturnal enuresis [8, 32, 100]. A thorough assessment of the conditions is appropriate [89, 99]. For 
this, insight in the association with nocturnal polyuria and valid definitions for the different causes 
are needed [89]. 
Small bladder capacity
Throughout the life span, micturition changes. Neonates show reflex voiding. Postnatally, both 
enlargement of the bladder capacity and the regulation of the urination by upper central neurons, 
result in control of both daytime and nighttime micturition [110]. Voided volumes in normal children 
have a circadian rhythm, the first morning void being larger than all other voidings [113, 114]. 
Definitions of (small) bladder capacity
The term bladder capacity refers to the amount of urine the bladder is able to store. It can be measured 
by different means: by cystometry, by cystometry under anesthesia, by the maximum voided volume 
(MVV) on a Frequency Volume Chart (FVC), or by uroflowmetry [112, 115, 116]. The ICCS defined a 
small bladder capacity as a bladder capacity lower than 65% of the EBC [8]. For adults, this is unclear, as 
the most recent ICS report on nocturia terminology states that a definite range of normal or abnormal 
volumes is lacking and the physician has to evaluate patients based on FVCs and clinical judgment [93]. 
However, reference values for the general male population have been described: Functional bladder 
capacity (FBC) was shown to decline with increasing age and lower FBC was related to LUTS [117]. 
A reduced voided volume can be determined by comparing night-time voided volume with maximal 
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bladder capacity occurring at any time. Additionally, the ICS document states that the term ‘voided 
volume’ replaced the term FBC [93]. 
Reduced functional bladder capacity is often caused by bladder storage problems, due to BOO, OAB, 
by neurogenic bladder or by a high PVR, or developmental disturbances [58, 89, 99]. Other causes 
include LUT cancer, stones and aging [99]. 
Sleep problems
Both in enuresis and in nocturia, sleep problems are present. In enuresis, these are mainly referred 
to as arousal problems. In nocturia, it is difficult to distinguish if there is a primary sleep problem that 
causes people to wake and then to void, or if people awake due to an urge to void, and therefore 
experience sleep problems. 
Children with enuresis are difficult to awake from sleep. For decades, this has been thought to be 
caused by deep sleep, as questionnaire studies show that enuresis is associated with a subjectively 
high arousal threshold [118]. Recent research using night-time polysomnography measures however 
suggests that enuresis patients are merely light, or superficial sleepers. The arousal problems are 
therefore probably due to several factors. Yeung et al. found that children with severe enuresis (≥5 
nights/week) had more light sleep and unstable bladder contractions than non-enuretic children, 
which was associated with frequent cortical arousals, but no complete awakenings. So, arousal 
thresholds are increased, probably to maintain sleep time [119]. Respiratory arousal stimuli [120], 
sleep fragmentation [121], and periodic limb movements during sleep [122] are other factors in play. 
Additionally, disturbed sleep has a bidirectional relationship with NP; NP can cause sleep deprivation, 
but sleep deprivation in itself can result in NP as well, by a higher nocturnal blood pressure and 
lower levels of AVP [123]. The disturbed sleep has an association with behavioral problems. Periodic 
limb movements were associated with a lower quality of life in 30 MNE patients [122].   
So, enuresis can be caused by nocturnal polyuria, bladder problems like detrusor over activity and 
inadequate arousal mechanisms. This last mechanism can be caused by disturbed sleep, which 
can be caused by detrusor overactivity, by airway problems (sleep apnea), and has a bidirectional 
relationship with NP.
Overall, enuresis and nocturia are two conditions with similar etiologies, although many things 
remain unclear considering definitions and associations of causal factors like nocturnal polyuria 
and small bladder capacity. Enuresis has mainly been investigated in younger age groups, whereas 
older patients more often have therapy-resistant enuresis. For this latter group, adapted DBT was 
developed.
General aims and outline of this thesis
The general aim of this thesis was to study different aspects of enuresis and nocturia, in order to 
provide a more united view of these two related conditions, focusing on associations with NP, critical 
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appraisal of current definitions, and evaluating adapted DBT in treatment resistant enuresis patients.
Part I - Nocturia and nocturnal polyuria
This part involves a systematic review and meta-analysis on the association of nocturia and nocturnal 
polyuria, including a quality assessment of internal and external validity and informativity of included 
studies. Chapter 2 focuses on the association of nocturia and nocturnal polyuria. It was unclear 
to what extent NP should be considered the (main) cause of nocturia. Drugs like desmopressin, 
aiming at reducing nocturnal urine production became newly available in the field of nocturia, to 
reduce nocturnal voiding frequency. This stresses the importance of assessing the actual association 
between nocturia and NP in a systematic way. Research questions were as follows: What is the 
prevalence of NP for people with and without nocturia? What is the nocturnal voiding frequency of 
people with and without NP? In Chapter 3, the impact of the ICS-2002 report on standardization of 
terminology in nocturia on publications reporting on nocturia and NP is evaluated in a systematic 
way. In particular, used nocturia and NP definitions are discussed.
Part II - Enuresis, nocturnal polyuria and functional bladder capacity: focus on definitions
This part focuses on NP and FBC definitions in enuresis instead of in nocturia. The data presented 
are derived from FVCs and uroflowmetries collected at the initial assessment of adolescent and 
adult enuresis patients. These patients were treated in a special secondary and tertiary care enuresis 
center, founded in 2003 by a urologist, a continence nurse and the patient association. In this center, 
patients suffering from incontinence are assessed. The population studied in this thesis represents 
a group of 907 therapy-resistant adolescent and adult enuresis patients, treated by adapted 
Dry Bed Training (DBT) from 2003 to 2013. This training is more extensively described in part III. 
This part merely focuses on the data of the initial patient assessment, before the adapted DBT. 
In Chapter 4, the pediatric ICCS and the adult ICS NP definition are compared, as enuresis patients 
are normally mainly assessed by the ICCS definition, but part of our patients are adults. Additionally, 
reference values for other FVC and uroflowmetry parameters are presented, as they were lacking 
for this age group of enuresis patients. Both FVC and uroflowmetry have their advantages and 
disadvantages, and Chapter 5 focuses on the comparison of these methods to assess FBC.
Part III - Enuresis in adolescents and adults: adapted Dry Bed Training
In this part, adapted DBT for therapy resistant, adolescent and adult enuresis patients is presented. 
For this, a retrospective cohort study was conducted. Chapter 6 focuses on the description and 
results of the adapted DBT. Given that these patients have experienced many treatment modalities 
before, the substantial impact of enuresis and the time-consuming nature of adapted DBT, it 
is worthwhile to investigate which patients benefit most. Therefore, in Chapter 7, predictors for 
successful treatment response to adapted DBT in this population are identified. In Chapter 8, long 
term follow up of adapted DBT is presented. It represents a cross-sectional questionnaire study. 
Unfortunately, large difficulties regarding response rates were experienced. Therefore, the focus of 
this chapter is on these problems and on possible solutions.
Finally, in Chapter 9 (Dutch translation in Chapter 10), a summary of this thesis is given, combined 
with a discussion, recommendations and future research perspectives.
24
References
1. Quincy-Lefebvre P. To punish, treat, or pardon:French society and the enuretic child in the nineteenth and 
twentieth centuries. History of the Family. 2001;6:329-43.
2. Salmon MA. An historical account of nocturnal enuresis and its treatment. Proceedings of the Royal Society of 
Medicine. 1975;68:443-5.
3. Ashtiyani SC, Shamsi M, Cyrus A, Tabatabayei SM. Rhazes, a Genius Physician in the Diagnosis and Treatment of 
Nocturnal Enuresis in Medical History. Iran Red Cresc Med J. 2013;15:633-8.
4. Hurl C. Urine trouble: a social history of bedwetting and its regulation. History of the Human Sciences. 
2011;24:48-64.
5. Pahwa HS, Kumar A, Srivastava R, Kumar S, Goel A, Ahmad A. Partial penile amputation due to penile tourniquet 
syndrome in a child troubled with primary nocturnal enuresis--a rare emergency. Urology. 2013;81:653-4.
6. Felthous AR, Bernard H. Enuresis, firesetting, and cruelty to animals: the significance of two thirds of this triad. J 
Forensic Sci. 1979;24.
7. Heller MS, Ehrlich SM, Lester D. Childhood cruelty to animals, firesetting, and enuresis as correlates of 
competence to stand trial. J Gen Psychol. 1984;110:151-3.
8. Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children 
and adolescents: update report from the Standardization Committee of the International Children’s Continence 
Society. J Urol. 2014;191:1863-5.
9. Hindmarsh JR. Terminology of enuresis. Br Med J. 1978;2:1714.
10. Nevéus T, Eggert P, Evans JHC, et al. Evaluation of and treatment for monosymptomatic enuresis: a 
standardization document from the International Children’s Continence Society. J Urol. 2010;183:441-7.
11. Nevéus T, von Gontard A, Hoebeke P, et al. The Standardization of Terminology of Lower Urinary Tract Function 
in Children and Adolescents: Report from the Standardisation Committee of the International Children’s 
Continence Society. J Urol. 2006;176:314-24.
12. Tek M, Erdem E. Advances in the management of enuresis. F1000prime reports. 2014;6:106.
13. Glazener CMA, Evans JHC, Peto RE. Treating nocturnal enuresis in children: review of evidence. J Wound Ostomy 
Continence Nurs. 2004;31:223-34.
14. von Gontard A, Hollmann E, Eiberg H, Benden B, Rittig S, Lehmkuhl G. Clinical enuresis phenotypes in familial 
nocturnal enuresis. Scand J Urol Nephrol Suppl. 1997;183:11-6.
15. Arnell H, Hjalmas K, Jagervall M, et al. The genetics of primary nocturnal enuresis: inheritance and suggestion of 
a second major gene on chromosome 12q. J Med Genet. 1997;34:360-5.
16. Nothwang HG, Wirth J, Brandl B, et al. Identification of positional candidates for neurological disorders on 
chromsome 13q14-->q22. Cytogenet Cell Genet. 1997;79:293-7.
17. Eiberg H, Berendt I, Mohr J. Assignment of dominant inherited nocturnal enuresis (ENUR1) to chromosome 13q. 
Nat Genet. 1995;10:354-6.
18. von Gontard A, Eiberg H, Hollmann E, Rittig S, Lehmkuhl G. Molecular genetics of nocturnal enuresis: linkage to a 
locus on chromosome 22. Scand J Urol Nephrol Suppl. 1999;202:76-80.
19. Eiberg H. Total genome scan analysis in a single extended family for primary nocturnal enuresis: evidence for a 
new locus (ENUR3) for primary nocturnal enuresis on chromosome 22q11. Eur Urol. 1998;33 Suppl 3:34-6.
20. Figueroa TE, Benaim E, Griggs ST, Hvizdala EV. Enuresis in sickle cell disease. J Urol. 1995;153:1987-9.
21. McGrath KH, Caldwell PH, Jones MP. The frequency of constipation in children with nocturnal enuresis: a 
comparison with parental reporting. Journal of paediatrics and child health. 2008;44:19-27.
22. Waleed FE, Samia AF, Samar MF. Impact of sleep-disordered breathing and its treatment on children with 
primary nocturnal enuresis. Swiss medical weekly. 2011;141:w13216.
23. Leonard H, Plant N. Nocturnal enuresis is a common complication following cardiac transplantation. Arch Dis 
Child. 2003;88:1048-50.
24. Van der Weide MJ, Cornelissen EA, Van Achterberg T, de Gier RP, Feitz WF. Lower urinary tract symptoms after 
renal transplantation in children. J Urol. 2006;175:297-302; discussion 
25. El-Bahnasawy MS, Shaaban H, Gomha MA, Nabeeh A. Clinical and urodynamic efficacy of oxybutynin and 
verapamil in the treatment of nocturnal enuresis after formation of orthotopic ileal neobladders. A prospective, 
randomized, crossover study. Scand J Urol Nephrol. 2008;42:344-51.
26. von Gontard A, Baeyens D, Van Hoecke E, Warzak WJ, Bachmann C. Psychological and psychiatric issues in 
urinary and fecal incontinence. J Urol. 2011;185:1432-6.
27. Baeyens D, Roeyers H, Vande Walle J, Hoebeke P. Behavioural problems and attention-deficit hyperactivity 
disorder in children with enuresis: a literature review. Eur J Pediatr. 2005;164:665-72.
28. Yamak WR, Hmaimess G, Makke Y, et al. Valproate-induced enuresis: a prospective study. Developmental 
medicine and child neurology. 2015;57:737-41.
29. Kantrowitz JT, Srihari VH, Tek C. Three cases of risperidone-induced enuresis. Schizophrenia research. 
2006;84:174-5.
30. Hergüner S, Mukaddes NM. Risperidone-Induced Enuresis in Two Children with Autistic Disorder. Journal of Child 
and Adolescent Psychopharmacology. 2007;17:527-30.
1
G
eneral introduction
25
31. Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance 
treatment of bipolar disorder. Cochrane Database Syst Rev. 2013;10:CD003196.
32. Goessaert AS, Everaert K, Hoebeke P, Kapila A, Walle JV. Nocturnal enuresis and nocturia, differences and 
similarities - lessons to learn? Acta Clin Belg. 2015;70:81-6.
33. Rittig S, Knudsen UB, Norgaard JP, Pedersen EB, Djurhuus JC. Abnormal diurnal rhythm of plasma vasopressin 
and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-71.
34. Bower WF, Moore KH, Adams RD, Shepherd RB. Frequency-volume chart data from incontinent children. British 
journal of urology. 1997;80:658-62.
35. Rasmussen PV, Kirk J, Rittig S, Djurhuus JC. The enuretic episode--a complete micturition from a bladder with 
normal capacity? A critical reappraisal of the definition. Scand J Urol Nephrol Suppl. 1997;183:23-4.
36. Kanaheswari Y. Epidemiology of childhood nocturnal enuresis in Malaysia. Journal of paediatrics and child health. 
2003;39:118-23.
37. Hansakunachai T, Ruangdaraganon N, Udomsubpayakul U, Sombuntham T, Kotchabhakdi N. Epidemiology of 
enuresis among school-age children in Thailand. J Dev Behav Pediatr. 2005;26:356-60.
38. Yeung CK, Sihoe JD, Sit FK, Bower W, Sreedhar B, Lau J. Characteristics of primary nocturnal enuresis in adults: an 
epidemiological study. BJU Int. 2004;93:341-5.
39. Eapen V, Mabrouk AM. Prevalence and correlates of nocturnal enuresis in the United Arab Emirates. Saudi Med 
J. 2003;24:49-51.
40. Osungbade KO, Oshiname FO. Prevalence and perception of nocturnal enuresis in children of a rural community 
in southwestern Nigeria. Trop Doct. 2003;33:234-6.
41. Gür E, Turhan P, Can G, et al. Enuresis: prevalence, risk factors and urinary pathology among school children in 
Istanbul, Turkey. Pediatrics international : official journal of the Japan Pediatric Society. 2004;46:58-63.
42. Byrd RS, Weitzman M, Lanphear NE, Auinger P. Bed-wetting in US children: epidemiology and related behavior 
problems. Pediatrics. 1996;98:414-9.
43. Bower W, Moore KH, Shepherd RB, Adams RD. The epidemiology of childhood enuresis in Australia. British 
journal of urology. 1996;78:602-6.
44. Spee-van der Wekke J, Hirasing RA, Meulmeester JF, Radder JJ. Childhood nocturnal enuresis in The Netherlands. 
Urology. 1998;51:1022-6.
45. Hirasing RA, van Leerdam FJM, Bolk-Bennink LF, Janknegt RA. Enuresis nocturna in adults. Scand J Urol Nephrol. 
1997;31:533-6.
46. Forsythe WI, Redmond A. Enuresis and spontaneous cure rate. Arch Dis Child. 1974;49:259-63.
47. Huang T, Shu X, Huang YS, Cheuk DKL. Complementary and miscellaneous interventions for nocturnal enuresis in 
children. Cochrane Database Syst Rev. 2011.
48. Hirasing RA, van Leerdam FJM, Bolk-Bennink LF, Koot HM. Effect of dry bed training on behavioural problems in 
enuretic children. Acta Paediatr. 2002;91:960-4.
49. Williams K, Chambers M, Logan S, Robinson D. Association of common health symptoms with bullying in primary 
school children. BMJ. 1996;313:17-9.
50. Hirasing RA, van Leerdam FJM, Bolk-Bennink LF, Bosch JD. Bedwetting and behavioural and/or emotional 
problems. Acta Paediatr. 1997;86:1131-4.
51. Hägglöf B, Andrén O, Bergström E, Marklund L, Wendelius M. Self-esteem before and after treatment in children 
with nocturnal enuresis and urinary incontinence. Scand J Urol Nephrol. 1997;183:79-82.
52. Marschall-Kehrel D. Update on nocturia: the best of rest is sleep. Urology. 2004;64 Suppl 6A:21–4.
53. Schulpen TW. The burden of nocturnal enuresis. Acta Paediatr. 1997;86:981-4.
54. Yeung CK, Sreedhar BIJI, Sihoe JDY, Sit FKY, Lau J. Differences in characteristics of nocturnal enuresis between 
children and adolescents: a critical appraisal from a large epidemiological study. BJU int. 2006;97:1069-73.
55. Naitoh Y, Kawauchi A, Soh J, Kamoi K, Miki T. Health related quality of life for monosymptomatic enuretic children 
and their mothers. J Urol. 2012;188:1910-4.
56. Dunlop A. Meeting the needs of parents and pediatric patients: results of a survey on primary nocturnal 
enuresis. Clin Pediatr (Phila). 2005;44:297-303.
57. Nabeel Al-Zaben F, GGamal Sehlo M. Punishment for bedwetting is associated with child depression and reduced 
quality of life. Child Abuse and Neglect. 2014.
58. Franco I, von Gontard A, De Gennaro M, Society ICC. Evaluation and treatment of nonmonosymptomatic 
nocturnal enuresis: a standardization document from the International Children’s Continence Society. J Pediatr 
Urol. 2013;9:234-43.
59. Doroshow DB. An alarming solution: Bedwetting, medicine, and behavioral conditioning in mid-twentieth-
century America. Isis. 2010;101:312-37.
60. Forsythe WI, Butler RJ. Fifty years of enuretic alarms. Arch Dis Child. 1989;64:879-85.
61. Caldwell PHY, Deshpande AV, von Gontard A. Management of nocturnal enuresis. BMJ. 2013;347.
62. Butler RJ, Gasson SL. Enuresis alarm treatment. Scand J Urol Nephrol. 2005;39:349-57.
63. Glazener CMA, Evans JHC, Peto RE. Alarm interventions for nocturnal enuresis in children. Cochrane Database 
Syst Rev. 2009:CD002911.
64. Glazener CMA, Evans JHC. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. 
26
2009:CD002112.
65. Canning DA. Effect of alarm treatment on bladder storage capacities in monosymptomatic nocturnal enuresis. J 
Urol. 2005;174:1104.
66. Kiddoo D. Nocturnal enuresis. CMAJ. 2012;184:908-11.
67. Petersen KE, Andersen OO, Hansen T. Mode of action and relative value of imipramine and similar drugs in the 
treatment of nocturnal enuresis. European journal of clinical pharmacology. 1974;7:187-94.
68. Miller K, Atkin B, Moody ML. Drug therapy for nocturnal enuresis. Current treatment recommendations. Drugs. 
1992;44:47-56.
69. Goel KM, Shanks RA. Amitriptyline and imipramine poisoning in children. Br Med J. 1974;1:261-3.
70. Juul KV, Van Herzeele C, De Bruyne P, Goble S, Walle JV, Norgaard JP. Desmopressin melt improves response and 
compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis. Eur J Pediatr. 
2013;172:1235-42.
71. Lottmann H, Froeling F, Alloussi S, et al. A randomised comparison of oral desmopressin lyophilisate (MELT) and 
tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract. 2007;61:1454-
60.
72. Rushton HG. Older pharmacologic therapy for nocturnal enuresis. Clin Pediatr (Phila). 1993;Spec No:10-3.
73. Ferrara P, Romano V, Cortina I, Ianniello F, Fabrizio GC, Chiaretti A. Oral desmopressin lyophilisate (MELT) for 
monosymptomatic enuresis: structured versus abrupt withdrawal. J Pediatr Urol. 2014;10:52-5.
74. Ohtomo Y, Umino D, Takada M, Fujinaga S, Niijima S, Shimizu T. Gradual tapering of desmopressin leads to 
better outcome in nocturnal enuresis. Pediatrics international : official journal of the Japan Pediatric Society. 
2015;57:656-8.
75. Moffatt ME, Harlos S, Kirshen AJ, Burd L. Desmopressin acetate and nocturnal enuresis: how much do we know? 
Pediatrics. 1993;92:420-5.
76. Thumfart J, Roehr CC, Kapelari K, Querfeld U, Eggert P, Muller D. Desmopressin associated symptomatic 
hyponatremic hypervolemia in children. Are there predictive factors? J Urol. 2005;174:294-8; discussion 8.
77. Robson WL, Norgaard JP, Leung AK. Hyponatremia in patients with nocturnal enuresis treated with DDAVP. Eur J 
Pediatr. 1996;155:959-62.
78. Robson WL, Leung AK, Norgaard JP. The comparative safety of oral versus intranasal desmopressin for the 
treatment of children with nocturnal enuresis. J Urol. 2007;178:24-30.
79. Azrin NH, Sneed TJ, Foxx RM. Dry-bed training: rapid elimination of childhood enuresis. Behav Res Ther. 
1974;12:147-56.
80. Bollard RJ, Woodroffe P. The effect of parent-administered Dry-Bed training on nocturnal enuresis in children. 
Behav Res Ther. 1977;15:159-65.
81. Bollard J, Nettelbeck T, Roxbee L. Dry-bed training for childhood bedwetting: a comparison of group with 
individually administered parent instruction. Behav Res Ther. 1982;20:209-17.
82. Bollard J. A 2-year follow-up of bedwetters treated by dry-bed training and standard conditioning. Behav Res 
Ther. 1982;20:571-80.
83. Butler RJ. A comparison of two approaches to the treatment of nocturnal enuresis and the prediction of 
effectiveness using pre-treatment variables. J Child Psychol Psychiat. 1988;29:501-9.
84. Glazener CMA, Evans JHC, Peto RE. Complex behavioural and educational interventions for nocturnal enuresis in 
children. Cochrane Database Syst Rev. 2008:CD004668.
85. Reynard JM, Cannon A, Yang Q, Abrams P. A novel therapy for nocturnal polyuria: a double-blind randomized 
trial of frusemide against placebo. British journal of urology. 1998;81:215-8.
86. Crooks JE, Khan AB, Meddings RN, Abel BJ. Bladder transection revisited. British journal of urology. 1995;75:590-
1.
87. Lv ZT, Song W, Wu J, et al. Efficacy of Acupuncture in Children with Nocturnal Enuresis: A Systematic Review 
and Meta-Analysis of Randomized Controlled Trials. Evidence-based complementary and alternative medicine : 
eCAM. 2015;2015:320701.
88. Kiddoo D. Nocturnal enuresis: non-pharmacological treatments. BMJ clinical evidence. 2015;2015.
89. Bosch JL, Everaert K, Weiss JP, et al. Would a new definition and classification of nocturia and nocturnal polyuria 
improve our management of patients? ICI-RS 2014. Neurourol Urodyn. 2015;[Epub ahead of print].
90. Bliwise DL, Rosen RC, Baum N. Impact of Nocturia on Sleep and Quality of Life: A Brief, Selected Review for the 
International Consultation on Incontinence Research Society (ICI-RS) Nocturia Think Tank. Neurourol Urodyn. 
2014;33:S15-S8.
91. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and 
other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306-14; 
discussion 14-5.
92. Tikkinen KA, Tammela TL, Huhtala H. Is nocturia equally common among men and women? A population based 
study in Finland. . J Urol. 2006;175:596-600.
93. van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: report from the 
Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:179-83.
94. Tikkinen KA, Johnson TM, 2nd, Tammela TL, et al. Nocturia frequency, bother, and quality of life: how often is too 
1
G
eneral introduction
27
often? A population-based study in Finland. Eur Urol. 2010;57:488-96.
95. Temml C, Ponholzer A, Gutjahr G, Berger I, Marszalek M, Madersbacher S. Nocturia is an age-independent risk 
factor for hip-fractures in men. Neurourol Urodyn. 2009;28:949-52.
96. Chen FY, Dai YT, Liu CK, Yu HJ, Liu CY, Chen TH. Perception of nocturia and medical consulting behavior among 
community-dwelling women. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:431-6.
97. Madhu C, Coyne K, Hashim H, Chapple C, Milsom I, Kopp Z. Nocturia: risk factors and associated comorbidities; 
findings from the EpiLUTS study. Int J Clin Pract. 2015.
98. Umlauf MG, Chasens ER, Greevy RA, Arnold J, Burgio KL, Pillion DJ. Obstructive sleep apnea, nocturia and 
polyuria in older adults. Sleep. 2004;27:139-44.
99. Van Kerrebroeck P, Andersson KE. Terminology, epidemiology, etiology, and pathophysiology of nocturia. 
Neurourol Urodyn. 2014;33 Suppl 1:S2-5.
100. Marshall SD, Raskolnikov D, Blanker MH, et al. Nocturia: Current Levels of Evidence and Recommendations From 
the International Consultation on Male Lower Urinary Tract Symptoms. Urology. 2015;85:1291-9.
101. van Doorn B, Blanker MH, Kok ET, Westers P, Bosch JL. Prevalence, incidence, and resolution of nocturnal 
polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-7.
102. Van Doorn B, Blanker MH, Kok ET, Westers P, Bosch JLHR. Once nocturia, always nocturia? Natural history 
of nocturia in older men based on frequency-volume charts: The Krimpen study. Journal of Urology. 
2011;186:1956-61.
103. Blanker MH, Groeneveld FP, Prins A, Bernsen RM, Bohnen AM, Bosch JL. Strong effects of definition and 
nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male 
urogenital tract problems and general health status. BJU Int. 2000;85:665-71.
104. van Haarst EP, Bosch JL. The optimal duration of frequency-volume charts related to compliance and reliability. 
Neurourol Urodyn. 2014;33:296-301.
105. Gravas S, Bach T, Bachmann A, et al. Guidelines on the Management of Non-Neurogenic Male Lower Urinary 
Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). EAU; 2015.
106. Verbalis JG. Renal physiology of nocturia. Neurourol Urodyn. 2014;33 Suppl 1:S6-S9.
107. Graugaard-Jensen C, Rittig S, Djurhuus JC. Nocturia and circadian blood pressure profile in healthy elderly male 
volunteers. J Urol. 2006;176:1034-9; discussion 9.
108. Hvistendahl GM, Frokiaer J, Nielsen S, Djurhuus JC. Gender differences in nighttime plasma arginine vasopressin 
and delayed compensatory urine output in the elderly population after desmopressin. J Urol. 2007;178:2671-6.
109. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of 
central and peripheral clocks. Annu Rev Physiol. 2010;72:517-49.
110. Negoro H, Kanematsu A, Yoshimura K, Ogawa O. Chronobiology of micturition: putative role of the circadian 
clock. J Urol. 2013;190:843-9.
111. Goessaert AS, Krott L, Hoebeke P, Vande Walle J, Everaert K. Diagnosing the pathophysiologic mechanisms of 
nocturnal polyuria. Eur Urol. 2015;67:283-8.
112. Hjälmås K. Micturition in infants and children with normal lower urinary tract. A urodynamic study. Scand J Urol 
Nephrol Suppl. 1976;37:1-106.
113. Van Hoeck K, Bael A, Lax H, Hirche H, van Gool JD. Circadian variation of voided volume in normal school-age 
children. Eur J Pediatr. 2007;166:579-84.
114. Rittig S, Kamperis K, Siggaard C, Hagstroem S, Djurhuus JC. Age related nocturnal urine volume and maximum 
voided volume in healthy children: reappraisal of International Children’s Continence Society definitions. J Urol. 
2010;183:1561-7.
115. van Venrooij GE, Eckhardt MD, Gisolf KW, Boon TA. Data from frequency-volume charts versus filling cystometric 
estimated capacities and prevalence of instability in men with lower urinary tract symptoms suggestive of benign 
prostatic hyperplasia. Neurourol Urodyn. 2002;21:106-11.
116. Koff SA. Estimating bladder capacity in children. Urology. 1983;21:248.
117. Blanker MH, Groeneveld FPMJ, Bohnen AM, et al. Voided volumes: normal values and relation to lower urinary 
tract symptoms in elderly men, a community-based study. Urology. 2001;57:1093-8.
118. Neveus T, Hetta J, Cnattingius S, et al. Depth of sleep and sleep habits among enuretic and incontinent children. 
Acta Paediatr. 1999;88:748-52.
119. Yeung CK, Diao M, Sreedhar B. Cortical arousal in children with severe enuresis. N Engl J Med. 2008;358:2414-5.
120. Nevéus T, Leissner L, Rudblad S, Bazargani F. Respiration during sleep in children with therapy-resistant enuresis. 
Acta Paediatr. 2014;103:300-4.
121. Cohen-Zrubavel V, Kushnir B, Kushnir J, Sadeh A. Sleep and Sleepiness in Children with Nocturnal Enuresis Sleep. 
2011;34:191-4.
122. Van Herzeele C, Dhondt K, Roels SP, et al. Periodic limb movements during sleep are associated with a lower 
quality of life in children with monosymptomatic nocturnal enuresis. Eur J Pediatr. 2015.
123. Mahler B, Kamperis K, Schroeder M, Frokiaer J, Djurhuus JC, Rittig S. Sleep deprivation induces excess diuresis 
and natriuresis in healthy children. Am J Physiol Renal Physiol. 2012;302:F236-43.
Part I
Nocturia and nocturnal polyuria
Part I
Nocturia and nocturnal polyuria
Chapter 2
The association between nocturia and nocturnal 
polyuria in clinical and epidemiological studies: 
a systematic review and meta-analyses
Ilse Hofmeester1, Boudewijn J. Kollen2, Martijn G. Steffens1, J.L.H. Ruud Bosch3,
Marcus J. Drake4, Jeffrey P. Weiss5, Marco H. Blanker2
1. Department of urology, Isala, Zwolle, the Netherlands
2. Department of general practice, University of Groningen, University Medical
Centre Groningen, Groningen, the Netherlands
3. Department of urology, University Medical Centre Utrecht, Utrecht, The Netherlands
4. University of Bristol, Bristol, UK
5. SUNY Downstate College of Medicine, Brooklyn, NY, USA
Journal of Urology, 2014 Apr;191(4): 1028-33
Chapter 2
The association between nocturia and nocturnal 
polyuria in clinical and epidemiological studies: 
a systematic review and meta-analyses
Ilse Hofmeester1, Boudewijn J. Kollen2, Martijn G. Steffens1, J.L.H. Ruud Bosch3,
Marcus J. Drake4, Jeffrey P. Weiss5, Marco H. Blanker2
1. Department of urology, Isala, Zwolle, the Netherlands
2. Department of general practice, University of Groningen, University Medical
Centre Groningen, Groningen, the Netherlands
3. Department of urology, University Medical Centre Utrecht, Utrecht, The Netherlands
4. University of Bristol, Bristol, UK
5. SUNY Downstate College of Medicine, Brooklyn, NY, USA
Journal of Urology, 2014 Apr;191(4): 1028-33
32
Abstract
Purpose
To determine the relationship between nocturia and nocturnal polyuria (NP). 
Methods
The Pubmed and Embase databases were searched for studies, written in English, German, French 
or Dutch, with original data on adult participants, that investigate the relationship between nocturia 
and NP. A meta-analysis of the difference in mean nocturnal voiding frequencies between patients 
with and without NP was conducted. Next, NP risk was compared between participants with and 
without nocturia. The resulting odds ratio (OR) was subsequently converted to relative risk (RR) with 
95% confidence interval (CI).
Results
From 511 references identified, we selected 78 publications of 66 studies, 15 of which met the 
inclusion criteria of this study. Quality scores of studies were generally high for internal validity, 
but low for external validity. In 7 studies (1,416 participants), we estimated a standardized mean 
difference of 0.59 (95%CI 0.29-0.89) for nocturnal voidings between NP and non-NP participants. 
In 8 other studies (with 2,320 participants) we calculated a pooled OR of 4.99 (3.92-6.37) for NP 
in individuals with nocturia; the corresponding RR, based on a NP risk in the pooled population of 
63.8%, was 1.41 (1.37-1.44).
Conclusions
The association between nocturia and NP is apparent and robust. The clinical importance of the 
association, however, appears to be less obvious than previously suggested based on single studies. 
The observed high prevalence of NP, as a result of the applied ICS definition, may be responsible for 
this discrepancy.
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Introduction
Nocturia is a common and often bothersome symptom in older men and women, associated with 
many conditions [1, 2]. One of the potential mechanisms underlying nocturia is that the nocturnal 
urine production exceeds the nocturnal bladder capacity [3]. Based on this assumption, in 2002 
the ICS consensus committee on nocturia, defined nocturnal polyuria (NP) as an age dependent 
nocturnal urine volume greater than 20% (younger people) to 33% (older people) of 24-hour urine 
volume (in short Nocturnal Polyuria Index, NPi) [4]. These estimates were based on very low quality 
evidence [5, 6].
In recent consensus meetings, the ICS definitions were re-evaluated and left unchanged [7]. Two 
or more nocturnal voidings are considered to be symptomatically bothersome [8]. Recently, Weiss 
et al. suggested that the majority of patients with nocturia have NP [9]. The cross-sectional nature 
of the studied population, and the sole inclusion of patients with nocturia, however, preclude a 
causal inference of this association. Simultaneously, Van Doorn et al. showed that in the general 
population, the majority of men without nocturia also have NP according to the ICS definition [10]. 
Earlier, Swithinbank et al. had shown that NP was much more prevalent than nocturia in women [11]. 
This may be caused by the inclusion of the volume of the first morning void to the nocturnal urinary 
volume measurement. In patients without nocturia, this morning volume may be large. It might also 
suggest that NP is not the cause of nocturia, but rather is a concomitant finding. Furthermore, this 
might suggest that the ICS definition should be re-evaluated. However, it is unclear to what extent 
NP should be considered as the (main) cause of nocturia.
With the availability of drugs aimed to reduce nocturnal urine production, in order to decrease 
nocturnal voiding frequency (NVF), we believe it is important to evaluate and review the actual 
association between nocturia and NP based on study outcomes on this topic, especially when 
considering the potential side effects in older adults. Therefore, we performed a systematic review 
and meta-analysis with the main goal to summarize and analyse the pooled association between 
nocturia and NP. This was evaluated by addressing two research questions. First: what is the 
prevalence of NP for people with and without nocturia? And secondly: what is the nocturnal voiding 
frequency of people with and without NP? 
Methods
 
Search strategy
We performed a systematic review of the literature by searching the Pubmed and Embase database 
without time restrictions. On April 12th 2013, we searched the databases using the terms:  Embase: 
[“nocturnal polyuria” OR [nocturnal AND [“urine production” OR “urine volume”]] NOT child 
Pubmed: [“nocturnal polyuria” OR [nocturnal AND [“urine production” OR “urine volume”]] NOT 
children (MeSH Terms). Two authors (IH and MHB) independently screened title and available 
abstracts. Potential relevant publications were read full text to see if the study included original 
patient data and associations between nocturia and NP were studied. For feasibility reasons, we 
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used the following language restrictions: English, German, French, and Dutch. Case reports, reports 
on specific patient groups (e.g. renal transplantation, diabetes insipidus) and nocturnal enuresis in 
children, as well as studies in laboratory settings, were excluded. 
Selection of studies
Each citation was classified as ‘inclusion’, ‘uncertain’, or ‘exclusion’. In case of disagreement between 
the two reviewers, consensus was reached based on discussion. After this, excluded studies were no 
longer considered. Reference lists of included publications, as well as relevant reviews on this topic, 
were checked for studies not included in the primary search.
Methodological data assessment
We expected that the majority of studies on this topic would be observational studies. Therefore, 
we chose to apply a criterion list for the methodological quality assessment, which was used in an 
earlier systematic review of observational data [12]. This includes three categories: external validity, 
relating to the applicability of study results to other populations, internal validity, implying accurate 
measurement apart from random error, and informativity, indicating the presentation of the reports. 
We tailored this list for this topic by adding criteria on the completeness of data on nocturia and NP, 
including the definition of night, and use of actual sleeping times (see Appendix A).
Data extraction
Two reviewers (IH, MHB) independently extracted results from the included studies. For feasibility 
reasons, the quality assessment was not blinded. In case of disagreement, consensus was reached. 
When no or insufficient information was provided in the article, earlier publications on the same 
study were used for lacking information, if available. No additional searches were performed 
and we did not attempt to get in direct contact with authors of published papers. If more than 
one publication was available from one study, information from those publications was grouped. 
Meta-analyses on the association between nocturia and NP
To address the first study question, we selected studies in which NP was compared between 
participants with and without nocturia, or between participants with various degrees of nocturia. For 
the second study question, we selected studies in which NVF was compared between participants 
with and without NP. Studies including only participants with nocturia (without presenting the 
degree of nocturia) and NP were excluded from the meta-analyses, because no relevant associations 
can be obtained from such studies. 
Meta-analyses were performed with RevMan 5.2 (The Cochrane Library). The percentage of 
participants with NP was compared between patients with and without nocturia. For this purpose, 
2 or more nocturnal voidings were defined as nocturia and less than 2 voidings as no-nocturia. We 
chose to use this cut-off value for NVF, as this represents a threshold at which nocturia is more 
likely to be symptomatically bothersome [8]. The pooled odds ratio (OR) was estimated for available 
studies, using a Mantel-Haenszel Fixed effects model. In this analysis, a significant OR > 1 implies an 
increased risk for NP in participants with nocturia.
As NP is a prevalent disorder, and interpretation of the pooled OR presents a challenge. ORs are 
often interpreted as relative risks (RR), but this is only reliable for non-prevalent conditions. Because 
N
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RRs are better understood by physicians, we converted the OR into RR, using the following formula, 
in which p presents the risk in the studied population and results from the prevalence of the pooled 
population: [13] 
For the comparison of the mean NVF between patients with and without NP, we estimated the 
standardized mean difference, using a random effects model. SMD is presented with 95% confidence 
intervals (CI95%).
Results
Selection of studies
The search strategy resulted in 78 publications with information about 66 studies on this topic (see 
Figure 1). To answer our research questions, 15 studies contained sufficient data for meta-analysis. 
Bibliographic information of these studies is presented in Appendix B.
Methodological quality assessment and description of selected studies
Table 1 shows the quality assessment. On average, 1.73 items (range 0-5) on external validity were 
scored positive. On internal validity this was 5.4 (range 4-6). Cohen’s Kappa coefficient was 0.74. 
Figure 1. Flow chart of study selection
Reference found through  
reference checking: 3
Quality assessment performed on
78 articles 
(on 66 studies)
Exclusion based on full text reading: 9
Sufficient data available for meta-
analyses on nocturnal voiding 
frequency according to NP status:
8 articles
on 7 studies
Sufficient data available for meta-
analyses on prevalence of NP 
according to nocturia status:
13 articles
on 8 studies
Exclusion based on title/abstract: 427
References: 511
Exclusion of duplicate files: 273
Primary search in 
Pubmed: 271
Primary search in 
Embase: 513
Read full text: 84
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Appendix A. Quality score criteria and informativity* 
External validity
Selection of the study population
A Clear description of the research population?**
B Inclusion and exclusion criteria described?***
Participants and non-responders
C Response rate > 70% or sufficient information on non-responders?¥
Relationship with source population?
D Extrapolating results possible for the complete population?¥¥
Description of the study period
E Clear description of the study period? 
Internal validity
Data collection
F Data prospectively collected?
Measurement instrument
G Measuring instrument for nocturia¥¥¥
H Measuring instrument for nocturnal polyuria∞
I Measuring period: length of FVC or questionnaire presented?
J Definition of night described and actual sleeping times (as reported on FVC) used?
Confounders
K Confounders described?∞∞
Informativity#
L Clear theoretical introduction with relevant references to support the research question?
M Aims of the study clearly described?
N Research questions being answered?
O Definition of nocturia clearly described, or nocturnal frequencies clearly presented (without a cut-
off for nocturia)?
P Definition of NP clearly described, or nocturnal urine production, nocturnal voided volumes, or 
nocturnal polyuria indices clearly presented (without a cut-off for abnormal values)?
Q Clear description of the way data were analysed?
R Enough original data to evaluate their interpretation
* Items were scored positive if clear information was presented in the articles. Unclear data are 
presented as “?” and consequently scored negative for the quality score summation.
**  Clear description of source and two or more of the following: age distribution, relevant comorbidity, 
medication
*** Scored positive if both inclusion and exclusion criteria were provided
¥ Sufficient information on non-responders: were reasons for non-response studied and presented, 
including information on age distribution, gender, main topic under study?
¥¥ Did the study selection procedure result in a representative sample of the study population?
¥¥¥ Data on nocturnal frequency collected through FVC or validated questionnaire
∞ Data on NP or nocturnal voided volumes collected through FVC
∞∞ Description of confounders not necessarily including actual statistical adjustment for confounders.
#  Informativity was not included in the quality score. 
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For both meta-analyses, we included in total one RCT, three non-randomized trials, two case control 
studies and nine cross-sectional observational studies totalling 3,736 participants (Table 2). Five 
studies were community-based, one originated from primary care populations, 4 from secondary 
and/or tertiary care and in 5 studies the setting of the participants was not clear. In 8 studies, the 
study period was not reported. In 5 studies, only participants with nocturia were included. Most 
studies used a frequency volume chart (FVC) for the collection of NVF and voided volumes.
Comparison of NP prevalence between people with and without nocturia
Eight studies with 2,320 participants (1,503 male, 817 female) were available for the comparison 
of the NP prevalence between people with and without nocturia [10, 11, 14-19]. A funnel plot 
showed no indication of publication bias. As presented in Figure 2, this equation yielded a pooled 
OR of 4.99 (3.92-6.37). Estimated RR, based on the NP risk in the studied population of 63.8%, was 
1.41 (1.37-1.44). Excluding the largest study from these analyses did not impact the results (5.10 
[3.78-6.88]). There was a small difference between the pooled OR of the four studies using the 
NPi33 definition (5.45 [4.07-7.32]) and the 2 studies using the NPi35% definition (3.71 [1.74-7.90]). 
Subgroup analyses showed no apparent differences (p=0.72) between the 7 descriptive studies (OR 
4.93, 3.81-6.37) and the included case control study (OR 5.68, 2.74-11.77).
Comparison of NVF between people with and without NP
Seven studies totalling 1,416 participants (368 male, 43 female [20-25]; one study with 1,005 male 
and female participants did not present gender differences [26]) were available for the comparison 
of NVF between participants with and without NP. Funnel plot analysis showed no indication of 
publication bias. Pooled analyses generated a standardised mean difference in NVF of 0.59 (95% CI 
0.29-0.89). Subgroup analyses showed no significant difference (p=0.28) between the two descriptive 
studies and three non-randomised trials: SMD, respectively, 1.32 (0.55-2.09) and 0.79 (0.21-1.37).
For both comparisons, the selected studies did not present gender-specific findings, making 
subgroup analyses based on gender impossible.
Figure 2. Risk (OR) of nocturnal polyuria according to nocturia status. Pooled Odds Ratio with 95% confidence interval 
(CI), resulting from meta-analyses using Mantel Haenszel Fixed effects model. Nocturia defined as ≥2 voidings per night. 
Presentation sorted on applied definition of nocturnal polyuria. NPi: nocturnal polyuria index; NUP: nocturnal urine 
production; UP: urine production; NUV: nocturnal urine volume; BW: body weight.
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Figure 3. Standardised mean difference in nocturnal voiding frequency between participants with and without nocturnal 
polyuria (NP). Standardised mean difference with 95% confidence interval (CI) in nocturnal voiding frequency between 
participants with and without nocturnal polyuria (NP), resulting from meta-analyses using a random effects model. 
Presentation in order of publication year.
Discussion
In this systematic review and meta-analyses the observed association and difference between 
nocturia and NP is conclusive: the relative risk for NP was 1.43 for patients with NVF ≥ 2, compared 
to those with less nocturnal voidings. It appeared, however, that the mean NVF for patients with NP 
is only 0.59 higher than for those without NP. 
To the best of our knowledge, this is the first publication investigating the association between 
NP and nocturia in a systematic way. Previous reports, including a number of reviews, were 
limited to single studies, or were non-systematic, lacking quality assessment and critical review 
of earlier publications [1, 7]. As nocturia is believed to have a multifactorial origin, it should be 
remembered that there are other possible causes of nocturia, such as reduced bladder capacity 
and sleep quality. In only a few of the included studies in this review, such factors were considered. 
The search strategy appeared to be both specific and sensitive. That is, only three studies were not 
included in the primary search, but were identified based on reference checking. Due to the applied 
language restrictions, we may not have identified all relevant publications on this subject. In our 
study, a large number of publications originated from Asian countries. Therefore, we cannot rule out 
that other available publications were not included in our review.
The external validity of most studies included in our review is considered a problem. This even 
pertained to the report on the RCT, for which clarity of reporting is crucial. Sufficient information on 
the background of study population was provided in only two studies. We argue that results of only 
three studies could be extrapolated to the population at large. Internal validity and informativity 
scores were generally high. Conspicuously, NP and nocturia were not defined in one and three 
studies, respectively. In one study, night was undefined and in one fixed sleeping time periods were 
used. The ICS definition for NP, or definitions with closely approximated cut-off values, was the most 
often used in the included studies. We were somewhat surprised to notice that in many of the 
78 assessed publications, unusual comparisons were made, such as NVF between author -defined 
groups of people with and without nocturia, and mean urine production or voided volumes between 
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NP and non-NP participants. 
Only 15 studies were available for meta-analyses. This reflects a limitation in available data in 
publications on this topic. A large number of studies included only participants with nocturia, or only 
participants with NP. From such studies, no conclusions can be drawn on the possible association 
between nocturia and NP. It appeared that for both analyses, study results were quite similar. In the 
comparison of NVF between NP and non-NP, only one out of seven studies showed a lower NVF 
in NP-participants. All included studies on the comparison of NP-prevalence according to nocturia 
status showed a clear increased risk for NP in people with nocturia. It should be noticed that included 
data were based on cross sectional studies. The results of cross-sectional studies do not allow to 
make any causal inferences. Although non-causal associations may be of clinically importance as 
well, the reported OR should be interpreted with some caution. Additionally, it should be stressed, 
that the observed ORs must not be interpreted as a RRs, which is often done in clinical research [13]. 
Especially, due to the high prevalence of NP in the pooled study population (63.8%), the OR only 
reflects a relative risk of 1.43. 
This small relative risk we observed is in accordance with the small difference in NVF between 
individuals with and without NP. This shows that the clinical relevance of the association between 
nocturia and NP is less obvious than previously suggested. We believe that this might reflect a problem 
with the applied ICS definition of NP. This consensus definition was based on low quality evidence 
[5, 6]. Although applying this definition results in a majority of nocturia patients being diagnosed 
with NP [9], it is now clear that the majority of people  also meet the criteria for NP. In fact, the 
prevalence of NP according to the ICS definition is higher than the prevalence of (symptomatically 
bothersome) nocturia [11]. Therefore, the ICS definition has a very limited discriminative value in 
patients with nocturia. To date, other NP definitions also lack an evidence base. For future studies 
and for daily practice, it is important that definitions of diseases or conditions are based on a solid 
pathophysiological background, but also on thoroughly testing of definitions in different settings.
Both nocturia and NP vary over time [10, 27]. Only recently, Van Doorn et al. presented the longitudinal 
data on possible risk factors for nocturia from their population-based study [28]. This clearly showed 
that NP was an important predictor for the presence of nocturia. In their analyses, two definitions 
of NP were included: i.e. one based on the ICS definition (a ratio between daytime and nocturnal 
urine production) and one on a cut off value of 90 ml/hr for nocturnal urine production (NUP90) 
(not considering daytime urine production). Both definitions appeared to be of importance, without 
showing statistical interaction, possibly reflecting a difference of principle. Although the ORs for both 
definitions in that publication were comparable, the corresponding RR differed. Due to a relatively 
low prevalence of NUP90 (17.5%), its corresponding RR is relatively high at 3.2, whereas the RR for 
the ICS definition is much lower (RR 1.2) as a result of its high baseline prevalence rate of 77.8% 
[10]. Likewise, the clinical impact of the two definitions differs as well. Still, because no study has yet 
replicated the analyses performed by Van Doorn et al., it is unclear how this definition performs in 
other populations, for example in secondary care.
N
octuria and nocurnal polyuria: association
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Conclusions
Despite the methodological problems encountered in this review, we conclude that the association 
between nocturia and NP is apparent and robust. The clinical importance of the association, however, 
appears to be less obvious than previously suggested based on single studies. The observed high 
prevalence of NP, as a result of the applied ICS definition, may be responsible for this discrepancy.
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Abstract
Introduction
To systematically review and evaluate the impact of the ICS-2002 report on standardisation of 
terminology in nocturia, on publications reporting on nocturia and NP. In 2002, the International 
Continence Society (ICS) defined nocturnal polyuria (NP) as a NP index (nocturnal urine volume/total 
24-h urine volume) exceeding 0.2-0.33, depending on age.
Methods
In April 2013 the Pubmed and Embase databases were searched for studies (in English, German, 
French or Dutch) based on original data and adult participants, investigating the relationship between 
nocturia and NP. A methodological quality assessment was performed, including scores on external 
validity, internal validity and informativity. Quality scores of items were compared between studies 
published before and after the ICS-2002 report.
Results
The search yielded 78 publications based on 66 studies.  Quality scores of studies were generally 
high for internal validity (median 5, IQR 4-6) but low for external validity. Following publication of the 
ICS-2002 report, external validity showed a significant change from 1 (IQR 1-2) to 2 (1-2.5, p=0.019). 
Nocturia remained undefined in 12 studies. Nineteen different definitions were used for NP, most 
often being the ICS (or similar) definition: this covered 52% (n=11) of studies before and 66% (n=27) 
after the ICS-2002 report.  Clear definitions of both nocturia and NP were identified in 67% and 76% 
before, and in 88% and 88% of the studies, respectively, after the ICS-2002 report.
Conclusions
The ICS-2002 report on standardisation of terminology in nocturia appears to have had a beneficial 
impact on reporting definitions of nocturia and NP, enabling better interpretation of results and 
comparisons between research projects. Because the external validity of most of the 66 studies 
is considered a problem, the results of these studies may not be validly extrapolated to other 
populations. The ICS definition of NP is used most often. However, its discriminative value seems 
limited due to the estimated difference of 0.6 nocturnal voidings between individuals with and 
without NP. Refinement of current definitions based on robust research is required. Based on 
pathophysiological reasoning, we argue that it may be more appropriate to define NP based on 
nocturnal urine production or nocturnal voided volumes, rather than on a diurnal urine production 
pattern.
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Introduction
Nocturia is a common and often bothersome symptom in older men and women. It is associated 
with many conditions, including depression and obstructive sleep apnoea [1-3], and it is widely 
acknowledged that nocturia has multiple aetiologies. Nocturnal polyuria (NP) is often considered to 
be an important cause of nocturia, especially when the nocturnal urine volume exceeds the nocturnal 
bladder capacity [4]. In the 2002 consensus document on nocturia, the International Continence 
Society (ICS) subcommittee on the standardisation of terminology in nocturia (hereafter referred to 
as the ICS-2002 report) provided relevant definitions on this topic. As such, NP was defined as an 
age-dependent nocturnal urine volume ≥ 20% of 24-h urine volume in younger people, and up to 
33% in older people (in short: the Nocturnal Polyuria Index, NPi) [5]. However, this definition was 
based on limited evidence [6, 7].
In addition to the ICS definition of nocturia (i.e. awakening at night to void), two or more nocturnal 
voidings are increasingly considered to be the threshold at which nocturia is more likely to be 
symptomatically bothersome [8]. 
Until recently, it was unclear to what extent NP should be considered as the (main) cause of nocturia. 
To clarify this issue we published a systematic review and meta-analyses [9]. This latter study 
reported a relative risk of NP of 1.4 for people with two or more nocturnal voidings compared to 
those with less nocturnal voidings, based on the ICS definition of NP or closely related definitions 
(NPi 0.30, 0.35). The mean nocturnal voiding frequency of people with NP was 0.6 higher than in 
individuals without NP [9]. In most patients this small difference may not be considered clinically 
relevant, although no threshold value exists for improvement in nocturia.
The current systematic review examines the completeness of reports on nocturia and NP. In 
particular, we aimed to evaluate the impact of the ICS-2002 report on the applied definitions for 
nocturia and NP in relevant publications. 
Methods
 
The design of the systematic review and meta-analyses has been published in detail elsewhere [9]. 
On April 12th 2013 the Embase and Pubmed databases were searched using the terms: [“nocturnal 
polyuria” OR [nocturnal AND [“urine production” OR “urine volume”]]. 
Two authors (IH and MHB) independently screened the title and available abstracts of relevant 
studies (published in English, German, French, or Dutch). Then, the full text of potentially relevant 
publications was read to establish whether the study included original patient data and whether 
associations between nocturia and NP were investigated. Excluded were case reports, reports on 
nocturnal enuresis in children or specific patient groups (e.g. renal transplantation, or diabetes 
insipidus), as well as studies performed in a laboratory setting. 
We classified each citation as ‘inclusion’, ‘uncertain’, or ‘exclusion’. In case of disagreement between 
the two reviewers, consensus was reached based on discussion. After this, excluded studies were no 
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longer considered. Reference lists of the included publications, as well as relevant reviews on this 
topic, were checked for studies not included in the primary search. Publications before and after 
publication of the ICS-2002 report on the standardisation of terminology in nocturia were included. 
Methodological data assessment
As most studies on this topic were expected to be observational studies, we chose to apply the 
criterion list for the methodological quality assessment used in an earlier systematic review of 
observational data [10]. This includes three categories: external validity, related to the applicability of 
the study results to other populations, internal validity, implying accurate measurement apart from 
random error, and informativity, dealing with the presentation of the reports. For the present study, 
we tailored this list by adding criteria on the completeness of data on nocturia and NP, including the 
definition of ‘night’, and use of actual sleeping hours (Table 2).
Data extraction
Two reviewers (IH, MHB) independently extracted results from the included studies. If required, 
earlier publications on the same study were consulted to substitute/complete missing information. 
No additional searches were performed and no attempts made to contact the authors of the included 
publications. If more than one publication was available based on the same study, information from 
those publications was grouped. 
Comparison of studies according to ICS definitions
To study the possible impact of the ICS-2002 report, completeness of publications (assessed by the 
above-mentioned quality scores) was compared between studies published before and after March 
2002. For this, we used the reported date of data collection, date of first submission or acceptation, 
or date of publication. For the latter, a two-year period was subtracted, reflecting an estimated 
average time delay between data collection and publication. 
In those studies in which data collection started in 2002 but the month was not specified, it is unclear 
whether data collection took place before or after publication of the ICS-2002 report. Therefore, 
these studies were excluded from the present ‘study’.
Statistical analysis
As quality scores were not normally distributed, these scores are presented as median scores with 
interquartile ranges (IQR). Differences in internal and external validity scores of studies before and after 
the ICS-2002 report were tested using the Mann-Whitney U-test. Subgroup analyses were performed 
for the different study designs. Additionally, for both publication eras (i.e. pre- and post ICS-2002 report), 
we compared the quality scores between different study types, expecting higher scores for drug trials. 
For this analysis we grouped randomised controlled trials (RCT) and non-randomised trials (such as 
open label studies) on the one hand, and case control studies and descriptive studies on the other. 
For the sub-items of the quality scores, numbers are presented representing the amount of 
studies that scored positive. Fisher’s exact test was used to test the differences before and after 
the ICS-2002 report for the most relevant sub-items (i.e. the definition of nocturia and NP). 
Reported p-values are two-sided and a p-value of <0.05 was considered statistically significant. 
Level of agreement (percentage) was calculated to denote the inter-observer agreement. Statistical 
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analyses were performed using IBM SPSS Statistics 20.
Results
Selection and description of studies
The search strategy resulted in 78 publications with information on 66 studies, including 3 
studies found by reference checking (Figure 1). Bibliographic information of these studies is 
presented in Appendix A. All these studies were published in the English language. Of the 
66 studies, 21 were published before and 41 after the ICS-2002 report; note that 4 of the 66 
studies were excluded from the analysis of differences between pre- and post ICS publications. 
We included 16 RCTs (5 before and 10 after the ICS-2002 report, 1 excluded from ICS analysis); 19 
non-randomized trials (4 vs. 15), 5 case control studies (2 vs. 3), and 26 cross-sectional observational 
studies (10 vs. 13, 3 were excluded). 
Study characteristics are presented in Table 1. A total of 20,291 participants were included, the 
majority of which originated from secondary or tertiary care populations. In 40 studies, [8 (38% of all 
Reference found by 
reference checking: 3
Quality assessment performed on
78 articles 
(based on 66 studies)
Exclusion based on full-text reading: 9
41 studies performed after the 
ICS-2002 consensus report
21 studies performed before
the ICS-2002 consensus report
Exclusion based on title/abstract: 427
References: 511
Exclusion of duplicate files: 273
Primary search in 
Pubmed: 271
Primary search in 
Embase: 513
Full text: 84
4 studies not included in the comparison of 
studies performed before and after the ICS-
2002 consensus report
Figure 1. Flow chart of study selection. 
(ICS: International Continence Society) 
54
 
Total Before 
ICS-2002
After  
ICS-2002
n (%) n (%) n (%) p-value
  66 21 41
External validity
Selection of the study population
A Clear description of the research population?** 5 (8) 1 (5) 4 (10)
B Inclusion and exclusion criteria described?*** 54 (82) 16 (76) 34 (83)
Participants and non-responders
C Response rate >70% or sufficient information on non-responders?¥ 16 (24)  3 (14) 12 (29)
Relationship with source population?
D Extrapolating results possible for the entire population?¥¥ 7 (11) 2 (10) 5 (12)
Description of the study period
E Clear description of the study period? 29 (44) 7 (33) 21 (51)
Total external validity score: med [interquartile range] 2 [1-2] 1 [1-2] 2 [1-2.5] 0.019
Internal validity
Data collection
F Data prospectively collected? 63 (95) 20 (95) 39 (95)
Measurement instrument
G Measuring instrument for nocturia¥¥¥ 58 (88) 17 (81) 37 (90)
H Measuring instrument for nocturnal polyuria∞ 58 (88) 17 (81) 37 (90)
I Measuring period: length of FVC or questionnaire presented? 54 (82) 15 (71) 35 (85)
J Definition of night described and actual sleeping times (as 
reported on FVC) used?
43 (65) 13 (62) 26 (63)
Confounders
K Confounders described?∞∞ 36 (55) 14 (67) 20 (49)
Total internal validity score: med [interquartile range] 5 [4-6] 5 [3-6] 5 [4-6] 0.944
Informativity
L Clear theoretical introduction with relevant references to 
support the research question?
63 (95) 19 (90) 40 (98)
M Aims of the study clearly described? 60 (91) 19 (90) 37 (90)
N Research questions adequately answered? 60 (91) 19 (90) 37 (90)
O Definition of nocturia clearly described, or nocturnal 
frequencies clearly presented (without a cut-off for 
nocturia)?
54 (82) 14 (67) 36 (88) 0.086
P Definition of NP clearly described, or nocturnal urine 
production, nocturnal voided volumes, or NP indices clearly 
presented (without a cut-off for abnormal values)?
56 (85) 16 (76) 36 (88) 0.285
Q Clear description of the way data were analysed? 57 (86) 17 (81) 36 (88)
R Enough original data to evaluate their interpretation 51 (77) 14 (67) 33 (80)
Total informativity score: med [interquartile range] 7 [5.75-7] 7 [4-7] 7 [6-7] 0.389
 
Table 2. Comparison of quality score items for studies published before and after the ICS-2002 report. 
P-values for the overall scores were computed by the Mann-Whitney U-test, for sub-score O and P by Fisher’s exact test. 
FVC: frequency-volume chart, IQR: interquartile range, ICS: International Continence Society ; Med: median, NP: nocturnal 
polyuria. 
* Items were scored positive if clear information was presented in the articles. Unclear data are presented as “?” and 
consequently scored negative for the quality score summation. 
** Clear description of source and two or more of the following: age distribution, relevant comorbidity, medication 
*** Scored positive if both inclusion and exclusion criteria were provided 
¥ Sufficient information on non-responders: were reasons for non-response studied and presented, including information 
on age distribution, gender, main topic under study? 
¥¥ Did the study selection procedure result in a representative sample of the study population? 
¥¥¥ Data on nocturnal frequency collected through FVC or validated questionnaire 
∞ Data on NP or nocturnal voided volumes collected through FVC 
∞∞ Description of confounders not necessarily including actual statistical adjustment for confounders. 
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studies before the ICS-2002 report) vs. 30 (78% of all studies after the ICS-2002 report], participants 
with nocturia were included but no participants without nocturia.
Internal/external validity and informativity scores
Table 2 shows the quality assessment scores for all studies, categorised according to the two 
publication eras (i.e. before and after the ICS-2002 report). Agreement between the two observers 
was 86% for all quality items. For all 66 included studies the median score for external validity was 2 
(IQR 1-2); the internal validity score was 5 (4-6), and the informativity score was 7 (5.75-7). 
After the ICS-2002 report, the external validity score showed a significant change for all the studies, 
whereas the internal validity and informativity scores showed no significant change (Table 2). No 
differences between study types were apparent for the two publication eras (Table 3), and there was 
no change over time for the separate study types. However, for internal validity scores there was a 
distinct difference between the drug studies and non-drug studies, with higher scores for the latter 
before the ICS-2002 report. After the ICS-2002 report, these differences were absent, mostly due to 
an increase in quality scores for the RCTs (Table 3). For the total group of studies, the change over 
time was not significant (Table 2). 
Completeness of data
In 57 studies, the setting or background of the study population was unclear: 20 (95% of all studies 
before the ICS-2002 report) vs. 37 (90% of all studies after the ICS-2002 report). In 37 studies the 
study period was not reported: 14 (67%) vs. 20 (49%).  Most studies used a frequency-volume 
chart (FVC) for both the collection of nocturnal voiding frequency and for voided volumes. In 11 
reports the method of data collection was unclear: 4 (19%) vs. 3 (7%), whereas in 5 studies nocturia 
questionnaires were used: 1 (5%) vs. 4 (10%). In 17 studies, the definition of ‘night’ was unclear. In 
Before  
ICS-2002
Difference* After  
ICS-2002
Difference* Difference before and 
after ICS-2002*
External validity score
RCT 1 (1-1.5) 2 (1-3) 0.165
Non-RCT 1 (1-1.75) 2 (2-2) 0.124
0.754 0.778
Descriptive study 1.5 (0.75-2) 2 (1-2.5) 0.738
Case control study 1 (1-1) 3 (1-..) 0.400
Internal validity score
RCT 3 (3-4.5) 5 (4-5) 0.055
Non-RCT 4.5 (1.75-5.75) 5 (3-5) 0.736
0.034 0.181
Descriptive study 6 (4.75-6) 5 (4-6) 0.232
Case control study 4 (2-..) 6 (6-6) 0.400
Informativity score
RCT 7 (4-7) 7 (6.75-7) 0.513
Non-RCT 5 (4-6.75) 6 (5-7) 0.307
0.702 0.453
Descriptive study 7 (4.75-7) 6 (6-7) 0.483
Case control study 4.5 (3-..) 7 (5-..) 0.400
 
Table 3. Comparison of quality scores before and after the ICS-2002 report for the different study types. 
Expressed in medians and interquartile range 
*p-values for the Mann-Whitney U test, for comparisons between study types within pre- or post-ICS era, or comparison of 
study type scores between the two eras. ICS: International Continence Society, RCT: randomised controlled trial 
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41 studies, actual sleeping hours were used. The duration of the FVC was undefined in 8 studies.
Applied definitions of nocturia and NP
The following nocturnal voiding frequencies were used to define nocturia: ≥ 1 nocturnal voidings 
(16 studies), ≥ 2 (34 studies), ≥ 3 (7 studies), and ≥ 4 nocturnal voidings (1 study). However, several 
studies used more than one definition (Table 1). In 12 studies, nocturia remained undefined: 7 (33%) 
vs. 5 (12%). Nineteen different definitions for NP were used (Table 4); again, several studies used 
more than one definition. Most often (n=41) the ICS definition for older people (i.e. NPi >0.33) or 
definitions similar to that (0.30, 0.35) were used; this covered 52% (11) and 66% (27) of the included 
studies, before and after the ICS-2002 report, respectively.
 
Reporting of clear definitions of both nocturia and NP increased after publication of the ICS-2002 
report; however, this increase was not significant, 67% vs. 88% (Fisher’s exact test p=0.086) and 76% 
vs. 88 (p=0.285), respectively.
Nr. of studies
Nocturnal polyuria index (NPi)
NPi > 0.2 (if < 60 years) or > 0.3 (if > 60 years) 1
NPi > 0.30 1
NPi > 0.33 26
NPi > 0.35 14
NPi > 0.53 1
NPi without cut-off 4
modified NPi > 0.33, based on 8 hr of sleep 2
Nocturnal urine volume (NUV) definitions
NUV > 0.9 ml/min 2
NUV > 0.9 ml/min * sleep duration 1
NUV > (sleeping hours / 24 h)*24 h 1
NUV / total volume > sleeping hours/24 h 1
NUV > 10 ml/kg body weight 2
NUV > 6.4 ml/kg 1
Nocturnal urine production (NUP) definitions
NUP > 2 standard deviations of the mean (of the controls) 1
NUP > 90 ml/h 1
Nocturia index (Ni; NUV/maximum voided volume)
Ni > 1 2
Ni > 1.5 1
Other
"Passing large amounts of urine at night" 1
 Nocturnal Bladder Capacity index 2
Proportion NUP rate (ml/min)/daytime UP rate > 1 1
NP not defined 9
 
Table 4. Various definitions used for nocturnal polyuria in the 66 included studies.  
Several studies used more than one definition for nocturnal polyuria. Therefore, these 
numbers total to more than 66 (the number of studies included).
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Discussion
This systematic review shows that the quality of reports on nocturia and NP increased after publication 
of the ICS-2002 report. This document may have been instrumental in encouraging researchers to 
be clearer about the applied definitions and data collection. This is similar to the study of Cartwright 
and Cardozo showing that the 2002 ICS standardisation report on lower urinary tract terminology 
resulted in a significant change in the usage of this terminology [11].
 
Nevertheless, we encountered several problems that still need attention. For example, in most 
studies the external validity is considered a major problem. Low external validity impairs the ability 
to extrapolate the results to the general population. In our opinion, the results of only 7 of the 66 
studies might be extrapolated to the population at large; for example, sufficient information on the 
background of the study population was provided in only 4 studies.
 
In contrast to the low external validity scores, the internal validity scores were generally 
high. This implies that measurements in the selected studies were accurate, apart from 
random error. However, even with these high scores, some essential points were lacking. For 
example, in 17 studies, ‘night’ was not defined, or fixed sleeping time periods were used; 
this even included RCTs for which unambiguous reporting is crucial, as they are often used to 
make treatment choices. Additionally, NP and nocturia were not defined in 9 and 12 studies, 
respectively. With a variety of definitions available and being applied, it is important to know 
which definition is used in each study to enable meaningful comparison between studies. 
Overall, the majority of studies used a FVC, which is considered the gold standard for collecting 
information on various measures like urinary production and frequency; this is in line with the ICS 
recommendations. However, the duration (measurement period) of the FVC needs to be sufficient 
and clear; this was not the case in all studies.
Effects of the ICS-2002 report on standardisation of terminology in nocturia
After the ICS-2002 report the external validity scores showed a (significant) 1-point increase (on a 
5-point scale). We observed an increase of the 25th percentile of 1 and 2 points for, respectively, 
internal validity (on a 6-point scale) and informativity (on a 7-point scale). 
 
From our data no causal association can be shown between publication of the ICS-2002 report and 
the change of quality scores. In the ICS-2002 report, although no specific guidelines for reporting 
are provided, definitions with background information were given. For the majority of the studies, 
the ICS definition for NP for older people, or closely related definitions, were used. Before the 
publication of the consensus statement this covered 52% of the included studies compared with 
66% after this publication. Moreover, after the ICS-2002 report various other definitions were also 
used. The various definitions can be grouped according to the concept on which they are based 
(Table 4). Notably, none of these definitions have been sufficiently validated in different populations.
Nocturnal polyuria index
The nocturnal polyuria index (NPi), as proposed by the ICS, reflects a ratio between night time 
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urine production and the 24-h voided volume. This definition was based on a small number of low-
quality studies, including small groups of patients: i.e. 9 enuretics and 9 healthy controls [6], and 24 
young and 21 elderly patients [7]. This definition reflects alterations in the diurnal pattern, which is 
apparent in men aged ≤ 65 years but not in older men [12].  
 
Based on the ICS definition, NP was present in most patients with nocturia participating in drug 
trials [13]. On the other hand, the majority of both community-dwelling men and women without 
nocturia also have NP [14], [15].  Van Haarst and Bosch challenged the ICS definition by proposing a 
different cut-off value for the NPi, based on a study with healthy volunteers [16]. In that study, the 
NPi was normally distributed and showed a wide variation. They proposed the upper limit of the 
95% confidence interval (CI), being 0.53, to be the cut-off value for NP [16]. Although this intuitively 
seems a sensible way to express a definition, this results in only a very small proportion of the 
population having a deviating symptom. In various other conditions (e.g. obesity and hypertension), 
definitions differentiate in clinically-relevant deviations instead of 95% CIs of the general population 
[17, 18].
 
Our earlier meta-analyses showed that people with NP according to the ICS definition experience 0.6 
more voids at night than individuals without NP [9]. Hence, the ICS definition probably has a limited 
added and clinical value. A possible explanation for this is that the first morning void is included in 
the night-time urine production estimation, but not in the nocturnal voiding count. Hence, people 
with a large first morning void, who do not get up at night, can easily be categorised as having NP 
without having nocturia. 
 
To evaluate the actual clinical value of the additional 0.6 nocturnal voidings that people with NP 
experience according to the ICS definition, more studies are needed to assess the quality of sleep 
patterns. Only 8 of the 66 studies investigated the number of hours of undisturbed sleep (HUS). 
If waking 0.6 times less often would result in more HUS and/or initial slow wave sleep, this could 
have had an impact on well-being and daytime alertness [19]. Possibly, this together with the actual 
number of nocturnal voids could be responsible for the observed difference between the healthy – 
or non-bothersome symptom – population and the group of patients with bothersome symptoms of 
nocturia. If nocturnal voidings are present, but sleep is not considerably disturbed, patients may not 
necessarily seek medical advice. 
Nocturnal urine volume and nocturnal urine production definitions
Ten of the studies used a definition based on night-time assessments only. In this way, inclusion 
of the first morning voided volume in night-time estimations results in the same problems as for 
the NPi calculations. Some of the used definitions take the amount of sleeping hours into account. 
The reference value of nocturnal urine volume > 0.9 ml/min was based on a study in young 
men (aged 25-35 years) [7, 20]. We believe that these healthy young subjects cannot serve as a 
reference for older people, because of the diurnal variation of urine production with ageing [12]. 
The reference value of nocturnal urine production >90 ml/h is based on the Krimpen study, in 
which 1,432 FVCs from men aged 50-78 years from the general Dutch population were collected at 
baseline. The nocturnal urine production was estimated as the mean hourly urine production from 1 
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AM to 6 AM, in which 90% of the men were asleep [21]. The cut-off value resulted from multivariable 
logistic regression analyses in which various cut-off values were entered. The model including the 
90 ml/h value was determined to be the best model, based on the highest percentage of explained 
variance. However, even this best cut-off value appeared to have only modest discriminative value in 
cross-sectional analyses [21]. Although rigorous analyses were the basis for this definition, additional 
testing in other patient groups has not yet been performed.
Nocturia index
The nocturia index (applied in three studies) represents the nocturnal urine volume divided by 
the maximum voided volume. If the nocturnal volume exceeds the maximum voided volume (or 
functional bladder capacity), nocturia will occur. In the FVC study in asymptomatic volunteers, the 
nocturia index was the best predictor of nocturia [16]. However, in our opinion, this cannot be used 
for NP because this definition is more a measure of the association between bladder capacity and 
nocturnal urine volume as a possible explanation for nocturia.
Other definitions for nocturnal polyuria
The Nocturnal Bladder Capacity index (NBCi) was used in two studies. The NBCi is calculated by 
subtracting the predicted number of nocturnal voids from the actual number of nocturnal voids 
(nocturia index -1) [22]. In this definition, the problem of the first morning void (included in volume 
assessment but not in frequency counting) is fixed. The NBCi reflects the essence of the association 
between NP and nocturia. Although, strictly speaking, the NBCi is not a definition for NP it has been 
used as such [4]. We argue that the NBCi cannot be used as an explanatory variable for nocturnal 
voiding frequencies, because the formula for the NBCi incorporates the actual nocturnal voiding 
frequencies. However, the NBCi may well be valuable for other comparisons, such as sleep quality 
or quality of life. 
Many of the studies included in this review only contained data on patients with nocturia. A distinction 
must be made between data derived from clinical samples consisting of patients suffering from 
bothersome symptoms of nocturia, and data from individuals showing signs without necessarily 
reporting them symptomatically, the latter usually originating from study populations taken from 
the general public. Important to notice is that in many clinical studies included in this review, it 
is unclear whether patients were included with bothersome symptoms of nocturia, or based on 
nocturnal voiding frequency without bothersome signs/symptoms. We reiterate that the definitions 
of illnesses or diseases should be applicable to all patients included. 
Conspicuously, the ICS definitions of nocturia and NP were all based on small clinical samples. 
From these samples it appeared that NP (ICS definition) was the cause of nocturia in the greater 
majority of patients with nocturia. When applying these definitions to an unselected population it 
appeared that not only people with nocturia (as a symptom, not particularly bothersome), but also a 
majority of those without nocturia were classified as NP based on the ICS definition. Therefore, this 
latter casts doubt on the validity of this definition. On the other hand, other definitions have been 
suggested in general population based studies [21]. However, these definitions lack any validation 
in clinical samples. As a consequence, to date no conclusive and valid definition on NP is available 
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which can be recommended.
We believe that a validation procedure for the definition of NP is needed. This should include the 
assessment of both its discriminative value, as well as its prognostic value. Re-analyses of available 
databases, derived from population based samples, clinical samples, and randomised controlled 
trials may be suitable for this. The previously suggested definitions (other than the ICS definition) 
could be applied to these databases, to test their validity. This procedure should include participants 
with or without nocturnal voidings (as a symptom), as well as patients with or without bothersome 
syptoms of nocturia. Data derived from frequency-volume charts are vital for such analyses, and 
prospective cohort studies are the preferred study design.  
Conclusions
The ICS-2002 report on the standardisation of terminology in nocturia appears to have had a 
beneficial impact on the reporting of definitions of nocturia and NP in relevant publications, enabling 
a better interpretation of results and comparisons between studies. However, all used definitions of 
NP lack validation procedures. The discriminative value of the ICS definition, yielding a difference 
of 0.6 nocturnal voidings between individuals with and without NP seems limited [9] and needs 
to be established in future studies using outcomes relevant to the quality of sleep and daytime 
performance. Refinement of current definitions based on robust research remains desirable. Based 
on pathophysiological reasons we argue that it may be more appropriate to define NP based on 
nocturnal urine production or nocturnal voided volumes rather than on a diurnal urine production 
pattern.
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 d
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 b
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 d
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 d
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l d
ys
fu
nc
tio
n 
(s
er
um
 c
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 c
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 c
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l c
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 m
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 m
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 n
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re
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 r
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 r
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ra
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 m
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ra
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 d
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 d
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m
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ay
s)
ni
gh
t
N
oc
tu
ri
a
N
P
XX
XI
II
20
09
U
SA
m
en
w
it
h 
no
ct
ur
ia
PC
A
ge
 ≥
 5
0,
 n
oc
tu
ri
a
ex
pe
ct
ed
 s
ur
vi
va
l o
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) c
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 c
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os
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 c
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l c
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, m
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 d
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 p
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ad
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 m
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m
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 p
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f b
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 c
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f p
ro
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re
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 d
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w
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 o
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de
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 c
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at
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 d
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, d
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l f
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f d
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 p
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 o
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 d
is
or
de
rs
 a
ff
ec
ti
ng
 
LU
T 
fu
nc
ti
on
st
ud
y 
1:
 Q
m
ax
 <
10
 m
l/
se
c,
 P
V
R
>3
0 
m
l 
st
ud
y 
2:
 n
ot
 d
efi
ne
d
67
 +
 3
9 
/ ?
?
?
FV
C
FV
C
1
ac
tu
al
2 
or
 m
or
e 
vo
id
s
NU
V/
bo
dy
 
w
ei
gh
t 
>1
0 
m
l/
kg
LI
I
20
00
Ja
pa
n
m
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
CB
A
ge
 ≥
55
, p
ar
tic
ip
ati
ng
 in
 
m
as
s 
sc
re
en
in
g 
pr
og
ra
m
 
fo
r 
pr
os
ta
tic
 d
is
ea
se
BP
H
, p
ro
st
ati
c 
ca
nc
er
 d
ia
gn
os
ed
 
hi
st
ol
og
ic
al
ly
, D
M
, r
en
al
, h
ea
rt
, c
er
eb
ra
l, 
va
sc
ul
ar
 o
r 
ps
yc
hi
at
ri
c 
di
se
as
es
, u
sa
ge
 o
f 
sl
ee
pi
ng
 p
ill
s 
or
 d
ru
gs
 in
flu
en
ci
ng
 v
oi
di
ng
 o
r 
di
ur
eti
c 
co
nd
iti
on
s
32
0/
51
9 
(6
3%
)
O
ct
ob
er
 - 
N
ov
em
be
r 
19
95
FV
C
FV
C
3
ac
tu
al
no
t 
de
fin
ed
no
t 
de
fin
ed
68
M
ea
su
re
m
en
t 
m
et
ho
d
FV
C 
le
ng
th
A
pp
lie
d 
de
fin
iti
on
s
St
ud
y 
nr
.
Ye
ar
Co
un
tr
y
Pa
rti
ci
pa
nt
s
O
ri
gi
n 
In
cl
us
io
n 
cr
ite
ri
a
Ex
cl
us
io
n 
cr
ite
ri
a
N
o.
 (%
)
St
ud
y 
pe
ri
od
N
oc
tu
ri
a
N
P
(d
ay
s)
ni
gh
t
N
oc
tu
ri
a
N
P
LI
X
20
02
U
SA
w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
CB
am
bu
la
to
ry
 n
on
-
pr
eg
na
nt
 a
du
lt
 w
om
en
 
w
ho
 c
on
si
de
re
d 
th
em
se
lv
es
 to
 h
av
e 
no
rm
al
 lo
w
er
 u
ri
na
ry
 
tr
ac
t 
fu
nc
tio
n.
 
an
y 
sy
m
pt
om
s 
of
 U
I o
r 
vo
id
in
g 
di
ffi
cu
lt
y,
 
pe
lv
ic
 o
rg
an
 p
ro
la
ps
e 
or
 p
el
vi
c 
pa
in
, c
ur
re
nt
 
or
 p
as
t 
us
e 
of
 m
ed
ic
ati
on
s 
w
it
h 
pr
im
ar
y 
an
tic
ho
lin
er
gi
c 
eff
ec
t,
 r
el
ev
an
t 
ne
ur
ol
og
ic
 
di
so
rd
er
, p
re
vi
ou
s 
su
rg
er
y 
fo
r 
U
I o
r 
pe
lv
ic
 
or
ga
n 
pr
ol
ap
se
, c
ur
re
nt
 v
ag
in
al
 p
es
sa
ry
 u
se
, 
or
 w
ho
 w
er
e 
w
or
ki
ng
 p
ri
m
ar
ily
 a
t 
ni
gh
t.
 
Po
si
tiv
e 
re
sp
on
se
 a
t 
In
co
nti
ne
nc
e 
Im
pa
ct
 
Q
ue
sti
on
na
ir
e 
an
d 
th
e 
U
ro
ge
ni
ta
l D
is
tr
es
s 
In
ve
nt
or
y
30
0/
??
?
FV
C
FV
C
1
ac
tu
al
bo
th
 1
 
an
d 
2 
or
 
m
or
e
N
Pi
 3
5%
, 
N
U
V
>0
.9
m
L/
m
in
, 
N
U
V
>6
.4
m
L/
kg
LX
20
02
 
20
03
US
A
m
en
/w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
CB
ag
e 
≥ 
65
ov
er
t 
an
d 
sy
m
pt
om
ati
c 
co
ng
es
ti
ve
 h
ea
rt
 
fa
ilu
re
, v
en
ou
s 
in
su
ffi
ci
en
cy
 w
it
h 
pi
tti
ng
 
ed
em
a,
 D
M
 w
it
h 
po
or
 c
on
tr
ol
, B
O
O
 o
r 
in
co
m
pl
et
e 
bl
ad
de
r e
m
pt
yi
ng
 (P
VR
 >
 2
00
 
m
l)
, a
ne
m
ia
 o
r 
U
I m
or
e 
th
an
 o
nc
e 
da
ily
.
45
/1
90
 
(2
4%
)
Ju
ly
 1
99
7 
- 
Se
pt
em
be
r 
20
00
FV
C
FV
C
7
Fi
xe
d 
(1
1 
PM
 - 
7 
A
M
, 
11
 P
M
 - 
2 
AM
 fo
r 
vo
lu
m
es
, 
11
 P
M
-7
 
AM
 fo
r 
fre
qu
en
cy
)
2 
or
 m
or
e 
vo
id
s
NP
i 0
.3
5
XL
V
III
20
03
UK
w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
PC
A
ge
 ≥
50
, p
re
vi
ou
sl
y 
ta
ke
n 
pa
rt
 in
 th
e 
pr
ev
al
en
ce
 st
ud
y 
of
 
LU
TS
 a
m
on
g 
w
om
en
 
re
gi
st
er
ed
 w
it
h 
on
e 
fa
m
ily
 d
oc
to
r 
pr
ac
ti
ce
no
t 
de
fi
ne
d
26
4/
 1
18
3 
(1
9.
5%
)
?
?
FV
C
7
ac
tu
al
2 
or
 m
or
e 
vo
id
s
NP
i 0
.3
3
XL
IX
20
03
Sw
ed
en
m
en
/w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
CB
in
ha
bi
ta
nt
s 
ag
ed
 ≥
65
 
ye
ar
s 
in
 T
ie
rp
, a
 r
ur
al
 
co
m
m
un
it
y 
in
 S
w
ed
en
no
t 
de
fi
ne
d
28
66
/ 
42
64
 
(6
7%
);
 
29
0/
51
7 
(5
6%
)/
 
22
4/
51
7 
(4
3%
)
?
FV
C
FV
C
3
ac
tu
al
2 
or
 m
or
e 
vo
id
s
NP
i 0
.3
3
L
20
03
Sw
ed
en
m
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
SC
m
en
 h
os
pi
ta
liz
ed
 fo
r 
TU
R-
P
ca
rd
ia
c 
di
se
as
e,
 D
M
, k
no
w
n 
or
 s
us
pe
ct
ed
 
pr
os
ta
tic
 c
an
ce
r, 
de
m
en
tia
, o
r 
in
dw
el
lin
g 
ca
th
et
er
s
15
/1
6 
sn
or
er
s 
11
/?
? 
N
on
-
sn
or
er
s
N
ov
em
be
r 
20
00
 - 
Fe
br
ua
ry
 
20
02
FV
C
FV
C
2
Fi
xe
d 
(1
1 
PM
 - 
8 
A
M
)
no
t 
de
fin
ed
no
t 
de
fin
ed
XL
V
I
20
04
Ko
re
a
w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
?
w
om
en
 r
ef
er
re
d 
fo
r 
th
e 
ev
al
ua
tio
n 
of
 
LU
TS
, a
ge
 ≥
 2
0,
 a
bi
lit
y 
to
 c
om
m
un
ic
at
e,
 
un
de
rs
ta
nd
 a
nd
 
co
m
pl
y 
w
it
h 
th
e 
st
ud
y 
re
qu
ir
em
en
ts
.
co
nf
us
ed
 s
ta
te
 o
r 
de
pr
es
si
on
, U
TI
, 
m
ed
ic
ati
on
 k
no
w
n 
to
 a
ffe
ct
 v
oi
di
ng
, 
ne
ur
og
en
ic
 b
la
dd
er
 d
ys
fu
nc
tio
n,
 p
re
gn
an
cy
, 
re
st
ri
ct
ed
 m
ob
ili
ty
 a
nd
 t
ho
se
 w
ho
 w
er
e 
w
or
ki
ng
 p
ri
m
ar
ily
 a
t 
ni
gh
t.
 P
ati
en
ts
 w
it
h 
an
 in
co
m
pl
et
e 
w
or
ku
p 
du
e 
to
 c
ha
rt
s 
w
it
h 
m
is
si
ng
 d
at
es
, n
on
-c
on
se
cu
tiv
e 
da
ys
 o
r 
on
ly
 
2 
da
ys
 o
f d
at
a
10
6/
12
3 
(8
6%
)
?
IP
SS
FV
C
3
ac
tu
al
2 
or
 m
or
e 
vo
id
s
N
Pi
 0
.3
5
3
N
octuria and nocurnal polyuria: definitions
69
M
ea
su
re
m
en
t 
m
et
ho
d
FV
C 
le
ng
th
A
pp
lie
d 
de
fin
iti
on
s
St
ud
y 
nr
.
Ye
ar
Co
un
tr
y
Pa
rti
ci
pa
nt
s
O
ri
gi
n 
In
cl
us
io
n 
cr
ite
ri
a
Ex
cl
us
io
n 
cr
ite
ri
a
N
o.
 (%
)
St
ud
y 
pe
ri
od
N
oc
tu
ri
a
N
P
(d
ay
s)
ni
gh
t
N
oc
tu
ri
a
N
P
XL
V
II
20
04
Ko
re
a
m
en
/w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
?
co
ns
ec
uti
ve
 p
ati
en
ts
 
w
it
h 
LU
TS
, a
ge
 ≥
50
, 
co
ul
d 
co
m
m
un
ic
at
e,
 
un
de
rs
ta
nd
 a
nd
 
co
m
pl
y 
w
it
h 
th
e 
st
ud
y 
re
qu
ire
m
en
ts
co
nf
us
ed
 s
ta
te
 o
r 
de
pr
es
se
d,
 u
se
d 
m
ed
ic
ati
on
s 
to
 c
on
tr
ol
 b
la
dd
er
 s
ym
pt
om
s,
 
pr
eg
na
nc
y,
 U
TI
 (b
ac
te
ri
ur
ia
 o
f ≥
 1
04
 
ba
ct
er
ia
/m
L 
of
 v
oi
de
d 
ur
in
e)
, w
or
ki
ng
 
pr
im
ar
ily
 a
t 
ni
gh
t,
 in
co
m
pl
et
e 
ev
al
ua
ti
on
 
be
ca
us
e 
th
e 
ch
ar
ts
 h
ad
 m
is
si
ng
 d
at
es
, n
ot
 
co
ns
ec
uti
ve
 d
ay
s 
or
 o
nl
y 
2 
da
ys
 o
f d
at
a
10
4/
...
.?
 
(?
%
)
?
FV
C
FV
C
3
ac
tu
al
1 
or
 
m
or
e,
 
or
 2
 o
r 
m
or
e 
in
 3
 
ni
gh
ts
NP
i 0
.3
5 
&
 
NB
Ci
XL
II
20
05
M
al
ay
si
a
m
en
w
it
h 
no
ct
ur
ia
SC
BP
H
 t
re
at
ed
 w
it
h 
a 
ur
ad
re
ne
rg
ic
 b
lo
ck
er
 a
nd
 
sti
ll 
ha
vi
ng
 n
oc
tu
ri
a
us
e 
of
 d
iu
re
tic
s,
 n
ot
 a
bl
e 
to
 u
nd
er
st
an
d 
in
st
ru
cti
on
s 
or
 u
na
bl
e 
to
 r
ec
or
d 
a 
FV
C 
du
e 
to
 s
oc
ia
l r
ea
so
ns
 
41
/4
9=
 
84
%
 
Ju
ly
 - 
Se
pt
em
be
r 
20
03
FV
C
FV
C
3
Fi
xe
d 
(1
2 
PM
 - 
8 
A
M
)
1 
or
 m
or
e 
vo
id
s
N
Pi
 0
.3
3
XL
III
20
05
Ja
pa
n
m
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
?
A
ge
 ≥
 5
0,
 IP
SS
≥ 
8,
 Q
oL
 
in
de
x 
≥ 
2,
 s
le
ep
in
g 
pe
ri
od
 b
et
w
ee
n 
8-
9 
h 
(n
ot
ed
 o
n 
FV
C)
ne
ur
og
en
ic
 b
la
dd
er
 d
is
or
de
r, 
pr
os
ta
te
 
ca
nc
er
, u
re
th
ra
l s
tr
ic
tu
re
, o
r 
ac
tiv
e 
U
TI
, a
s 
w
el
l a
s 
th
os
e 
w
ho
 w
er
e 
ta
ki
ng
 m
ed
ic
ati
on
s 
th
at
 c
ou
ld
 in
flu
en
ce
 u
ri
na
tio
n 
or
 u
ri
na
ry
 
ou
tp
ut
11
4 
/ 
?
A
pr
il 
20
02
 - 
D
ec
em
be
r 
20
03
FV
C
FV
C
2
ac
tu
al
2 
or
 m
or
e 
vo
id
s
no
t 
de
fin
ed
XL
IV
20
05
U
SA
w
om
en
w
it
h 
no
ct
ur
ia
TC
pr
es
en
tin
g 
at
 
ur
og
yn
ec
ol
og
y 
cl
in
ic
, 
no
ct
ur
ia
 a
nd
 O
A
B 
sy
m
pt
om
s 
su
ch
 a
s 
ur
ge
nc
y,
 fr
eq
ue
nc
y,
 a
nd
 
ur
ge
 in
co
nti
ne
nc
e 
no
t 
de
fin
ed
55
/6
0 
(9
2%
)
Ja
nu
ar
y 
20
03
 - 
N
ov
em
be
r 
20
03
FV
C
FV
C
3
ac
tu
al
IC
S 
de
fin
iti
on
: 
on
ce
 o
r 
m
or
e,
 fo
r 
th
is
 s
tu
dy
 
tw
ic
e 
or
 
m
or
e
m
od
ifi
ed
 N
Pi
 
>3
3%
, b
as
ed
 
on
 8
-h
ou
r 
sl
ee
p 
pe
ri
od
XL
V
20
05
N
et
he
rl
an
ds
w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
TC
pr
es
en
tin
g 
at
 
ur
og
yn
ae
co
lo
gi
c 
pr
ac
tic
e 
w
it
h 
co
m
pl
ai
nt
s 
of
 
ur
in
ar
y 
in
co
nti
ne
nc
e
no
t 
de
fin
ed
11
1/
14
0 
(7
9%
)
Ja
nu
ar
y 
20
02
 - 
M
ay
 
20
03
FV
C
FV
C
3
ac
tu
al
2 
or
 m
or
e 
vo
id
s
N
Pi
 0
.3
3
XL
20
06
Sw
ed
en
m
en
/w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
CB
m
em
be
rs
 o
f t
he
 
pe
ns
io
ne
rs
’ a
ss
oc
ia
tio
n 
SP
F 
in
 t
he
 S
w
ed
is
h 
co
un
tie
s 
of
 V
as
te
rb
ott
en
 
an
d 
N
or
rb
ott
en
 
no
t 
de
fin
ed
6,
10
3/
 
10
,2
16
 
(5
9,
7%
)
?
un
de
fin
ed
 
qu
es
tio
nn
ai
re
?
?
no
t 
de
fin
ed
no
t 
de
fin
ed
"p
as
si
ng
 la
rg
e 
am
ou
nt
s 
of
 
ur
in
e 
at
 n
ig
ht
"
XL
I
20
06
Ta
iw
an
m
en
w
it
h 
no
ct
ur
ia
?
pa
ti
en
ts
: n
oc
tu
ri
a.
 
Co
nt
ro
ls
: a
sy
m
pt
om
ati
c 
yo
un
g 
m
en
hi
st
or
y 
of
 C
VA
, c
on
ge
sti
ve
 h
ea
rt
 fa
ilu
re
, 
liv
er
 d
is
ea
se
 w
it
h 
as
ci
te
s,
 C
O
PD
, c
hr
on
ic
 
re
na
l i
ns
uffi
ci
en
cy
, m
al
ig
na
nc
y 
of
 t
he
 
ge
ni
to
ur
in
ar
y 
sy
st
em
, p
ol
yd
ip
si
a,
 o
r 
ps
yc
ho
ge
ni
c i
ns
om
ni
a.
41
 / 
?
?
FV
C
FV
C
3
ac
tu
al
2 
or
 m
or
e 
vo
id
s
NP
i 0
.3
5
LV
I
20
06
D
en
m
ar
k
m
en
w
it
ho
ut
 
no
ct
ur
ia
?
he
al
th
y,
 a
ge
 5
5-
73
no
t 
de
fin
ed
18
/.
..?
?
FV
C
FV
C
7
ac
tu
al
1 
or
 m
or
e 
vo
id
s
no
t 
de
fin
ed
70
M
ea
su
re
m
en
t 
m
et
ho
d
FV
C 
le
ng
th
A
pp
lie
d 
de
fin
iti
on
s
St
ud
y 
nr
.
Ye
ar
Co
un
tr
y
Pa
rti
ci
pa
nt
s
O
ri
gi
n 
In
cl
us
io
n 
cr
ite
ri
a
Ex
cl
us
io
n 
cr
ite
ri
a
N
o.
 (%
)
St
ud
y 
pe
ri
od
N
oc
tu
ri
a
N
P
(d
ay
s)
ni
gh
t
N
oc
tu
ri
a
N
P
XX
XV
II
20
07
U
K,
 M
al
ay
si
a
m
en
w
it
h 
no
ct
ur
ia
TC
A
ge
 ≥
40
, A
si
an
 a
nd
 
Ca
uc
as
ia
n 
et
hn
ic
it
y,
 
LU
TS
, n
oc
tu
ri
a
Su
rg
er
y 
fo
r 
BO
O
, a
nti
ch
ol
in
er
gi
c 
m
ed
ic
ati
on
29
3 
/ 
? 
Ju
ly
 2
00
2 
- 
Ju
ne
 2
00
5
FV
C
FV
C
3
ac
tu
al
1 
or
 m
or
e 
vo
id
s
no
ct
ur
ia
 r
ati
o 
>0
.2
 (<
60
 
ye
ar
) o
r 
>0
.3
 
(>
60
 y
ea
r)
XX
XV
III
20
07
Ko
re
a
m
en
/w
om
en
w
it
h 
no
ct
ur
ia
?
ag
e>
20
, I
PS
S 
su
m
>8
, 
no
ct
ur
ia
, a
bl
e 
to
 
co
m
m
un
ic
at
e,
 
un
de
rs
ta
nd
, a
nd
 
co
m
pl
y 
w
it
h 
th
e 
st
ud
y 
re
qu
ir
em
en
ts
co
nf
us
ed
 o
r 
de
pr
es
se
d 
st
at
e,
 m
ed
ic
ati
on
s 
to
 c
on
tr
ol
 b
la
dd
er
 s
ym
pt
om
s,
 p
re
vi
ou
s 
su
rg
er
y 
fo
r 
LU
TS
, s
ed
ati
ve
s 
or
 t
ra
nq
ui
lli
ze
rs
, 
pr
eg
na
nc
y,
 U
TI
, u
ri
na
ry
 s
to
ne
s,
 u
ro
ge
ni
ta
l 
ca
nc
er
, u
re
th
ra
l s
tr
ic
tu
re
, n
eu
ro
ge
ni
c 
bl
ad
de
r, 
SU
I, 
re
st
ri
ct
ed
 m
ob
ili
ty
, w
or
ki
ng
 
pr
im
ar
ily
 a
t 
ni
gh
t,
 a
nd
 a
n 
in
co
m
pl
et
e 
ev
al
ua
tio
n
14
2/
?
Ja
nu
ar
y -
 
Ju
ne
 2
00
5
IP
SS
FV
C
3
ac
tu
al
1 
or
 m
or
e 
vo
id
s
N
Pi
 0
.3
3
XX
XI
X
20
07
?
m
en
w
it
h 
no
ct
ur
ia
?
ag
e≥
 5
0,
 n
oc
tu
ri
a
pa
st
 o
r 
pr
es
en
t 
hi
st
or
y 
of
 h
ea
rt
 d
is
ea
se
, 
D
M
 w
it
h 
a 
fa
sti
ng
 b
lo
od
 g
lu
co
se
 o
f 2
00
 
m
g/
dL
 o
r 
m
or
e,
 s
er
um
 C
r 
gr
ea
te
r 
th
an
 
1.
5 
ng
/d
L,
 h
yd
ro
ne
ph
ro
si
s,
 P
V
R
≥5
0 
 m
l, 
ur
in
ar
y 
in
co
nti
ne
nc
e 
th
at
 in
fl
ue
nc
ed
 t
he
 
ex
ac
t 
m
ea
su
re
m
en
t 
of
 t
he
 u
ri
ne
 v
ol
um
e,
 
or
 U
TI
, h
ab
it
ua
l u
se
 o
f d
iu
re
ti
cs
 o
r 
lit
hi
um
 
or
 a
 2
4-
h 
pr
od
uc
ti
on
 ≥
 4
0 
m
L/
kg
 b
od
y 
w
ei
gh
t
16
5/
 1
89
 =
 
87
%
?
FV
C
FV
C
?
Fi
xe
d 
(1
0 
PM
 –
 6
 
AM
)
no
t 
de
fi
ne
d
NP
i 0
.3
5 
an
d 
NU
V 
> 
0.
9m
L/
m
in
*s
le
ep
in
g 
ho
ur
s
XX
XV
I
20
09
A
us
tr
ia
m
en
/w
om
en
w
it
h 
no
ct
ur
ia
SC
no
ct
ur
ia
un
tr
ea
te
d 
U
TI
, P
V
R 
>2
00
 m
l, 
un
w
ill
in
gn
es
s 
to
 s
ig
n 
an
 in
fo
rm
ed
 c
on
se
nt
 fo
rm
 
32
4 
/ 
?
?
?
FV
C
2
no
t 
de
fin
ed
2 
or
 m
or
e 
vo
id
s
N
Pi
 0
.3
3
LV
20
10
Ko
re
a
w
om
en
w
it
h 
no
ct
ur
ia
TC
ag
e>
20
, I
PS
S 
su
m
>8
, 
no
ct
ur
ia
 (I
PS
S 
Q
7)
co
nf
us
ed
 o
r 
de
pr
es
se
d 
m
en
ta
l s
ta
tu
s,
 
m
ed
ic
ati
on
 t
ha
t 
m
ay
 a
lte
r 
or
 c
on
tr
ol
 b
la
dd
er
 
sy
m
pt
om
s,
 s
ym
pt
om
ati
c 
U
TI
, u
ro
pa
th
ol
og
ic
 
co
nd
iti
on
 (u
ri
na
ry
 s
to
ne
s,
 u
ro
ge
ni
ta
l c
an
ce
r, 
pe
lv
ic
 o
rg
an
 p
ro
la
ps
ed
 >
 s
ta
ge
 3
, n
eu
ro
ge
ni
c 
bl
ad
de
r, 
SU
I s
ta
m
ey
 g
ra
de
 3
, r
es
tr
ic
te
d 
m
ob
ili
ty
, n
ig
ht
 w
or
ki
ng
 jo
b 
11
8/
45
0 
(2
6%
)
Ja
nu
ar
y 
20
06
 - 
D
ec
em
be
r 
20
08
FV
C
FV
C
3
ac
tu
al
1 
or
 m
or
e 
vo
id
s
N
Pi
 0
.3
5
LV
II
20
09
 
20
10
Ja
pa
n
m
en
/w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
CB
co
m
m
un
it
y-
dw
el
lin
g 
pe
op
le
 w
ho
 u
nd
er
w
en
t 
m
as
s s
cr
ee
ni
ng
 p
ro
gr
am
 
in
 a
 r
ur
al
 t
ow
n 
in
 
H
ok
ka
id
o,
 J
ap
an
, a
nd
 
75
 o
ut
pa
ti
en
ts
 w
ho
 
co
ns
ul
te
d 
th
e 
De
pt
 
of
 U
ro
lo
gy
, M
ei
ji 
U
ni
ve
rs
it
y 
of
 In
te
gr
ati
ve
 
M
ed
ic
in
e,
 w
it
h 
va
ri
ou
s 
co
m
pl
ai
nt
s i
nc
l n
oc
tu
ria
24
-h
ou
r 
po
ly
ur
ia
 (>
40
m
L/
kg
),
 s
us
pe
ct
ed
 
of
 s
uff
er
in
g 
fr
om
 d
efi
ni
te
 p
at
ho
lo
gi
ca
l 
di
so
rd
er
s 
su
ch
 a
s 
ca
nc
er
 o
f t
he
 b
la
dd
er
, 
bl
ad
de
r 
st
on
e,
 b
ac
te
ri
al
 c
ys
ti
ti
s,
 c
an
ce
r 
of
 
th
e 
pr
os
ta
te
 a
nd
 p
ro
st
ati
ti
s,
 n
o 
co
m
pl
et
ed
 
bl
ad
de
r 
di
ar
y,
 n
o 
co
ns
en
t 
to
 p
ar
ti
ci
pa
te
 in
 
th
e 
st
ud
y 
45
0/
 6
94
 
Ap
ril
 
20
05
 - 
De
ce
m
be
r 
20
06
FV
C
FV
C
3
ac
tu
al
m
ild
: 1
, 
se
ve
re
 2
 
or
 m
or
e.
 
Re
f 1
42
: 1
 
or
 m
or
e
Pr
op
or
ti
on
 
NU
P 
ra
te
 
(m
l/
m
in
) /
 
da
ty
im
e 
UP
 
ra
te
 >
 1
 , 
N
Pi
 
0.
33
3
N
octuria and nocurnal polyuria: definitions
71
M
ea
su
re
m
en
t 
m
et
ho
d
FV
C 
le
ng
th
A
pp
lie
d 
de
fin
iti
on
s
St
ud
y 
nr
.
Ye
ar
Co
un
tr
y
Pa
rti
ci
pa
nt
s
O
ri
gi
n 
In
cl
us
io
n 
cr
ite
ri
a
Ex
cl
us
io
n 
cr
ite
ri
a
N
o.
 (%
)
St
ud
y 
pe
ri
od
N
oc
tu
ri
a
N
P
(d
ay
s)
ni
gh
t
N
oc
tu
ri
a
N
P
LV
III
20
07
 
20
11
U
K,
 U
SA
m
en
/w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
SC
co
nt
ro
ls
: n
ot
 s
ta
te
d,
 
pa
tie
nt
s:
 L
U
TS
LU
TS
 a
nd
 d
is
or
de
rs
, m
ed
ic
ati
on
s,
 a
nd
 
su
rg
er
ie
s 
th
at
 m
ig
ht
 a
ffe
ct
 u
ri
na
tio
n,
 (e
.g
. 
D
M
, h
ea
rt
 d
is
ea
se
, n
eu
ro
lo
gi
c 
di
so
rd
er
s)
, 
an
d 
pr
ev
io
us
 in
co
nti
ne
nc
e 
su
rg
er
y,
 n
on
-
st
an
da
rd
 s
le
ep
 p
att
er
ns
 (e
.g
., 
ni
gh
t 
sh
ift
s)
, 
if 
a 
st
an
da
rd
iz
ed
 q
ue
sti
on
na
ir
e 
re
ve
al
ed
 
bl
ad
de
r 
sy
m
pt
om
s,
 p
re
vi
ou
s 
ur
ol
og
ic
al
 o
r 
co
nti
ne
nc
e 
su
rg
er
y,
 m
ed
ic
ati
on
s 
in
flu
en
ci
ng
 
bl
ad
de
r 
ha
bi
ts
 a
nd
 a
 n
ig
ht
-s
hi
ft
 s
le
ep
 
pa
tt
er
n,
 if
 d
ia
ri
es
 c
on
ta
in
ed
 o
ne
 o
r 
m
or
e 
in
co
nti
ne
nc
e 
ep
is
od
es
, r
ec
or
di
ng
 o
f v
ol
um
es
 
of
 o
nl
y 
25
%
 o
r 
le
ss
 o
f a
ll 
vo
id
s 
or
 r
ec
or
di
ng
 
of
 o
nl
y 
10
%
 o
r 
le
ss
 o
f a
ll 
ni
gh
t 
vo
id
s.
16
1+
92
 
/.
..?
?
FV
C
FV
C
3
ac
tu
al
1 
or
 m
or
e 
vo
id
s
N
BC
i, 
N
Pi
 
w
it
ho
ut
 c
ut
 
off
LX
I
20
00
 
20
02
 
20
12
Ne
th
er
la
nd
s
m
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
CB
Co
m
m
un
it
y-
dw
el
lin
g 
m
en
 li
vi
ng
 in
 K
rim
pe
n 
aa
n 
de
n 
IJ
ss
el
, t
he
 
N
et
he
rl
an
ds
, a
ge
d 
50
-
75
 y
ea
rs
,  
fi
lle
d 
in
 F
V
C
pr
ev
io
us
 tr
an
su
re
th
ra
l o
r o
pe
n 
pr
os
ta
te
ct
om
y,
 p
ro
st
at
e 
or
 b
la
dd
er
 c
an
ce
r, 
ne
ur
og
en
ic
 b
la
dd
er
 d
is
ea
se
, o
r 
ne
ga
ti
ve
 
ad
vi
ce
 fr
om
 th
ei
r p
rim
ar
y 
ca
re
 p
hy
sic
ia
n 
(P
CP
) b
as
ed
 o
n 
po
or
 h
ea
lt
h 
(e
.g
., 
be
in
g 
be
dr
id
de
n)
.
13
96
/1
59
7 
= 
87
%
, 
16
88
/3
94
2 
(5
0%
)
19
95
-1
99
7
bo
th
 F
VC
 a
nd
 
IP
SS
FV
C
3 
da
y 
FV
C 
(1
-d
ay
 
vo
lu
m
e)
fi
xe
d 
fo
r N
P 
- 
ac
tu
al
 fo
r 
no
ct
ur
ia
*
no
ct
ur
ia
 
2 
(2
 o
r 
m
or
e)
 
an
d 
no
ct
ur
ia
 
3 
(3
 o
r 
m
or
e)
 v
ar
io
us
 
de
fi
ni
ti
on
s 
(N
Pi
 0
.3
3,
 
NU
P>
90
 
m
l/
h)
LI
V
20
12
N
et
he
rl
an
ds
m
en
/w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
CB
A
du
lt
 v
ol
un
te
er
s 
w
it
ho
ut
 
a 
ur
ol
og
ic
al
 c
om
pl
ai
nt
 
or
 a
 u
ro
lo
gi
ca
l h
is
to
ry
, 
re
cr
ui
te
d 
fr
om
 h
os
pi
ta
l 
st
aff
 a
nd
 fa
m
ili
es
, a
nd
 
pa
tie
nt
s’
 fa
m
ili
es
.
25
%
 o
f s
le
ep
in
g 
tim
e 
ex
ce
ed
ed
 b
et
w
ee
n 
tim
e 
of
 r
is
in
g 
an
d 
fir
st
 m
or
ni
ng
 v
oi
d,
 m
is
si
ng
 
fir
st
 m
or
ni
ng
 v
oi
d 
on
 F
V
C
89
4/
11
52
 
(7
8%
)
?
FV
C
FV
C
1
ac
tu
al
1,
 2
 o
r 
m
or
e 
th
an
 2
N
Pi
 0
.5
3
Ca
se
 co
nt
ro
l s
tu
di
es
LX
IV
 
19
98
It
al
y
m
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
SC
al
l: 
su
bm
itt
ed
 to
 o
pe
n 
or
 t
ra
ns
ur
et
hr
al
 a
bl
ati
on
 
of
 a
n 
ob
st
ru
cti
ve
 B
PH
. 
Pa
tie
nt
s:
 n
oc
tu
ri
a 
w
it
ho
ut
 s
ym
pt
om
s 
re
la
te
d 
to
 r
es
id
ua
l 
bl
ad
de
r 
in
st
ab
ili
ty
. 
Co
nt
ro
ls
: c
om
pl
et
e 
re
so
lu
tio
n 
of
 n
oc
tu
ri
a 
(o
r 
m
ax
 o
ne
 v
oi
d/
ni
gh
t)
 o
ne
 
ye
ar
 p
os
t-
op
er
ati
ve
ly
as
so
ci
at
ed
 s
ym
pt
om
s 
re
la
te
d 
to
 r
es
id
ua
l 
bl
ad
de
r 
in
st
ab
ili
ty
, h
is
to
ry
 o
f i
sc
ha
em
ic
 
he
ar
t 
di
se
as
e,
 c
on
ge
sti
ve
 h
ea
rt
 fa
ilu
re
, m
ild
 
or
 s
ev
er
e 
hy
pe
rt
en
si
on
, d
iu
re
tic
 o
r 
ot
he
r 
an
tih
yp
er
te
ns
iv
e 
th
er
ap
ie
s.
 
12
/2
7 
(4
4%
)
?
?
?
24
 h
 
ur
in
ar
y 
vo
lu
m
e
Fi
xe
d 
(8
 P
M
 
- 8
 A
M
)
no
t 
de
fin
ed
no
t 
de
fin
ed
LX
V
19
99
 
20
03
De
nm
ar
k
m
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
SC
/T
C
pa
ti
en
ts
: c
on
se
cu
ti
ve
ly
 
re
fe
rr
ed
 to
 d
ep
ar
tm
en
t 
w
it
h 
LU
TS
 fo
r 
B
PH
 
ev
al
ua
ti
on
 &
 a
ge
-
m
at
ch
ed
 c
on
tr
ol
s 
w
it
h 
no
 h
ist
or
y 
of
 n
oc
tu
ria
 
or
 a
ny
 o
th
er
 u
ro
lo
gi
ca
l 
co
m
pl
ai
nt
s
A
ll:
 a
bn
or
m
al
iti
es
 o
n 
ph
ys
ic
al
 e
xa
m
in
ati
on
, 
hi
st
or
y 
of
 r
en
al
, c
ar
di
ac
 o
r 
he
pa
ti
c 
di
se
as
e,
 a
bn
or
m
al
 c
lin
ic
al
 b
lo
od
 p
re
ss
ur
e,
 
ba
ct
er
iu
ri
a,
 p
ro
te
in
ur
ia
 a
nd
 g
lu
co
su
ri
a.
 
Co
nt
ro
ls
: Q
m
ax
 <
 1
4 
m
L/
s
11
 +
 2
3 
/ ?
?
?
FV
C
FV
C
7
ac
tu
al
no
t 
de
fi
ne
d
NU
P 
> 
2 
SD
 o
f 
th
e 
m
ea
n 
(o
f 
th
e 
co
nt
ro
ls)
72
M
ea
su
re
m
en
t 
m
et
ho
d
FV
C 
le
ng
th
A
pp
lie
d 
de
fin
iti
on
s
St
ud
y 
nr
.
Ye
ar
Co
un
tr
y
Pa
rti
ci
pa
nt
s
O
ri
gi
n 
In
cl
us
io
n 
cr
ite
ri
a
Ex
cl
us
io
n 
cr
ite
ri
a
N
o.
 (%
)
St
ud
y 
pe
ri
od
N
oc
tu
ri
a
N
P
(d
ay
s)
ni
gh
t
N
oc
tu
ri
a
N
P
LX
III
20
05
Ja
pa
n
m
en
/w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
SC
pa
tie
nt
s:
 n
oc
tu
ri
a 
as
 
pr
in
ci
pa
l c
om
pl
ai
nt
 
at
 u
ro
lo
gi
c 
co
ns
ul
t,
 
co
nt
ro
ls
: a
ge
-g
en
de
r 
m
at
ch
ed
 v
ol
un
te
er
s 
w
it
ho
ut
 n
oc
tu
ri
a
ac
tiv
e 
lo
w
er
 U
TI
, a
cti
ve
 lo
w
er
 u
ri
na
ry
 t
ra
ct
 
ca
lc
ul
i, 
ac
tiv
e 
bl
ad
de
r 
ca
nc
er
, o
r 
lo
ca
lly
 
ad
va
nc
ed
 p
ro
st
at
e 
ca
nc
er
 
11
0/
11
7 
(9
4%
)
N
ov
em
be
r 
20
02
 
- M
ar
ch
 
20
04
IP
SS
FV
C
2
ac
tu
al
m
ild
 3
 
or
 le
ss
, 
se
ve
re
 4
 
or
 m
or
e
N
U
V/
to
ta
l v
ol
um
e 
> 
tim
e 
sp
en
t 
in
  b
ed
/2
4 
h
LX
II
20
11
U
K
m
en
/w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
?
co
nt
ro
l: 
st
an
da
rd
 
sl
ee
p 
pa
tt
er
n,
 g
oo
d 
he
al
th
 p
ati
en
ts
: u
nd
er
 
in
ve
sti
ga
tio
n 
fo
r 
sl
ee
p-
di
so
rd
er
ed
 b
re
at
hi
ng
 b
y 
a 
st
an
da
rd
 s
le
ep
 s
tu
dy
 
att
en
di
ng
 t
he
 G
w
en
t 
Sl
ee
p 
Ce
nt
re
pa
tie
nt
s:
 n
ot
 s
ta
te
d 
co
nt
ro
l: 
ni
gh
t 
sh
ift
 
w
or
ke
rs
89
+2
1/
...
.?
?
FV
C
FV
C
1
ac
tu
al
no
t 
de
fin
ed
N
Pi
 w
it
ho
ut
 
cu
t-
off
LX
V
I
20
07
 
20
12
De
nm
ar
k
m
en
/w
om
en
w
it
h/
w
it
ho
ut
 
no
ct
ur
ia
CB
re
sp
on
de
nt
s i
n 
a 
po
pu
la
ti
on
 s
tu
dy
 o
f 
4,
00
0 
m
en
/w
om
en
 6
0-
80
 y
ea
rs
 o
ld
, a
ns
w
er
in
g 
a 
qu
es
ti
on
 o
n 
no
ct
ur
ia
ni
gh
t 
sh
ift
 w
or
k,
 s
ev
er
e 
ph
ys
ic
al
 d
is
ab
ili
ty
, 
or
 m
en
ta
l i
m
pa
ir
m
en
t 
(d
em
en
ti
a)
 a
nd
 
in
ab
ili
ty
 t
o 
fo
llo
w
 in
st
ru
cti
on
s.
15
0 
/ 1
11
1 
(1
3,
5%
)
Ja
nu
ar
y 
20
03
 - 
Ja
nu
ar
y 
20
05
FV
C
FV
C
3
ac
tu
al
2 
or
 m
or
e 
vo
id
s
NP
i 0
.3
3
Ta
bl
e 
1.
 C
ha
ra
ct
er
is
tic
s 
of
 t
he
 in
cl
ud
ed
 s
tu
di
es
.  
St
ud
y 
nu
m
be
rs
 r
ef
er
 to
 A
pp
en
di
x 
A
. R
ef
er
en
ce
s 
pr
in
te
d 
bo
ld
 a
re
 in
cl
ud
ed
 in
  C
ha
pt
er
 2
 fo
r 
th
e 
m
et
a 
an
al
ys
es
 [9
]. 
 
A
ll 
ag
es
 a
re
 in
 ‘y
ea
rs
’. 
A
bb
re
vi
ati
on
s:
 B
M
I: 
bo
dy
 m
as
s 
in
de
x;
 B
O
O
: b
la
dd
er
 o
ut
le
t 
ob
st
ru
cti
on
; B
P:
 b
lo
od
 p
re
ss
ur
e;
 B
PH
: b
en
ig
n 
 p
ro
st
at
e 
hy
pe
rp
la
si
a;
 C
B:
 c
om
m
un
it
y 
ba
se
d;
 C
O
PD
: c
hr
on
ic
 o
bs
tr
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e;
 C
VA
: c
er
eb
ro
va
sc
ul
ar
 a
cc
id
en
t;
 D
M
: d
ia
be
te
s 
m
el
lit
us
; D
RE
: d
ig
ita
l r
ec
ta
l e
xa
m
in
ati
on
; F
V
C:
 fr
eq
ue
nc
y 
vo
lu
m
e 
ch
ar
t;
 IC
S:
 In
te
rn
al
 C
on
tin
en
ce
 S
oc
ie
ty
; L
U
T:
 lo
w
er
 u
ri
na
ry
 t
ra
ct
; 
LU
TS
: l
ow
er
 u
ri
na
ry
 t
ra
ct
 s
ym
pt
om
s;
 N
BC
i: 
N
oc
tu
rn
al
 B
la
dd
er
 C
ap
ac
it
y 
in
de
x;
 N
P:
 n
oc
tu
rn
al
 p
ol
yu
ri
a;
 O
A
B:
 o
ve
ra
cti
ve
 b
la
dd
er
; P
C:
 p
ri
m
ar
y 
ca
re
; P
V
R:
 p
os
t 
vo
id
 r
es
id
ua
l v
ol
um
e;
 Q
m
ax
: m
ax
im
al
 
ur
in
ar
y 
flo
w
 r
at
e;
 S
C:
 s
ec
on
da
ry
 c
ar
e;
 S
U
I: 
st
re
ss
 u
ri
na
ry
 in
co
nti
ne
nc
e;
 T
: t
em
pe
ra
tu
re
; T
C:
 te
rti
ar
y 
ca
re
; U
TI
: u
ri
na
ry
 t
ra
ct
 in
fe
cti
on
; U
U
I: 
ur
ge
 u
ri
na
ry
 in
co
nti
ne
nc
e
3
N
octuria and nocurnal polyuria: definitions
73
Appendix A. Bibliographic information on the studies included in this systematic review.  
Those studies that were used in the meta-analysis are bolded. 
 
Study 
nr
References included and used for quality assessment and data extraction
I Yoshimura K, Shimizu Y, Masui K, et al. Furosemide versus Gosha-Jinki-Gan, a Blended Herbal 
Medicine, for Nocturnal Polyuria: A Randomized Crossover Trial. LUTS 2012; 4 (2): 77-81.
II Weiss JP, Zinner NR, Klein BM, Norgaard JP. Desmopressin orally disintegrating tablet effectively 
reduces nocturia: Results of a randomized, double-blind, placebo-controlled trial. Neurourol 
Urodyn 2012; 31 (4): 441-7.
III Yokoyama O, Yamaguchi O, Kakizaki H, et al. Efficacy of solifenacin on nocturia in Japanese 
patients with overactive bladder: Impact on sleep evaluated by bladder diary. J Urol 2011; 
186 (1): 170-4.
IV FG, Lavery HJ, Wu DL. Reducing nocturia in the elderly: A randomized placebo-controlled trial of 
staggered furosemide and desmopressin. Neurourol Urodyn 2011; 30 (3): 312-6.
V Wang CJ, Lin YN, Huang SW, Chang CH. Low dose oral desmopressin for nocturnal polyuria in 
patients with benign prostatic hyperplasia: A double-blind, placebo controlled, randomized 
study. J Urol 2011; 185 (1): 219-23.
VI Weiss JP, Blaivas JG, Jones M, Wang JT, Guan Z. Age Related Pathogenesis of Nocturia in Patients 
With Overactive Bladder. J Urol 2007; 178 (2): 548-51
VII Brubaker L, FitzGerald MP. Nocturnal polyuria and nocturia relief in patients treated with 
solifenacin for overactive bladder symptoms. Int Urogynecol J Pel 2007; 18 (7): 737-41.
VIII Addla SK, Adeyoju AB, Neilson D, O'Reilly P. Diclofenac for treatment of nocturia caused by 
nocturnal polyuria: A prospective, randomised, double-blind, placebo-controlled crossover 
study. Eur Urol 2006; 49 (4): 720-5.
IX Drake MJ, Mills IW, Noble JG. Melatonin pharmacotherapy for nocturia in men with benign 
prostatic enlargement. J Urol 2004; 171 (3): 1199-202.
X Lose G, Lalos O, Freeman RM, Van Kerrebroeck P. Efficacy of desmopressin (Minrin) in the 
treatment of nocturia: A double-blind placebo-controlled study in women. Am J Obstet 
Gynecol 2003; 189 (4): 1106-13.
XI Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the 
treatment of nocturia: A double-blind placebo-controlled study in men. BJU Int 2002; 89 (9): 
855-62.
XII Cannon A, Carter PG, McConnell AA, Abrams P. Desmopressin in the treatment of nocturnal 
polyuria in the male. BJU Int 1999; 84 (1): 20-4.
XIII Reynard JM, Cannon A, Yang Q, Abrams P. A novel therapy for nocturnal polyuria: A double-blind 
randomized trial of frusemide against placebo. BJU 1998; 81 (2): 215-8.
74
Study 
nr
References included and used for quality assessment and data extraction
XIV Asplund R, Sundberg B, Bengtsson P. Desmopressin for the treatment of nocturnal polyuria in the 
elderly: A dose titration study. Brit J Urol 1998; 82 (5): 642-6.
Asplund R, Sundberg B, Bengtsson P. Oral desmopressin for nocturnal polyuria in elderly subjects: 
A double-blind, placebo-controlled randomized exploratory study. BJU Int 1999; 83 (6): 591-
5.
Asplund R. Diuresis pattern, plasma vasopressin and blood pressure in healthy elderly persons 
with nocturia and nocturnal polyuria. Neth J Med 2002; 60 (7): 276-80.
XV Sigurdsson S, Geirsson G, Gudmundsdottir H, Egilsdottir PB, Gudbjarnason S. A parallel, 
randomized, double-blind, placebo-controlled study to investigate the effect of SagaPro on 
nocturia in men. Scand J Urol 2013; 47 (1): 26-32.
XVI Yamaguchi O, Nishizawa O, Juul KV, Norgaard JP. Gender difference in efficacy and dose response 
in Japanese patients with nocturia treated with four different doses of desmopressin orally 
disintegrating tablet in a randomized, placebo-controlled trial. BJU Int 2013; 111 (3): 474-84.
XVII Wada N, Watanabe M, Kita M, et al. Effect of Imidafenacin on Nocturia and Sleep Disorder in 
Patients with Overactive Bladder. Urol Int 2012; 89 (2): 215-21.
XVIII Kojima Y, Sasaki S, Imura M, Kubota Y, Hayashi Y, Kohri K. Tamsulosin reduces nighttime urine 
production in benign prostatic hyperplasia patients with nocturnal polyuria: A prospective 
open-label long-term study using frequency-volume chart. Neurourol Urodyn 2012; 31 (1): 
80-5.
XIX Cho SY, Lee SL, Kim IS, Koo DH, Kim HJ, Oh SJ. Short-term effects of systematized behavioral 
modification program for nocturia: A prospective study. Neurourol Urodyn 2012; 31 (1): 64-8.
XX Yokoyama O, Aoki Y, Tsujimura A, Takao T, Namiki M, Okuyama A. (alpha)1-Adrenoceptor blocker 
naftopidil improves sleep disturbance with reduction in nocturnal urine volume. World J Urol 
2011; 29 (2): 233-8.
XXI Lee HW, Choo MS, Lee JG, et al. Desmopressin is an effective treatment for mixed nocturia with 
nocturnal polyuria and decreased nocturnal bladder capacity. J Korean Med Sci 2010; 25 
(12): 1792-7.
XXII Soda T, Masui K, Okuno H, Terai A, Ogawa O, Yoshimura K. Efficacy of nondrug lifestyle measures 
for the treatment of nocturia. J Urol 2010; 184 (3): 1000-4.
XXIII Yoshida M, Inadome A, Masunaga K, Nagata T, Yoshiyasu T. Effectiveness of tamsulosin 
hydrochloride and its mechanism in improving nocturia associated with lower urinary tract 
symptoms/benign prostatic hyperplasia. Neurourol Urodyn 2010; 29 (7): 1276-81.
XXIV Cho MC, Ku JH, Paick JS. (alpha)-Blocker Plus Diuretic Combination Therapy as Second-line 
Treatment for Nocturia in Men With LUTS: A Pilot Study. Urology 2009; 73 (3): 549-53.
XXV Koseoglu H, Aslan G, Ozdemir I, Esen A. Nocturnal polyuria in patients with lower urinary tract 
symptoms and response to alpha-blocker therapy. Urology 2006; 67 (6): 1188-92.
XXVI Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T. Clinical efficacy of an 
(alpha)1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients 
with benign prostatic hyperplasia. Int J Urol 2006; 13 (1): 15-20.
XXVII Al-Waili NS, Al-Waili TN, Al-Waili AN, Saloom KY. Urinary nitrite excretion and urinary variables 
in patients with primary nocturnal frequency of micturition: Effects of indomethacin 
suppositories. World J Urol 2005; 23 (4): 287-94.
3
N
octuria and nocurnal polyuria: definitions
75
Study 
nr
References included and used for quality assessment and data extraction
XXVIII Kuo HC. Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 
years. Urology 2002; 59 (4): 485-9.
XXIX Chancellor MB, Atan A, Rivas DA, Watanabe T, Tai HL, Kumon H. Beneficial effect of intranasal 
desmopressin for men with benign prostatic hyperplasia and nocturia: Preliminary results. 
Techniques in Urology 1999; 5 (4): 191-4.
XXX Araki T, Yokoyama T, Araki M, Furuya S. A clinical investigation of the mechanism of loxoprofen, a 
non-steroidal anti-inflammatory drug, for patients with nocturia. Acta Med Okayama 2008; 
62 (6): 373-8.
XXXI Natsume O. A Clinical Investigation of Nocturnal Polyuria in Patients With Nocturia: A Diurnal 
Variation in Arginine Vasopressin Secretion and its Relevance to Mean Blood Pressure. J Urol 
2006; 176 (2): 660-4.
Natsume O. Diuretic pattern in adults with nocturnal polyuria: The possible contribution of blood 
pressure to the worsening of nocturnal polyuria. Int J Urol 2007; 14 (9): 822-7.
Natsume O, Kaneko Y, Hirayama A, Fujimoto K, Hirao Y. Fluid control in elderly patients with 
nocturia. Int J Urol 2009; 16 (3): 307-13.
XXXII Weiss JP, Blaivas JG, Stember DS, Brooks MM. Nocturia in adults: Etiology and classification. 
Neurourol Urodynam 1998; 17 (5): 467-72.
Weiss JP, Blaivas JG, Stember DS, Chaikin DC. Evaluation of the etiology of nocturia in men: The 
nocturia and nocturnal bladder capacity indices. Neurourol Urodyn 1999; 18 (6): 559-65.
XXXIII Vaughan CP, Endeshaw Y, Nagamia Z, Ouslander JG, Johnson TM. A multicomponent behavioural 
and drug intervention for nocturia in elderly men: Rationale and pilot results. BJU Int 2009; 
104 (1): 69-74.
XXXIV Jeong JY, Kim SJ, Cho HJ, et al. Influence of type of nocturia and lower urinary tract symptoms on 
therapeutic outcome in women treated with desmopressin. Korean J Urol 2013; 54 (2): 95-9.
XXXV Bae WJ, Bae JH, Kims SW, et al. Desmopressin add-on therapy for refractory nocturia in men 
receiving alpha-blockers for lower urinary tract symptoms. J Urol 2013; 190 (1): 180-6.
XXXVI Klingler HC, Heidler H, Madersbacher H, Primus G. Nocturia: An Austrian study on the 
multifactorial etiology of this symptom. Neurourol Urodyn 2009; 28 (5): 427-31.
XXXVII Mariappan P, Turner KJ, Sothilingam S, Rajan P, Sundram M, Stewart LH. Nocturia, nocturia 
indices and variables from frequency-volume charts are significantly different in Asian and 
Caucasian men with lower urinary tract symptoms: A prospective comparison study. BJU Int 
2007; 100 (2): 332-6.
XXXVIII Paick JS, Kim SW, Oh SJ, Ku JH. Voiding patterns in men and women with lower urinary tract 
symptoms combined with nocturia. Int J Urol 2007; 14 (8): 699-703.
XXXIX Akiyama T, Hirayama A, Fujimoto K, Torimoto K, Yoshida K, Hirao Y. Cutoff Value of Urinary 
Arginine Vasopressin for Nocturnal Polyuria in Elderly Men. Urology 2007; 69 (1): 98-102.
XL Asplund R. Hip fractures, nocturia, and nocturnal polyuria in the elderly. Arch Gerontol Geriat 
2006; 43 (3): 319-26.
XLI Chang SC, Lin ATL, Chen KK, Chang LS. Multifactorial nature of male nocturia. Urology 2006; 67 
(3): 541-4.
76
Study 
nr
References included and used for quality assessment and data extraction
XLII Yoong HF, Sundaram MB, Aida Z. Prevalence of nocturnal polyuria in patients with benign 
prostatic hyperplasia. Med J Malaysia 2005; 60 (3): 294-6.
XLIII Hirayama A, Fujimoto K, Matsumoto Y, Hirao Y. Nocturia in men with lower urinary tract 
symptoms is associated with both nocturnal polyuria and detrusor overactivity with positive 
response to ice water test. Urology 2005; 65 (6): 1064-9.
XLIV Drake NL, Flynn MK, Romero AA, Weidner AC, Amundsen CL. Nocturnal polyuria in women with 
overactive bladder symptoms and nocturia. Am J Obstet Gynecol 2005; 192 (5): 1682-6.
XLV Massolt ET, Wooning MM, Stijnen T, Vierhout ME. Prevalence, impact on the quality of life and 
pathophysiological determinants of nocturia in urinary incontinent women. Int Urogynecol J 
Pel 2005; 16 (2): 132-7.
XLVI Ku JH, Lim DJ, Byun SS, Paick JS, Oh SJ. Nocturia and complementary indices: Determination and 
quantification of the cause of nocturia by frequency-volume charts in women with lower 
urinary tract symptoms. Urol Res 2004; 32 (3): 181-4.
XLVII Ku JH, Lim DJ, Byun SS, Paick JS, Oh SJ. Nocturia in patients with lower urinary tract symptoms: 
Association with diurnal voiding patterns. BJU Int 2004; 93 (7): 1005-8.
XLVIII Swithinbank LV, Vestey S, Abrams P. Nocturnal polyuria in community-dwelling women. BJU Int 
2003; 93 (4): 523-7.
XLIX Rembratt A, Norgaard JP, Andersson KE. Differences between nocturics and non-nocturics in 
voiding patterns: An analysis of frequency-volume charts from community-dwelling elderly. 
BJU Int, Suppl 2003; 91 (1): 45-50.
L Kinn AC, Harlid R. Snoring as a cause of nocturia in men with lower urinary tract symptoms. Eur 
Urol 2003; 43 (6): 696-701.
LI Homma Y, Yamaguchi O, Kageyama S, Nishizawa O, Yoshida M, Kawabe K. Nocturia in the adult: 
Classification on the basis of largest voided volume and nocturnal urine production. J Urol 
2000; 163 (3): 777-81.
LII Kawauchi A, Tanaka Y, Soh J, Ukimura O, Kojima M, Miki T. Causes of nocturnal urinary frequency 
and reasons for its increase with age in healthy older men. J Urol 2000; 163 (1): 81-4.
LIII Saito M, Kondo A, Kato T, Yamada Y. Frequency-volume charts: Comparison of frequency 
between elderly and adult patients. BJU 1993; 72 (1): 38-41.
LIV van Haarst EP, Bosch JL. A cutoff value based on analysis of a reference population decreases 
overestimation of the prevalence of nocturnal polyuria. J Urol 2012; 188 (3): 869-74.
LV Kim SO, Kim JS, Kim HS, et al. Age related change of nocturia in women. Int Neurourol J 2010; 14 
(4): 245-9.
LVI Graugaard-Jensen C, Rittig S, Djurhuus JC. Nocturia and circadian blood pressure profile in 
healthy elderly male volunteers. J Urol 2006; 176 (3): 1034-9; discussion 9.
LVII Udo Y, Nakao M, Honjo H, Ukimura O, Kitakoji H, Miki T. Sleep duration is an independent factor 
in nocturia: Analysis of bladder diaries. BJU Int 2009; 104 (1): 75-9.
Udo Y, Nakao M, Honjo H, et al. Analysis of nocturia with 24-h urine volume, nocturnal urine 
volume, nocturnal bladder capacity and length of sleep duration: Concept for effective 
treatment modality. BJU Int 2011; 107 (5): 791-8.
3
N
octuria and nocurnal polyuria: definitions
77
Study 
nr
References included and used for quality assessment and data extraction
LVIII Burton C, Weiss JP, Parsons M, Blaivas JG, Coats AC. Reference values for the nocturnal bladder 
capacity index. Neurourol Urodyn 2011; 30 (1): 52-7.
Parsons M, Tissot W, Cardozo L, Diokno A, Amundsen CL, Coats AC. Normative bladder diary 
measurements: Night versus day. Neurourol Urodyn 2007; 26 (4): 465-73.
LIX FitzGerald MP, Stablein U, Brubaker L. Urinary habits among asymptomatic women. Am J Obstet 
Gynecol 2002; 187 (5): 1384-8.
LX Johnson TM, Sands JM, Ouslander JG. A prospective evaluation of the glomerular filtration rate in 
older adults with frequent nighttime urination. J Urol 2002; 167 (1): 146-50.
Johnson TM 2nd, Miller M, Pillion DJ, Ouslander JG. Arginine vasopressin and nocturnal polyuria 
in older adults with frequent nighttime voiding. J Urol 2003; 170 (2 Pt 1): 480-4.
LXI Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Ruud Bosch JL. Normal voiding 
patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly 
men. J Urol 2000; 164 (4): 1201-5.
Blanker MH, Bernsen RMD, Bosch JLHR, et al. Relation between nocturnal voiding frequency and 
nocturnal urine production in older men: A population-based study. Urology 2002; 60 (4): 
612-6.
Van Doorn B, Blanker MH, Kok ET, Westers P, Bosch JLHR. Prevalence, incidence, and resolution 
of nocturnal polyuria in a longitudinal community-based study in older men: The Krimpen 
study. Eur Urol 2013; 63 (3): 542-7.
LXII Waters P, Hack MA, Richards J, Penney MD. Quantitating nocturia: A study into the recording of 
solute and water excretion to determine causation. Ann Clin Biochem 2011; 48 (4): 321-6.
LXIII Yoshimura K, Terai A. Classification and distribution of symptomatic nocturia with special 
attention to duration of time in bed: A patient-based study. BJU Int 2005; 95 (9): 1259-62.
LXIV Bodo G, Gontero P, Casetta G, et al. Circadian antidiuretic hormone variation in elderly men 
complaining of persistent nocturia after urinary flow obstruction removal. Scand J Urol 
Nephrol 1998; 32 (5): 320-4.
LXV Matthiesen TB, Rittig S, Mortensen JT, Djurhuus JC. Nocturia and polyuria in men referred with 
lower urinary tract symptoms, assessed using a 7-day frequency-volume chart. BJU Int 1999; 
83 (9): 1017-22.
Matthiesen TB, Rittig S, Djurhuus JC. Functional bladder capacity and urodynamics in males with 
nocturia. APMIS Suppl 2003; (109): 59-65.
LXVI Bing MH, Moller LA, Jennum P, Mortensen S, Lose G. Pathophysiological Aspects of Nocturia in a 
Danish Population of Men and Women Age 60 to 80 Years. J Urol 2007; 178 (2): 552-7.
Bing MH, Jennum P, Moller LA, Mortensen S, Lose G. Obstructive sleep apnea in a danish 
population of men and women aged 60-80 years with nocturia. J Clin Sleep Med 2012; 8 (5): 
515-20.
78
References
1. Cornu JN, Abrams P, Chapple CR, et al. A contemporary assessment of nocturia: definition, epidemiology, 
pathophysiology, and management--a systematic review and meta-analysis. Eur Urol. 2012;62:877-90.
2. Breyer BN, Shindel AW, Erickson BA, Blaschko SD, Steers WD, Rosen RC. The association of depression, anxiety 
and nocturia: a systematic review. J Urol. 2013;190:953-7.
3. Chasens ER, Umlauf MG. Nocturia: A problem that disrupts sleep and predicts obstructive sleep apnea. Geriatric 
Nursing. 2003;24:76-81+105.
4. Weiss JP, Blaivas JG, Stember DS, Chaikin DC. Evaluation of the etiology of nocturia in men: The nocturia and 
nocturnal bladder capacity indices. Neurourol Urodyn. 1999;18:559-65.
5. van Kerrebroeck P, Abrams P, Chakin D, et al. The standardisation of terminology in nocturia: report from the 
Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:179-83.
6. Robertson G, Rittig S, Kovacs L, Gaskii MB, Zee P, Nanninga J. Pathophysiology and treatment of enuresis in 
adults. Scand J Urol Nephrol Suppl. 1999;202:36-8; discussion 8-9.
7. Kirkland JL, Lye M, Levy DW, Banerjee AK. Patterns of urine flow and electrolyte excretion in healthy elderly 
people. Br Med J (Clin Res Ed). 1983;287:1665-7.
8. Tikkinen KA, Johnson TM, 2nd, Tammela TL, et al. Nocturia frequency, bother, and quality of life: how often is too 
often? A population-based study in Finland. Eur Urol. 2010;57:488-96.
9. Hofmeester I, Kollen BJ, Steffens MG, et al. The association between nocturia and nocturnal polyuria in clinical 
and epidemiological studies: a systematic review and meta-analyses. J Urol. 2013;Oct 29 Epub ahead of print.
10. Prins J, Blanker MH, Bohnen AM, Thomas S, Bosch JL. Prevalence of erectile dysfunction: a systematic review of 
population-based studies. Int J Impot Res. 2002;14:422-32.
11. Cartwright R, Cardozo L. Usage of International Continence Society standardized terminology: A bibliometric and 
questionnaire study. Neurourol Urodyn. 2010;29:1373-9.
12. Blanker MH, Bernsen RM, Bosch JLHR, et al. Normal values and determinants of circadian urine production in 
older men: a population based study. J Urol. 2002;168:1453-7.
13. Weiss JP, van Kerrebroeck PE, Klein BM, Norgaard JP. Excessive nocturnal urine production is a major contributing 
factor to the etiology of nocturia. J Urol. 2011;186:1358-63.
14. van Doorn B, Blanker MH, Kok ET, Westers P, Bosch JL. Prevalence, incidence, and resolution of nocturnal 
polyuria in a longitudinal community-based study in older men: the Krimpen study. Eur Urol. 2013;63:542-7.
15. Swithinbank LV, Vestey S, Abrams P. Nocturnal polyuria in community-dwelling women. BJU Int. 2003;93:523-7.
16. van Haarst EP, Bosch JL. A cutoff value based on analysis of a reference population decreases overestimation of 
the prevalence of nocturnal polyuria. J Urol. 2012;188:869-74.
17. Bray GA. Overweight is risking fate. Definition, classification, prevalence, and risks. Ann N Y Acad Sci. 
1987;499:14-28.
18. Abrams P. Editorial comment on: A cutoff value based on analysis of a reference population decreases 
overestimation of the prevalence of nocturnal polyuria. J Urol. 2012;188:874.
19. Ancoli-Israel S, Bliwise DL, Norgaard JP. The effect of nocturia on sleep. Sleep Med Rev. 2011;15:91-7.
20. Asplund R, Sundberg B, Bengtsson P. Desmopressin for the treatment of nocturnal polyuria in the elderly: A dose 
titration study. Brit J Urol. 1998;82:642-6.
21. Blanker MH, Bernsen RMD, Bosch JLHR, et al. Relation between nocturnal voiding frequency and nocturnal urine 
production in older men: A population-based study. Urology. 2002;60:612-6.
22. Burton C, Weiss JP, Parsons M, Blaivas JG, Coats AC. Reference values for the nocturnal bladder capacity index. 
Neurourol Urodyn. 2011;30:52-7.
3
N
octuria and nocurnal polyuria: definitions
79
Part II
Enuresis, nocturnal polyuria and 
functional bladder capacity:
focus on definitions
Part II
Enuresis, nocturnal polyuria and 
functional bladder capacity:
focus on definitions
Chapter 4
Reference values for frequency volume chart 
and uroflowmetry parameters in adolescent 
and adult enuresis patients
Ilse Hofmeester1,2,3, A. (Astrid) E. Brinker4, Martijn G. Steffens1, Zwaan Mulder2,
Jan Willem van Capelle1,2, Wout F.J. Feitz3, Marco H. Blanker4
1. Department of urology, Isala, Zwolle, the Netherlands
2. Dry Bed Center, Isala Noorderboog, Meppel, the Netherlands
3. Pediatric Urology Center, Department of Urology, Radboudumc Amalia Children’s 
Hospital, Radboud University Medical Center, Nijmegen, the Netherlands
4. Department of General Practice, University of Groningen, 
University Medical Centre Groningen, Groningen, the Netherlands
Neurourol Urodyn, 2015 Dec 20 [Epub ahead of print]
Chapter 4
Reference values for frequency volume chart 
and uroflowmetry parameters in adolescent 
and adult enuresis patients
Ilse Hofmeester1,2,3, A. (Astrid) E. Brinker4, Martijn G. Steffens1, Zwaan Mulder2,
Jan Willem van Capelle1,2, Wout F.J. Feitz3, Marco H. Blanker4
1. Department of urology, Isala, Zwolle, the Netherlands
2. Dry Bed Center, Isala Noorderboog, Meppel, the Netherlands
3. Pediatric Urology Center, Department of Urology, Radboudumc Amalia Children’s 
Hospital, Radboud University Medical Center, Nijmegen, the Netherlands
4. Department of General Practice, University of Groningen, 
University Medical Centre Groningen, Groningen, the Netherlands
Neurourol Urodyn, 2015 Dec 20 [Epub ahead of print]
84
Abstract
Introduction
Reference values of Frequency Volume Chart (FVC) and uroflowmetry parameters for adolescent 
and adult enuresis patients are lacking. In this study, we aim to describe those parameters, in order 
to interpret findings from FVCs and uroflowmetries in those patients.
Methods
Retrospective, descriptive cohort study, concerning 907 patients aged 11 years and older, suffering 
from enuresis of at least one wet night per fortnight, treated in a secondary/tertiary centre, between 
2003 and 2013. The main FVC parameters of interest were: maximum voided volume (MVV), 24h 
urine production and nocturnal urine volume (NUV) including first morning void (FMV). Nocturnal 
polyuria (NP) was defined based on both International Children’s Continence Society (ICCS, 2014) 
and International Continence Society (ICS, 2002) definitions. Data of all patients were collected from 
the medical files. 
Results
Age had an impact on diurnal and nocturnal FVC parameters. Median MVV excluding FMV was 250 
ml in the youngest, 11-yr-old males and 363 ml in the eldest, ≥18-yr-old males. For females, these 
values were 230 ml and 310 ml.  Median 24h urine production increased from 1,025 ml to 1,502 ml 
(males) and from 1,007 ml to 1,557 ml (females). Median NUV showed an increase from 387 ml to 
519 ml (males) and from 393 ml to 525 (females). Forty-two percent of men and 30% of women had 
a small MVV (for age). Prevalence of NP differed when assessed by the ICS or the ICCS definition: 
following ICS guidelines, NP was present in 96% of our male and 93% of our female population, 
compared to 27% and 41%, respectively, following ICCS guidelines.
 
Conclusions
Both small MVV and NP were found frequently in our adolescent and adult enuresis patients, which 
is in line with the current thoughts on causal factors. NP prevalence is quite different when using ICS 
or ICCS definitions, respectively. We would like to encourage the development of an unambiguous 
definition of NP to use both in paediatric and adult urology.
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Introduction 
Enuresis has three main causal factors: nocturnal polyuria (NP), small bladder capacity (small 
maximum voided volume, MVV), and arousal problems [1]. Frequency Volume Charts (FVCs) are 
recommended as an important diagnostic tool in patients with enuresis, providing information on NP 
and bladder capacity. Findings on FVCs should be compared to reference values, which are available 
for children 6 – 11 years of age [2], but appear to be lacking for adolescents and adults. Reference 
values for uroflowmetry are available for the normal population [3], and have been described for 
children aged 6 – 15 years with daytime and night-time wetting [4], but appear to be lacking for older 
adolescents as well.
NP is generally defined as a nocturnal overproduction of urine. The actual definitions, as currently 
stated by the International Children’s Continence Society (ICCS, 2014) and the International 
Continence Society (ICS, 2002), differ for children and adults. For adults, the ICS defined NP as 
a nocturnal urine production exceeding 20-33% (age-dependent) of the 24-hour voided volume 
[5].  For children, the ICCS applies a different definition, in which both nocturnal urine production 
and bladder capacity are used [6]. This is comparable to the nocturnal bladder capacity index, as 
introduced by Weiss et al. [7]. The ICCS defines NP to be present when the nocturnal urine volume 
exceeds 130% of the expected bladder capacity (EBC) for age. EBC is defined for children aged 4-12 
years as (age in years +1)*30 and is expressed in millilitres [8]. Recently, the validity of this NP formula 
was questioned and a new formula was proposed, representing the 97.5 percentile in a normal 
paediatric population: nocturnal urine volume greater than 20 x (age + 9) ml [9].  The adolescent age 
group is not captured in either definition.
Reference values for nocturnal urine volumes, bladder capacity and uroflowmetry are lacking 
for adolescents and young adults with enuresis. In order to interpret findings from FVCs and 
uroflowmetry in adolescents and adults with enuresis, we aimed to describe reference values, based 
on current ICS and ICCS definitions, in adolescents and adults with enuresis treated in a secondary 
care center.
Methods
Patient selection
A retrospective, descriptive cohort study was performed in 907 adolescent and adult patients with 
enuresis of at least one wet night per fortnight, aged 11-42 years at initial visit to the outpatient 
department, of which 81% had non-monosymptomatic enuresis (NMNE), treated with Adapted Dry 
Bed Training (Adapted DBT) in the Dry Bed Centre, a specialised enuresis centre, from 2003-2013.
Treatment
Patient descriptives, content of Adapted DBT and its treatment results are described elsewhere [10]. 
In brief, Adapted DBT is a 5-days/4-nights in-hospital group-training consisting of a patient history on 
enuresis, explanation, alarm treatment, day-time activities with the purpose of increasing self-esteem 
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and group contact. Follow-up was performed by telephone until six months after the initial training. 
Before Adapted DBT was initiated, all patients filled in a 3-day FVC, and underwent uroflowmetry, 
followed by post voiding residual (PVR) volume measurement by abdominal ultrasonography. 
Data collection
Data collection is described elsewhere [10]. In brief, data were derived from written medical charts 
and manually entered in a database (Research Manager®). Duplicate subtraction was performed for 
10% of all files, in order to prevent errors. When uroflowmetry was performed more than once at 
the initial visit to the outpatient clinic, the uroflowmetry with the largest volume was used in the 
analysis. 
Outcome parameters
The main parameters of interest were as follows: maximum voided volume (MVV), average voided 
volume (AVV), voiding frequency, 24h urine production and nocturnal urine volume including 
first morning void (FMV) (as described by patients themselves, as no time of rise and going to 
bed were registered). Small bladder capacity (small MVV) was defined according to the ICCS 
definition of MVV <65% of EBC. For all study participants aged ≥ 12 years, EBC was defined as 390 
ml [6]. The nocturnal polyuria index (NPi) was calculated by dividing nocturnal urine production 
by 24h urine production. Presence of nocturnal polyuria was defined in two different ways: 
1. ICS definition: NPi > 0.20, as only young patients are included in our study [5]; 
2. ICCS definition: NUP > 130% of the EBC [6]. 
 
We calculated the MVV during the day in two ways: including the FMV and excluding the FMV. The 
latter is in line with former research. In a study of 148 children without enuresis, aged 3-15 years, 
using 4-day FVCs, the MVV with the FMV was significantly higher than without the FMV [9]. The 50th 
percentile without the FMV gave values identical to Koff’s formula of (age in years +1)*30 [9].
Statistical analysis
Descriptive univariate analyses of FVC parameters using available case analyses were conducted, by 
using pairwise deletion of those cases that have missing values of the variables of interest for that 
particular analysis. This resulted in three different subset-analyses with, consequently, a different 
number of patients due to missing values: (1) analyses of diurnal FVC parameters, including all 
patients with three FVC’s, two or more outputs and no missing voiding times. (2) analyses of nocturnal 
FVC parameters, including all aforementioned patients who also had three filled in nocturnal urinary 
volumes in the FVC. (3) analyses of uroflowmetry parameters, including all patients with available 
voided volume and post voiding residual volume (PVR) measurement. For each subset-analysis, the 
age and gender-distribution were assessed, comparing the included group to the excluded group, 
by Mann Whitney U and Chi-square testing, to assess whether any selection bias was present. 
 
Results are expressed in median and interquartile ranges (IQR), as we want to show the proportional 
distribution of the different values in our population. Results are presented in different age groups: 
11 years, 12-14, 15-17 and >18 years. Our rationale here is that Koff’s formula for EBC is applicable 
until 11 years of age, and we wanted to separate the adult from the adolescent group as well. 
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We decided to present reference values, as found in this population, without statistical testing of 
possible differences according to age or gender. As we faced missing values, we did however test 
possible differences between in- and excluded groups, to see if data were missing at random or not. 
 
The ICCS and ICS nocturnal polyuria measures – percentage of EBC and the NPi– are additionally 
analyzed for enuresis severity, over the different age groups. Enuresis severity was categorized after 
ICCS definitions, as frequent (≥ 4 days/week) or infrequent (<4 days/week) [6]. The reported p-values 
are two-sided and a p-value of ≤ 0.05 was considered statistically significant. Statistical analyses were 
performed using IBM SPSS Statistics 22.
11 years 12-14 years 15-17 years ≥ 18 years All
Diurnal FVC 
parameters (N=581)  N=92 N=261 N=129 N=99
MVV incl FMV 
(mL) (med, IQR]
M 250 [200-300] 300 [250-380] 375 [300-500] 425 [300-555]
F 275 [200-350] 300 [240-400] 400 [300-470] 375 [300-430]
Small MVV, incl 
FMV (%)
M 38 32 17 19 29
F 39 32 14 16 23
MVV excl FMV  
(mL) (med, IQR]
M 250 [200-300] 275 [220-315] 350 [250-400] 363 [250-500]
F 230 [200-300] 300 [200-350] 378 [300-450] 310 [280-400]
Small MVV, excl 
FMV (%)
M 49 47 27 27 42
F 52 40 16 23 30
AVV 
(mL) [med, IQR]
M 140 [109-162] 169 [133-203] 213 [179-253] 235 [185-270]
F 148 [124-196] 173 [139-214] 218 [170-260] 202 [154-230]
FMV 
(mL) [med, IQR]
M 157 [125-197] 190 [147-250] 267 [197-317] 273 [197-400]
F 167 [140-200] 192 [150-269] 233 [190-283] 233 [187-297]
Voiding frequency 
(nr) [med, IQR]
M 6 [5-7] 5.3 [4.3-6.3] 5.3 [4.7-6] 5.7 [5-7.3]
F 6 [4.7-6.3] 5.5 [4.3-6.3] 5 [4.2-6.7] 6.3 [5-8]
Nocturnal FVC 
parameters (N=390) N=75 N=179 N=72 N=64
24hr volume  
(mL) [med, IQR]
M 1025 [865-1253] 1113 [903-1350] 1334 [1128-1591] 1502 [1042-2260]
F 1007 [916-1252] 1117 [933-1282] 1265 [973-1517] 1557 [1243-1934]
Nocturnal volume 
(mL) [med, IQR]
M 387 [287-470] 400 [283-488] 450 [367-567] 519 [267-630]
F 392 [357-500] 428 [318-555] 410 [252-520] 525 [362-683]
NPi  
(mL) [med, IQR]
M .37 [.31-.42] .35 [.28-.43] .33 [.30-.39] .30 [.26-.35]
F .40 [.37-.47] .37 [.30-.43] .32 [.23-.38] .33 [.26-.41]
NP –  
ICCS definition (%)
M 26 22 36 53 27
F 35 31 32 55 41
NP –  
ICS definition [%)
M 93 96 100 93 96
F 88 100 88 92 93
Uroflowmetry (N=589)  N=88 N=275 N=135 N=91
Voided volume 
(mL) [med, IQR]
M 221 [155-284] 263 [184-338] 330 [246-442] 283 [157-400]
F 269 [205-323] 313 [179-402] 276 [220-459] 283 [193-395]
PVR 
(mL) [med, IQR]
M 0 [0-10] 0 [0-15] 0 [0-10] 0 [0-0]
F 0 [0-5] 0 [0-13] 10 [0-30] 0 [0-10]
Bladder capacity 
(mL) [med, IQR]
M 231 [160-290] 273 [190-350] 347 [246-442] 283 [157-412]
F 270 [204-328] 319 [189-414] 287 [220-466] 285 [204-403]
Qmax 
(mL/s) [med, IQR]
M 24 [18-28] 28 [22-35] 33 [27-41] 28 [21-32]
F 34 [26-42] 36 [29-48] 38 [29-47] 38 [24-47]
Table 1. Frequency volume chart and uroflowmetry parameters for age-groups and gender.  
Abbreviations: AVV: Average Voided Volume, FMV: First Morning Void, FVC: Frequency Volume Chart, ICCS: International 
Children’s Continence Society, ICS: International Continence Society, IQR: Interquartile Range, MVV: Maximum Voided 
Volume, NP: Nocturnal Polyuria, NPi: Nocturnal Polyuria index, PVR: post voiding residue, Qmax: maximum urinary flow rate 
in ml/sec
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Results
Diurnal FVC parameters
For the analysis of the diurnal FVC parameters, 581 patients were available. Median age was 
14 years [IQR 12-16], 66% males. The excluded patients had a significant lower median age (13 
years [IQR 11-15], p<0.001), the gender distribution was not significantly different (70% males). 
All daytime parameters for the different age groups are expressed in Table 1: MVV, AVV, FMV and 
voiding frequency. Both MVV, AVV and FMV increased over the age groups. Small MVV (excluding 
FMV) for age was present in 42% of men and 30% of women, a gender difference of this magnitude 
is mainly present in the age groups between 12 and 14 and between 15 and 17 years (47 vs 40 and 
27 vs 16, respectively). When including the FMV, small MVV for age was present in 29% of males and 
23% of females when considering the whole population.
Nocturnal FVC parameters
For the analysis of the nocturnal FVC parameters, 390 patients were available. Median age was 
13 years [IQR 12-16], 66% males. The excluded patients had a significant lower median age of 13 
[IQR 11-15] years, p=0.014.  Table 1 shows an increase of 24hour voided volume, nocturnal urinary 
volume and NPi over the age groups for both genders. Table 2 shows the nocturnal polyuria measures 
for the different age groups categorized by enuresis severity (infrequent versus frequent enuresis).
Following ICS guidelines, NP was present in 96% of our male and 93% of our female population. 
Following ICCS guidelines, NP was present in 27% of males and 41% of females, differing slightly 
between gender and the different age groups (Table 1, Figure 1).
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Figure 1. Nocturnal polyuria according to ICCS and ICS definitions. 
Nocturnal urine volume for the different age groups, as measured by frequency volume chart, in Box-Whisker plots (median 
and interquartile ranges). 
Left: expressed as a percentage of the Expected Bladder Capacity (EBC). Right: expressed as the Nocturnal Polyuria index 
(right).  
The dashed lines indicate the cut-off points for the definition of nocturnal polyuria, according to ICCS (middle) and ICS 
(right) definitions. The circles above and below the box whisker plots represent outliers. 
Enuresis: FV
C &
 uroflow
m
etry param
eters
4
89
Uroflowmetry parameters
For the analysis of the uroflowmetry parameters, 589 patients were available. Median age was 14 
years [IQR 12-16], 65% males. Age nor gender distribution were significantly different between 
included and excluded patients. Uroflowmetry parameters, being voided volume, PVR, bladder 
capacity (PVR added to voided volume) and maximum urinary flow rate (Qmax) are expressed in 
Table 1, showing that PVR most often was zero milliliters.
Discussion
In this article, we attempt to provide reference values for this specific population of adolescents and 
adults with enuresis. MVV and 24h voided volumes showed a clear increase with advancing age, 
which is comparable to the normal population. The most important finding, in our opinion, is the 
large disagreement found between NP-prevalences, as defined by the ICS or the ICCS. 
Nocturnal polyuria
The ICCS has defined NP as a nocturnal urine output exceeding 130% of the EBC for a specific age [6], 
and recommended reporting of actual nocturnal urine output and EBC’s as well. In comparison, the 
ICS has defined NP as age-dependent in a categorical way: a nocturnal urine volume of more than 
20-30% of total 24 hour urine volume [5]. In our male population, 27% or 96% of patients have NP, 
according to ICCS or ICS criteria, respectively. In women, this accounted for 41 and 93%. This large 
difference is noteworthy. The accuracy of the NP definition in adults has been questioned before 
[11]. The NPi is known to be affected by age [5]. Although the absolute increment is small in our 
population, when considering age differences, the increase is still considerable. 
 
Both the percentage of EBC and the NPi differ for infrequent and frequent enuresis among most 
age groups. However, all IQRs show substantial overlap. Therefore, the differences could be due to 
chance. Additionally, the 11-year-old group also shows differences between infrequent and frequent 
enuresis, in the opposite direction. We have no adequate explanation for this; the large IQR shows 
that this could be due to chance too.
11 years 12-14 years 15-17 years ≥ 18 years Total
Nocturnal polyuria N=71 N=164 N=64 N=57 N=356
Percentage 
of EBC 
(ICCS) 
(med, IQR]
Infrequent 
enuresis
109.2  
[97.5-133.2]
90.0  
[70.1-120.3]
105.6  
[84.2-145.3]
107.5  
[72.7-175.2]
105.1  
[78.7-142.4]
Frequent  
enuresis
107.6  
[80.6-134.3]
108.3  
[79.2-131.0]
109.8  
[82.5-136.8]
147.3  
[94.0-177.4]
109.7  
[81.8-141.0]
Nocturnal 
polyuria 
index (ICS)  
(med, IQR]
Infrequent 
enuresis .45 [.36-.51] .33 [.28-.39] .33 [.30-.39] .30 [.24-.35] .33 [.28-.40]
Frequent  
enuresis .37 [.32-.42] .37 [.29-.45] .33 [.25-.36] .34 [.28-.46] .35 [.29-.43]
 
Table 2. Nocturnal polyuria measures for age-groups and degree of enuresis. 
Abbreviations: EBC: Expected Bladder Capacity, ICCS: International Children’s Continence Society, ICS: International 
Continence Society, IQR: Interquartile Range
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The paediatric ICCS definition is based on the relation between nocturnal urine production and 
bladder capacity. This relationship fits pathophysiologic reasoning (enuresis occurs when the amount 
of urine produced is too large for the bladder to store it), but does not resemble the actual amount 
of urine produced at night. We [11] and others [12] already suggested adjusting the NP definition 
in adults based on nocturnal urine production alone.  Similarly, we suggest that for children, NP 
should also be defined based on nocturnal urine production alone, like others suggested as well [9]. 
Nevertheless, in our view, this should not necessarily be based on the 97.5 percentile in the normal 
population.  In the end: although bladder capacity is important in enuresis, it does not belong to the 
definition of NP.
Small MVV
In our population, MVV without FMV increased with age, similar to previous research [2, 13]. 
Nevertheless, small MVV for age was present in 42% of men and 30% of women. This is in accordance 
with the literature [14]. Lack of inhibition of the micturition reflex is part of the aetiology as well [15].
In the older age groups, the proportion of patients with a small MVV is smaller and the proportion 
of NP (ICCS definition) is larger than in the younger age groups. This seems counterintuitive, as 
older enuresis patients are known to more often have non-monosymptomatic enuresis (NMNE) with 
daytime LUTS, often including urgency and frequency. In that case, a small MVV could be more 
frequently found. However, in our population, a high proportion of NMNE was found (81%), not 
differing over the age groups. Additionally, the definition of small MVV relies on the definition of 
EBC, which is defined for 4-12 year old children. From 12 years onwards, it is steady at 390 ml. 
Difference between the sexes was mainly present in the age groups of 12-15 and 16-17 years in our 
population. Possibly, this could be explained by existing differences in (pre)pubertal developmental 
stages (Tanner stage) between males and females, influenced by hormonal changes. Additionally, 
other factors that could be taken into account are length and body weight. Due to the retrospective 
nature of the current study, these data were unfortunately not available.
Reference values and age differences
We showed that most parameters, like MVV, AVV and FMV, were positively influenced by age, as 
expected. Gender differences were not uniformly distributed over the age groups considering the 
different parameters assessed. As discussed, gender difference was present for specific age groups 
for small MVV. Koff presented his formula of bladder capacity in children ((age in years +2), in 
ounces) based on 35 non-enuretic children investigated by cystometry during anesthesia for urologic 
surgery like hypospadias repair. Bladder capacity was determined to be the volume above which 
the slope of the cystometric curve suddenly changed and pressure increased. Koff validated his 
formula in Starfields data of 203 non-enuretic siblings of enuresis patients [16]. Here, the larger of 
two voids during the daytime was taken as the bladder capacity. The most widespread, adjusted 
formula giving MVV in milliliters ((age in years +1)*30) [17], for children aged 4-12, was found to 
be valid in a healthy Danish population when the FMV was disregarded. When including the FMV, 
this overestimated the value found by Koff’s formula [9]. In hindsight, the initial formula was indeed 
based on data without FMV, as explained. 
 
For calculation of the MVV during the day, we therefore excluded the FMV. We did investigate an 
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older, tertiary care enuresis population, which could differ on several parameters from the healthy 
population. We showed that, in all age groups, at least 50% of our patients did not reach the 
expected 390 ml, as can be explained by the known high prevalence of low bladder capacity in 
enuresis patients. Additionally, we performed the analyses by including the FMV. This showed a 
lower prevalence of small MVV in all age groups, although one third of the younger age groups and 
one sixth of the older age groups still had small MVV, even when including this FMV.
 
Although it was previously stated that omitting the FMV could be in favour when assessing enuresis 
patients who do not void large amounts early in the morning due to enuresis episodes [9], it seems 
strange that for defining the largest voided volume during a day, the actual void that is often largest 
has to be excluded. The use of a circular argument like this for a theoretical model to be true is at 
least curious, while the theory should support reality as opposed to the current situation. Notably, 
Koff’s definition is based on a non-physiological condition of anesthesia. In daily clinical practice, the 
definition is challenged as well, as the large first void is often taken into account when evaluating 
effect of bladder training and other interventions. Possibly, another definition that does take the 
morning void into account, could be helpful. In any case, in our opinion, this issue needs to be 
further discussed and adapted in future guidelines. 
Adolescence – transition period
The results of our study highlight the differences in the prevalence of NP when using 
definitions reflecting different methodologies, currently used in pediatric and adult urology. 
Overall, ICCS has defined NP based on both bladder capacity and night-time urine production. 
Calculation of age based bladder capacity has been suggested by Koff [8] and Hjälmås [18]. Rittig 
et al. recently that these age based volumes were only valid if FMV was excluded [9].  The ICS-
definition on the other hand focuses on the fraction of 24-hour urine produced during night-time. 
Physiology changes with ageing, which results in a proportional production of urine during all 24 
hours. Because of this, it is difficult to evaluate if and when the amount of urine produced at night-
time is pathological. We showed that the two definitions conflict, both in adolescents and in young 
adults. In this transitional phase from childhood to adulthood, it is not clear which definition should 
be used.
 
Transition refers to the process of children becoming independent adolescents and adults 
and to the process of the movement of patients from pediatric to adult care [19]. It has been 
thoroughly investigated in other medical specialties [20-23], and recently in urologic patients [24]. 
In this transition period, an entity – in this case explanation for complaints - should not change 
according to very different definitions used. To improve and help the fruitful cooperation of 
pediatric and adult urologists, and the transition of the adolescent patient in particular, it would 
be helpful if definitions were concordant. The interaction between pediatric and adult urology 
has been described to be limited when concerning training, conferences and joint diagnostic and 
treatment algorithms [25]. Possibly, enuresis is not easily identified as a chronic disease, which, 
like Shrewsbury mentioned for obesity, probably reduces the likelihood of it being included 
in transition planning [19]. Still, as in other conditions perverting from childhood to adult life, 
patients with enuresis will have to be protected from falling into a void between. This stresses 
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the importance of looking deeper into the process of transition in different urological diseases. 
We would like to encourage the development of an unambiguous definition of nocturnal polyuria 
to use both in paediatric and adult urology. In our opinion, both continence societies should discuss 
and supervise this process, similar to the nephrology societies that published a consensus statement 
concerning the transition from pediatric to adult renal services [26]. Overall, our findings do point 
out the importance of developing a solution for the transition from childhood to adulthood.
Limitations
Patients that filled in an FVC and were included in the descriptive analyses of the FVC variables were 
significantly older than those that didn’t and were excluded. This could possibly be explained by the 
fact that older adolescents and adults are more dedicated to stop their enuresis, and thus will fill out 
the FVC more precisely.  As we have presented reference values for different age groups, and missing 
data are not likely to be associated with this outcome, we believe that the incompleteness of data in 
the younger age group doesn’t hamper the interpretation of these values. 
 
The used FVC in itself could be seen as a limitation as well. It did consist of a three-day registration 
of both intake and output. However, the instructions on the form were not clear cut considering 
the nocturnal urine production, because no sleep and waking times were registered. We have 
ultimately tried to minimize influence of this problem by careful selection of the FVCs that were filled 
in correctly. The retrospective design of our study impairs the possibility to correct this. Another 
possible limitation of this study is that it concerns a highly selected population in a secondary/
tertiary care setting. This made it feasible to examine such a large group of patients with enuresis 
of this age, although the extrapolation potential could be limited for all enuresis patients aged 11 
years and older.
Conclusions
Both small MVV and NP were found frequently in our adolescent and adult enuresis patients, which 
is in line with the current thought on causal factors. NP prevalence is quite different when using ICS 
or ICCS definitions, respectively. We would like to encourage the development of an unambiguous 
definition of nocturnal polyuria to use both in paediatric and adult urology.
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Abstract
Aims 
Frequency Volume Charts (FVC) are recommended for the evaluation of enuretic patients. 
Although this is a good instrument for the assessment of functional bladder capacity, it is known 
that patient compliance could introduce problems. Therefore, we assessed whether uroflowmetry 
and post-void residual volume could replace FVC recordings in specific cases, by comparing the 
bladder capacity as measured by FVC or uroflowmetry.
Methods 
We performed post-hoc analyses using data from a retrospective cohort study, in secondary/
tertiary care. This included 907 patients between 2003 and 2013, aged ≥11 years, suffering from 
enuresis (≥1 wet night/fortnight). Data were collected from the medical files. Bland Altman plots 
were made to compare the two methods.
Results 
Agreement between uroflowmetry and FVC was reasonable only when uroflowmetry was between 
200 and 450 ml.
Conclusions 
For individual clinical purposes, uroflowmetry can be used if values are in this range. For future 
research, we recommend to keep measuring bladder capacity with an FVC. 
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Introduction 
To assess Lower Urinary Tract Symptoms, Frequency Volume Charts (FVC) are mandatory, both in 
children [1] and in adults [2]. In specific, functional bladder capacity (FBC) is estimated by means 
of maximum voided volume (MVV) in the FVC. This is defined as the largest single voided volume, 
excluding the first morning void (FMV) [1]. The advocated FVC length is 3 days, at the optimal 
balance between compliance (73%) and reliability (80%) [3]. Although EAU guidelines for male LUTS 
do not mention the FVC for measuring FBC [4], the pediatric EAU guideline does state that a voiding 
diary is mandatory for assessing voiding frequency and drinking habits [1; 5].In daily clinical practice, 
FVCs provide clinicians with a feasible, non-invasive method of FBC assessment. Patient compliance 
may however be problematic. As reliable information on the FBC is needed to make treatment 
choices, we wondered if this could be overcome by assessing the FBC by means of uroflowmetry 
- already performed to gain information on anatomical and functional abnormalities. Therefore, we 
investigated the agreement between FBC as measured by FVC and by uroflowmetry.
Methods
We performed post-hoc analyses on data from a retrospective cohort study in 907 consecutive 
enuresis patients, median age 14.8 years, treated with adapted dry bed training (DBT) during 2003-
2013 in a specialized incontinence center. The data were manually collected from the medical files 
and entered in a database (Research Manager®). All patients filled in a 3-day FVC, and underwent 
three uroflowmetries followed by abdominal ultrasound to measure post voiding residual (PVR) 
volume, before DBT started. We selected the largest uroflowmetry void for analyses. Descriptions of 
DBT, data-collection, baseline characteristics and reference values for FVCs and uroflowmetry have 
been published in detail [6; 7]; 34% females, 65% primary enuresis, 81% non-monosymptomatic 
enuresis and 46% frequent enuresis (≥4 wet nights/week). 
In the current analyses, we included 502 patients with available FVCs (with ≥2 voids and no 
missing voiding times), and voided volume of uroflowmetry and PVR. Excluded patients had a 
significantly lower average initial degree of enuresis (7.8±5.4 vs 8.9±4.1 wet nights/fortnight), and 
were significantly younger (13.8±4.3 vs 14.9±4.9 years) than included patients. Gender was not 
significantly different. 
Definitions 
MBV
flow
: Maximum Bladder Volume, as measured by adding voided volume of uroflowmetry and 
PVR. MVV
fvc
: Maximum Voided Volume, largest micturition excluding the FMV, as measured by FVC.
Results
We created Bland-Altman plots to compare MBV
flow
 and MVV
fvc
. In these plots, the relation between 
MBV
flow
, and the difference between MBV
flow
 and MVV
fvc
 are graphically depicted (Figure). Mean 
difference was -54 ml (SD 150), meaning that MVV was on average 54 ml larger on FVC-measurement 
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than during uroflowmetry. The trend-line has a positive slope, showing a positive relation between 
increasing MBV
flow
 and difference between MBV
flow
 and MVV
fvc
. This was similar in all age groups. 
Discussion
Comparison of uroflowmetry and FVC for assessing bladder capacity. 
We evaluated the agreement between FVC and uroflowmetry for assessing bladder capacity 
and identified three different groups: MBV
flow
 <200 ml, 200-450 ml and >450 ml.  It appeared 
that for MBV
flow
 <200 ml, MVV
fvc
 was structurally larger than MBV
flow
. In our adolescent and 
young adult population, PVR was small or non-existent. In older, male populations, PVR could be 
larger, possibly resulting in a greater influence on the MBV
flow
.  Mainly for those uroflowmetries 
registering a capacity of 150 ml and less, or less than 50% of Expected Bladder Capacity (EBC) [4], 
current clinical practice is to redo the examination, as this is thought to be no valid observation. 
Although all patients underwent several uroflowmetries, and the largest voided volume was 
used for the analysis, several patients had a capacity of less than 100 ml. An explanation could 
be that, due to stress before the appointment, patients did not hold their urine accurately. 
The two measurement methods corresponded quite accurately in the MBV
flow
 200-450 ml range. For 
patients with a capacity of 450 ml or more at uroflowmetry, however, MVV
fvc
 was lower than MBV
flow
. 
One possible explanation is that some patients will hold their urine longer than they normally do 
when a uroflowmetry has to be performed. There may be a delay between the time patients would 
actually have gone to the toilet at liberty compared with when they’re given access in the flow rate 
clinic. Another possible explanation is that larger bladders void less efficiently, resulting in a greater 
influence of PVR which is included in MBV
flow
, but not in MVV
fvc
.  
The FVC represents (although not completely) the normal daily home situation, in contrast 
to uroflowmetry, which is performed in the hospital setting. Therefore, MVV
fvc
 most probably 
represents the normal situation more adequately.  Advantages of uroflowmetry is that it 
is quick and easy and it takes even less time to interpret and administrate than the FVC. 
Disadvantages are costs for equipment and nurses, while FVC is free of charge.  For both FVC and 
uroflowmetry, patient compliance is needed, for filling out the FVC or coming with a full bladder. 
In daily practice, information from both methods determines therapy.
Definition of bladder capacity/MVV
The first morning void will barely ever be registered during uroflowmetry. We compared the MBV
flow
 
with the MVV
fvc
, excluding the FMV, in line with current guidelines. Recently, it was found that if the 
FMV is taken into account, MVV does not equal the formula for EBC, whereas it does if the FMV is 
excluded [8]. EBC is defined as (age in years +1)*30, in ml  for children aged 4-12 years [9]. 
However, the bladder is able to accommodate this FMV. In daily practice, it is a commonly expressed 
thought that the actual bladder capacity consequently will be larger. Especially for children suffering 
from enuresis, this is important, as a large FMV shows that the storage capacity of the bladder is 
sufficient and other causes should be evaluated. In the current time-frame in which other definitions 
are being reassessed, this issue should be evaluated as well.
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Other measurement methods for bladder capacity
Previously, bladder capacity has been measured by other methods than the FVC, like cystometry or 
cystoscopy [9-11]. Measurement by cystometry under general anesthesia [9; 11] could overestimate 
the actual FBC, due to the influence of anesthetics on bladder behavior and the absence of reacting 
and waking to bladder stimuli. Cystometry without anesthesia showed a significant correspondence 
of cystometric capacity minus residual volume with MVV on FVCs [10]. Considering bladder capacity, 
FVC and uroflowmetry measurement were not compared before, as far as we are aware. As treatment 
choices are based on MVV/FBC, therefore, reliability of measurement methods is important.
Conclusion
In conclusion: FVC and uroflowmetry, used as measurement methods for assessing bladder 
capacity correspond accurately when capacity, measured by uroflowmetry, is between 200 and 450 
ml. Therefore, for clinical practice, uroflowmetry volumes in that range can be used for treatment 
decisions, as the deviation will probably not result in an aberrant treatment. For future research, 
we recommend to keep measuring bladder capacity with an FVC, as in this instance, more reliable 
measurements are needed.
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Figure 1. Bland-Altman plot comparing bladder capacity as measured by uroflowmetry and frequency volume chart.  
N=502. Difference is measured by subtracting MBVflow from MVVfvc and expressed in milliliters.  
MBVflow: Maximum Bladder Volume, as measured by adding voided volume of uroflowmetry and post-void residual 
volume. MVVfvc: Maximum Voided Volume, largest micturition excluding the first morning void, measured by frequency 
volume chart.
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Abstract
Introduction
Two percent of adolescents and adults suffer from therapy-resistant enuresis with considerable 
negative impact on self-esteem and relationships. We investigated the effect of Adapted Dry Bed 
Training (Adapted DBT) in previously treatment-resistant adolescents with enuresis.
Methods
Retrospective cohort study in 907 patients, treated between January 2003 and July 2013 by our 
Adapted DBT: a 5-days/4-nights in-hospital group-training consisting of enuresis-anamnesis, 
explanation, alarm treatment, day-time activities with the purpose of increasing self-esteem and 
group contact. Structured follow-up was performed by telephone. Data were collected from medical 
files. At 6 weeks, 3 and 6 months success of treatment was determined using ICCS-definitions. 
Secondary measurements included medication use after treatment. Sensitivity analyses were 
performed to control for missing values. Assumption worst-case/best-case scenario: patients with 
missing values had no response/ full response.
Results
Patients were aged 11–42 years (med 15, Inter Quartile Range 3.5), 34% female. At baseline, 81% 
had non-monosymptomatic, 65% primary, and 46% frequent enuresis. After 6 weeks, 46% (CI
95%
 43-
50) and 41% of patients had a full or partial response, respectively. After 6 months this accounted for 
68% (CI
95%
 65-72) and 25%. Sensitivity analyses showed that full responses ranged between 31% and 
64% after six weeks and 43-80% after six months. Limitations are the retrospective study design and 
the amount of missing values. The scarce data on short-term follow-up are in line with our results, 
although different treatment outcomes were used. Additionally, our population was older.
Conclusions
Adapted DBT showed a positive response on short term, in adolescents and adults with therapy-
resistant enuresis. Nevertheless, 32% of patients still had enuresis, indicating the persisting nature 
of the disorder.
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Introduction
Enuresis, or discrete episodes of incontinence while asleep, has a negative impact on a child’s self-
esteem, relationships and school performance [1-3]. In a Dutch study, 0.5-2% of adults experienced 
enuresis [4], in comparison to 6% of children between 5-15 years of age [5].
Various treatment options are available for enuresis, like urotherapy, simple and complex behavioral 
therapy including alarm therapy or dry bed training, and drug therapy with desmopressin or 
anticholinergics [5-7]. Studies on treatment outcome mainly focused on young children, and were 
performed in small groups [5]. Data on treatment of adolescents or young adults is scarce.
Two studies concerning modifications to dry bed training on an outpatient basis in treatment resistant 
children and adolescents (mean age 11 years), showed success rates at six months in 55% and 87% 
of patients [8, 9]. Patients who remain wet when growing older, had more severe complaints. Yeung 
et al. found that both depression scores and sleep disturbances were significantly higher in patients 
than in controls [10]. Furthermore, a substantial proportion of patients with enuresis felt that the 
bedwetting  had a significant adverse effect on their social life and career [11].
Guidelines for the assessment and treatment of enuresis are available in the Netherlands and in line 
with ICCS recommendations [12-14]. Nevertheless, for adolescents and young adults with therapy-
resistant enuresis adequate treatment was missing. A specialized facility center (the Dry Bed Center-
DBC) was initiated in 2003 by a collaboration of a continence nurse, urologist and the Dutch enuresis 
patient association. For patients who remained wet after regular outpatient treatment, an Adapted 
Dry Bed Training (Adapted DBT) was developed.
In this study we retrospectively evaluated the effects of this training program in adolescents and 
young adults with therapy-resistant enuresis. 
Methods 
A descriptive, retrospective cohort study was performed, based on chart data from consecutive 
patients treated with Adapted DBT between January 2003 and July 2013 in our center.  In the 
Dry Bed Center, all referred patients suffering from enuresis were structurally evaluated at initial 
consultation. This consisted of two self-designed questionnaires concerning voiding complaints, 
a short psychological screening, medical history taking, physical examination, frequency volume 
chart (FVC) and uroflowmetry (MMS FlowMaster®) with post void residual (PVR) volume. If present, 
urological problems were treated before the training was started. We pursued to give all participants 
basic education on the anatomy and function of the urinary tract as well as lifestyle advices. 
Therefore, all participants (including MNE) received standard urotherapy, as described by Austin 
et al. [1] before being enrolled in the Adapted DBT. On an outpatient basis, anticholinergics were 
started if age-dependent small bladder capacity was present, or nocturnal bladder overactivity was 
suspected. Urodynamics were not routinely performed.
Inclusion criteria for Adapted DBT were a maximum voided volume of ≥300 ml, age ≥11 years and 
enuresis despite earlier standard therapies like desmopressin, alarm-, urotherapy, anticholinergic 
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drug therapy, or combination therapy if indicated. Some patients were dry while using desmopressin 
but repeatedly did not succeed in staying dry after cessation. These patients were enrolled in 
Adapted DBT for they wanted to be dry without using medication.
Adapted DBT program
The Adapted DBT is described in Appendix A. In short, it consisted of a 5-days/4-nights in-hospital 
group-training consisting of enuresis-anamnesis, explanation, use of a book as a diary [15], alarm 
treatment and day-time activities with the purpose of increasing self-esteem. Structured follow-up 
was performed by telephone.
Data collection
All medical files of patients treated at the DBC were collected from the hospital registry. Files 
were manually searched for baseline characteristics and outcomes. Ten percent of all files were 
subtracted in duplicate to check for possible errors. All data were entered in a database (Research 
Manager®). This included initial amount of wet nights, family history for enuresis, comorbidities, 
earlier treatments, constipation, maximal flow rate (Qmax) and PVR and medication use. Follow 
up data consisted of the amount of wet nights after Adapted DBT, medication use, alarm-therapy 
use and eventual other treatments. If at least one of two questions concerning Lower Urinary Tract 
Symptoms in the initial questionnaire was positive, we categorized patients as having NMNE.
Outcome parameters
We defined primary treatment outcome according to current ICCS recommendations [1], 
based on the percentage decrease of number of wet nights compared to baseline symptoms. 
The ICCS defined ‘initial success’ as: no-response: <50% reduction, partial response: 50-99% 
reduction, complete response: 100% reduction[1]. Secondary measurements included the use of 
pharmacological therapy for enuresis during follow-up. To compute these response groups, both 
number of wet nights before Adapted DBT and outcome are needed. Alternatively, treatment effect 
can be expressed as complete if patients are dry after treatment – irrespective of pre-treatment 
severity. For this, only post-treatment severity is needed. We performed analyses, both according to 
the ICCS methodology, as well as to the alternative method.
Statistical analysis
Effect of treatment during follow-up was analyzed for different subgroups. Age distribution is 
presented as median and Inter-Quartile-Range (IQR) due to non-normal distribution of the data. 
We categorized the patients in two age groups, adolescents: 11-17 years old, and adults: 18-42 years 
old. Degree of enuresis was categorized as frequent (≥ 4 days/week) or infrequent (<4 days/week) [1]. 
Because of the high number of missing values during follow-up, a sensitivity analysis was performed, 
presenting a worst and a best-case scenario. The following assumptions were made: worst-case 
scenario: all patients with missing values had no response to treatment, best-case scenario: all 
patients with missing values had a full response to treatment. 
Those patients that were in follow up after six weeks, were assessed after six months for missing 
value pattern, to examine whether the best or worst-case scenario of response is most likely. 
Enuresis: adapted DBT
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Differences in treatment outcome for gender, age and degree of enuresis were tested using two-
sided Chi Square test. We considered a p-value of ≤.05 as statistically significant and analyzed all data 
using IBM SPSS Statistics version 22. 
Results
Patient characteristics
In this study we enrolled 907 patients, aged 11–42 years (median 15, IQR 3.5) (Table 1). Of these, 
866 patients followed the regular Adapted DBT, and 41 the Adapted DBT ‘plus-group’. Eleven 
 % (N) Median IQR [Q1-Q3]
Age, years 14.8 3.5 [13.4-16.9]
     11 – 17 81 (733)
     18 - 42 19 (174)
Gender
     Male 66 (601)
     Female 34 (306)
Baseline wet nights per week 4.5 3.5 [2.5-6]
     Mild (0-3) 33 (300)
    Severe (4-7) 46 (418)
    Missing information 21 (189)
Type of enuresis
     MNE 11 (98)
     NMNE 81 (735)
     Missing information 8 (74)
Specific questions for NMNE
     Urinary leakage during day 29 (262)
     Holding urine easily during day 65 (587)
Primary/secondary enuresis
     Primary 65 (593)
     Secondary 17 (153)
     Missing information 18 (161)
Family history of enuresis
     Yes 61 (550)
     No 30 (276)
     Missing 9 (81)
AD(H)D, ASD 11 (101)
Earlier treatments*
     Lifting 67 (608)
     Regular alarm clock 58 (528)
     Alarm training 92 (834)
     Desmopressin 83 (755)
     Anticholinergics  
       (Solifenacin, Tolterodin, Oxybutinin)
16 (143)
     Imipramin 4 (37)
Qmax (ml/sec) at initial visit 30 16 [23-39]
PVR (ml) at inital visit 0 10 [0-10]
Times pt underwent Adapted DBT
     Once (896)
     Twice (11)
Table 1. Patient characteristics at baseline. N=907  
#Combination of treatment options was possible. Abbreviations: AD(H)D: Attention Deficit (Hyperactivity) Disorder. 
ASD: Autism Spectrum Disorder. IQR: Inter Quartile Range. Adapted DBT: Adapted Dry Bed Training. NMNE: Non 
Monosymptomatic Nocturnal Enuresis. PVR: Post Void Residue. Qmax: maximal voided stream in ml/sec
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patients underwent Adapted DBT twice due to inadequate response to the first treatment and are 
consequently described twice. 
At baseline, 81% had NMNE, 65% had primary enuresis. 46% had frequent enuresis. All patients 
underwent several treatments in the past (Table 1). Twenty-four percent of the patients were using 
anticholinergics before and during the Adapted DBT.
Results of treatment 
ICCS-response categories could be estimated for 602 (66%), 590 (65%), and 568 (63%) patients after 
six weeks, three and six months, respectively. We encountered 85% missing values for the 1-year 
follow up. Therefore, these results are not presented.
The amount of full response increased over time, from 46% to 56% and 68%, after six weeks, 
three and six months, respectively. Partial response was shown in 41%, 33% and 25%, respectively. 
According to the post-treatment analyses, 46% (CI
95%
 43-50), 55% (CI
95%
 52-59) and 68% (CI
95%
 65-72) 
of the participants were dry after six weeks, three and six months, respectively (Table 2, Figure 1). 
Sensitivity analyses showed that full responses ranged between 31% and 64% after six weeks. For 
three and six months these ranges were 36-71% and 43-80% respectively. Missing values after six 
months were encountered in all three six-week response groups. The no response group at six weeks 
had a higher percentage of missing values after six months. This indicates that the true treatment 
effect will be in the direction of the worst-case scenario.
Subgroup analyses for the different time frames are presented in Table 2.  Adults had a significantly 
different response after three months compared to adolescents; in the other time frames, no 
76
249
277
46%
76
249
582
64%
39
141
727
80%
381
249
277
31%
378
141
388
43%
39
141388
68%
No response Partial response Full response
Data Best caseWorst case
6 weeks
6 months
Figure 1. Treatment results after 6 weeks and 6 months, including sensitivity analysis  
Assumption worst-case scenario: all patients with missing values had no response to treatment.  
Assumption best-case scenario: all patients with missing values had a full response to treatment. 
Response groups according to International Children’s Continence Society criteria.
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significant differences were found. In contrast, gender was found to be associated with significant 
different responses: fewer males had a full response than females in all time frames. Significantly 
more mild-enuresis patients had a full response in all time frames than severe enuresis patients, 
although it is questionable whether this difference is clinically meaningful. The normal and ‘plus-
group’ did not significantly differ in baseline severity of complaints, response or distribution of the 
response over the different response subgroups (data not shown). 
Medication use/other treatments
During the last outpatient clinic contact before the Adapted DBT, 60% of patients used medication 
(44% desmopressin, which was stopped before Adapted DBT as part of the training program). 
After six months, 3% of patients had restarted desmopressin and 5% used anticholinergics. 
During follow up, 13 patients underwent one or more additional treatments, like laxatives, diuretics, 
alternative medicine, Botulinum toxin, psychotherapy, or additional urological investigations.           
Discussion
In this retrospective study, an intensive training program appeared to be successful in the majority 
of adolescent and adult patients with enuresis, even when failing prior therapy. Despite this positive 
effect, about one third of patients still suffered from enuresis of some degree 6 months after the 
Adapted DBT. This emphasizes the possible persistence of the problem. We believe that this is the 
largest cohort study describing the effect of intensive training for enuresis in adolescents and young 
adults. 
We aimed to describe the effect of treatment up to one year after Adapted DBT. We encountered 
many missing values at this one-year follow-up. This may be due because there was no actual 
treatment-relationship with our clinic anymore. We therefore had to restrict our conclusions 
to a shorter period of six months. Due to the retrospective nature of our study, this could not 
be influenced. The ICCS currently defines complete success as having no relapse two years after 
treatment [1]. We are unaware of any publication for this duration of follow-up.  The scarce data on 
short-term follow-up are in line with our results, although different treatment outcomes were used. 
Full response of 55% (n=49) [8] and 87% (n=52) [9] at six months was shown in two small outpatient 
studies on dry bed training. Both included younger patients, aged 7-23 (mean 11) and 4-20 (mean 
10) years, respectively. The treatment effect of 68% after six months in our study is probably an 
overestimation, due to the large loss to follow up in the six-week-non-response group. 
To be enrolled in the Adapted DBT, persisting enuresis after other unsuccessful treatments was 
required. Although our patients all sought medical attention, this could represent only a small group 
of all adolescent enuresis patients. In a tertiary enuresis clinic in Hong Kong, 37% of primary enuresis 
patients had never sought medical attention nor received therapy in the past [16], alike to the 20% of 
the Italian population of adolescents who were referred to specialists in secondary care [17].
Between 10 and 19 years of age, an annual spontaneous cure rate of 16% is described [18]. 
However, for patients having been exposed to other therapies already, such spontaneous cure rates 
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are unknown. We do not expect that natural improvement has had a significant influence on the 
described response rates at 6 months in our study population. We do acknowledge that the lack of a 
control group limits the possibility to make firm conclusions on the efficacy of Adapted DBT.
In general, adolescents show a low motivation for treatment compliance [17]. However, in our study, 
patients were motivated to follow the Adapted DBT. In follow-up we experienced many missing 
values. First of all, this may be due to the retrospective character of our study. For some patients, 
the long term response was described in the medical chart as “improved/going better”, but not 
described in actual amount of dry and wet nights.  
Additionally, the amount of missing values may be explained by the fact that patients, after having 
been treated, have no interest in follow-up. Possibly, the best conclusion is that enuresis is a difficult 
disease to gather long term results, as was illustrated by the low response rates in other long term 
questionnaire studies [19]. In general, non-adherence is a major problem in all long-term therapies 
[20].
Of our patients, 46% suffered from severe enuresis, reflecting the nature of our secondary/
tertiary care center. Yeung et al. [10] suggested, based on their epidemiological study in the 
general population of Hong Kong, that children suffering from more severe symptoms might 
have a significantly higher chance that the enuresis persists into adulthood, representing a 
more pronounced form of the condition [10]. Nevertheless, more than half of our patient group 
had mild complaints. The fact that they applied for medical care indicates that complaints 
of mild enuresis can persist over time. Due to the uncertainty of having a wet or a dry night, 
mild enuresis patients have to take precautions every night, like desmopressin or diaper use. 
In our population, adults had a significantly different response after three months compared to 
adolescents; in the other time frames, no significant differences were found. We feel that this initial 
and fading difference could maybe due to reasons of motivation depending on age. 
The main changes of our modification to the classical dry bed training were that we performed 
the Adapted DBT in an age-matched group of participants, clinically during 5 days/4 nights with a 
bedwetting alarm. Neveus [21] described that new alarm treatment attempts can work in children, 
even if this was not successful two years before [21]. The social stigma associated with enuresis [10] 
and the fact that only 2% of adolescents and young adults suffers from persisting enuresis, results 
in patients being unaware of other patients. Group contact stimulates interaction and recognition 
by sharing emotions and obstacles in daily life, and patients can motivate and support one another 
[22-24]. The multidisciplinary approach implied both nursing interventions and reinforcement of 
self-esteem. 
Eighty-one percent of our patients had NMNE. In other populations with persisting enuresis, high 
incidences of NMNE [11], as well as high incidences of detrusor overactivity and bladder outlet 
obstruction on urodynamics are described [16, 25]. This emphasizes the importance of a careful 
diagnostic work-up in this group [8, 21]. 
Children with enuresis show clinically relevant behavioral problems at rates two to four times higher 
than non-bedwetting children [26]. The most common co-morbid behavioral disorder in enuresis is 
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ADHD. In our center we experienced that children with ADHD and ASD needed more attention and 
smaller groups. In 2011 we started with ‘plus-groups’. As the normal and plus-groups did not differ in 
baseline enuresis severity or treatment outcome, we decided to describe them in the overall group. 
At start of the Adapted DBT 24% of the patients used anticholinergics, decreasing to 5% at six months, 
which is comparable to literature [8]. This could indicate that additional training can help overcome 
small bladder capacity or even night-time detrusor overactivity, decreasing drug use and preventing 
possible side effects. A small group (3%) had restarted the use of desmopressin at six months.
Conclusions
Our data suggest that older patients (adolescents and young adults), even those who have failed 
prior therapy, seem to have a significant clinical response on the short term to Adapted DBT, with a 
full response in 68% of all patients at 6 months. Despite the positive effect of Adapted DBT, 32% of 
patients still had enuresis, indicating the persisting nature of the disorder.
Enuresis: adapted DBT
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Abstract
Introduction
Adapted Dry Bed Training (Adapted DBT) has been shown to be effective in therapy-resistant 
adolescents and adults with enuresis. Given the substantial impact of enuresis and time-consuming 
character of MDBT, we investigated which patients benefited most from MDBT. Therefore, we 
identified predictors for a successful treatment response to MDBT in this population.
Methods
Retrospective cohort study in 907 consecutive patients, aged 11-42 years, subjected to in-hospital 
Adapted DBT in our Dry Bed Center between January 2003 and July 2013. Outcome was defined as 
treatment success after six months (primary outcome) and six weeks. Results of logistic regression 
analyses are presented in odds ratios and 95% confidence intervals.
Results
Predictors for a successful treatment response to Adapted DBT in adolescents and adults with enuresis 
after six months are gender (female), initial degree of enuresis (mild: 0-3 nights/week), current diaper 
use, never used anticholinergics in the past and degree of enuresis six weeks after training. Predictors 
for successful treatment response after six weeks are only gender and initial degree of enuresis. 
Limitation is the low explained variance of our model, showing that many other factors, not included 
in our study, could be of interest in the prediction of success.
Conclusions
Several factors that predicted a successful treatment response of Adapted DBT after six weeks and 
six months were identified. However, the low explained variance of our model suggests that other 
non-identified factors are also important in predicting outcome.
Enuresis: adapted DBT - predictors for success
7
119
Introduction
Enuresis negatively affects the health related quality of life of patients and parents [1] and is 
associated with a lower self-esteem [2]. In adolescents and adults, it can cause stress and social 
problems [3], having more impact on self-esteem and quality of life than in younger children [4].
Treatment options for enuresis have been investigated mainly in children. Alarm treatment 
and desmopressin are both first-line treatments [5]. Only 18-38% of patients remain dry after 
discontinuing desmopressin [6], although alarm therapy also has a relapse rate of 50% [7]. There is 
some evidence that the relapse rate is lower when combining alarm therapy and dry bed training. 
Classical dry bed training consists of a clinical training night, waking every hour to go to the toilet, 
cleanliness training (changing the bed) and positive practice (patient practices getting up and going 
to the toilet several times) if the bed is wet [8]. 
Several authors slightly changed dry bed and alarm therapy and stated that adequate use of the 
alarm was essential to the success of treatment [9, 10]. A modified form of home-bound dry bed 
therapy (DBT-M) in 74 children, was as effective as alarm therapy alone [11]. Only a few studies 
reported predictive factors for success of enuresis treatment, but these results have so far not been 
replicated [12-15]. 
Adapted Dry Bed Training (Adapted DBT) in a specialized incontinence centre is effective in therapy-
resistant adolescents and adults. Given the impact of enuresis as well as the intensity and time 
(and money)- consuming character of Adapted DBT, it is important to identify patients that benefit 
most of Adapted DBT. Therefore, in this study we aim to predict a successful treatment response to 
Adapted DBT in adolescents and adults.
Methods
Patient selection
We performed a retrospective cohort study on 907 consecutive patients to evaluate the characteristics 
of patients that were treated with Adapted DBT in our Dry Bed Center (DBC) between January 2003 
and July 2013. Patients were adolescents and adults aged 11 to 42 years.
Treatment
The DBC is a secondary and tertiary care facility. At the initial visit to the DBC outpatient 
department, all new patients were asked to fill in a number of questionnaires, as well as a 3-day 
frequency volume chart. For the amount of wet nights, a chart was used which represented 14 
nights, on which patients had to fill in whether they were wet or dry. Patients were evaluated 
by uroflowmetry and ultrasound for assessing the Post Voiding Residual volume (PVR). If 
no additional urological investigations were needed, advice was given or desmopressin, 
anticholinergic treatment or alarm training was started. If maximum voided volume of 300 ml 
was reached but enuresis was still present, patients were considered eligible for Adapted DBT. 
The actual Adapted DBT consisted of an in-hospital stay for 5 days (4 nights), in a group with other 
patients of similar age. During the first training night, patients were woken every hour to drink a glass 
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of water and go to the toilet. During the following nights, patients slept with an alarm (Contessa ®, 
Urifoon B.V., Amstelhoek, the Netherlands) and they were instructed to set a personal alarm clock 
at an individually adequate moment during night-time to try to prevent wet nights. If a patient was 
wet, the attending social-pedagogic worker got a signal and could see whether or not the patient 
acted right (cleanliness training). Daytime activities included exercises to increase self-confidence. 
After the in-hospital stay, patients used their bed-wetting alarms and personal alarm clocks at home. 
They were regularly followed up by telephone by social-pedagogic workers weekly for the first six 
weeks, followed by monthly contact until six months.
Data collection
All medical files of patients treated at the DBC were collected from the hospital registry. Files were 
manually searched for baseline characteristics and outcomes. Data was separately extracted in 
duplicate from 10% of all files.  All data were entered in a database (Research Manager ®, Cloud9 
Health Solutions, Deventer, the Netherlands). If at least one of two questions concerning LUTS 
(any urinary leakage or inability to hold urine easily during the day) at the initial questionnaire 
was answered positive, patients were diagnosed having non-monosymptomatic enuresis. When 
uroflowmetry was performed more than once at the initial visit to the outpatient clinic – two to 
three times, as Dutch guidelines advise [16] -, the uroflowmetry with the largest volume was used. 
We categorized the degree of enuresis at initial visit to the outpatient clinic as mild (0-3 wet nights 
per week) and severe (4-7 wet nights per week), according to current International Children’s 
Continence Society (ICCS) guidelines (in-frequent 0-3/wk and frequent 4-7/wk) [17].
Outcome parameters
The primary outcome parameter was treatment success six months after training, as long-term 
effects are of primary interest. The secondary outcome parameter was treatment success six weeks 
after training. The patients were distributed in two categories: responders (dry) and non-responders 
(still wet), although the ICCS proposed recently to use other categories [17]. Main argument for 
this was our sense that patients are only really cured and satisfied with dryness. If patients are 
still sometimes wet they will always have to take precautions anyway, because in such cases, the 
moment of involuntary urine loss cannot be anticipated.
Statistical analysis
Causality is no issue in prediction models [18]. Therefore, all parameters available in our database 
were used as possible predictors. First, frequency tables of all variables were made. We found 
that up to 30% of data was missing. The data were missing at random, as tested by Little’s MCAR 
test, which was significant. We therefore performed multiple imputations, using pooled data of 30 
imputations [19], using the outcome parameter as the dependent variable in the imputation. This was 
performed in two separate databases for the primary and secondary outcome. For both outcomes, 
the following parameters were used for the imputation: gender, date of birth, earlier treatments, 
diaper use, family history, been dry in the past, constipation, year of treatment, character of voided 
stream (bell/tower/plateau shaped uroflowmetry curve), psychological features, sleeping problems, 
back problems (dimple, pain, deformities), degree of enuresis during intake (number of wet nights 
per fortnight) and age.
Enuresis: adapted DBT - predictors for success
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Secondly, we performed univariate analyses. For this we used univariate logistic regression between 
the outcome parameters and all individual explanatory variables. All explanatory parameters with a 
(chi-square) p-value of <0.25 were subsequently used in the correlation matrix, the other explanatory 
parameters were discarded from the subsequent analyses. Correlation matrices were checked for 
collinearity. As no variables had a collinearity > 0.8, no additional variables were discarded for the 
subsequent analysis [20].
For both outcomes, logistic regression models were run by using the hierarchic standard regression 
method (“Enter” method in SPSS) [21]. Treatment success was entered as dependent variable and 
possible predictors were entered as independent variables (see legend Table 2 and 3). Subsequently, 
a stepwise backward selection strategy was used, i.e. the model was run in steps after excluding 
the predictive parameter with the highest p-value in the last model, until the simplest model, only 
expressing significant predictors, was obtained.
Finally, the explained variance was expressed by Nagelkerkes R2 and the model fit was evaluated by 
the Hosmer and Lemeshow goodness-of-fit test [22].
We present the results of the analysis in the original and pooled imputed data. 
The predictive capacity of the variables is expressed in odds ratios (OR) with 95% confidence intervals 
(CI). Reported p-values are two-sided and a p-value of ≤ 0.05 was considered statistically significant. 
Statistical analyses were performed using IBM SPSS Statistics (version 22).
Results
Patient characteristics
Baseline characteristics of the 907 patients are presented in Chapter 6.
OR CI 95%
Original data
Gender (male vs female) 0.563 0.370 - 0.856
Initial degree enuresis (mild vs severe) 1.701 1.086 - 2.665
Diaper use (no vs yes) 0.542 0.354 - 0.832
Anticholinergic in past (no vs yes) 4.083 1.341 - 12.438
% wet nights at 6 wk 0.982 0.970 - 0.993
Pooled imputed data
Gender (male vs female) 0.628 0.429 - 0.920
Initial degree enuresis (mild vs severe) 1.839 1.204 - 2.808
Diaper use (no vs yes) 0.647 0.426 - 0.982
Anticholinergic in past (no vs yes) 2.814 1.056 - 7.500
Table 1. Results logistic regression analysis for primary outcome: success after six months 
OR: odds ratio, CI: confidence interval 
Independent variables with a p<0.25 in the univariate analyses included in the multivariable model were: gender, age 
(adolescent or adult), past treatments (taking up to go to toilet at night, desmopressin, anticholinergics), current diaper use, 
urgency, urinary tract infection in the past, family history positive of enuresis, (psychosocial) medical history, medication 
just before Adapted DBT, degree of enuresis before Adapted DBT, how often wet per night before Adapted DBT, degree of 
enuresis at six weeks, ever been dry, first or second time Adapted DBT, volume voided at uroflowmetry. Only the remaining 
variables are presented.
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Primary outcome: response after six months
Data from 600 (65%) patients were available for the final logistic regression model in the original 
data six months after in-hospital training. Of those, 408 (68%) patients were dry. After multiple 
imputation, data from 758 (84%) patients were available for performing the final logistic regression 
model, of whom 502 (66%) were dry. 
Gender (‘female’), initial degree of enuresis (‘mild’), diaper use at the intake (‘yes’), and previous 
use of anticholinergics (‘no’) are the predictors of success after six months in our cohort (Table 1) 
in both the original and the pooled data. In the original data, an additional predictor was found: 
degree of enuresis after six weeks, although the added value was limited with an OR of 0.982. 
The Nagelkerke R2 was 0.087 and 0.082 (original and imputed data). The Hosmer and Lemeshow 
goodness-of-fit test showed a non-significant value of 0.355 and 0.297 (original and imputed data) 
at the final step of our model, suggesting that the model fits to our data, especially when taking 
the high sample number into account. Nevertheless, the Nagelkerke R2 shows that the model only 
explains a minor part of the outcome parameter.
Secondary outcome: response after six weeks
Data from 689 (76%) patients were available for the final logistic regression model in the original data at 
six week follow-up. Of those, 314 (46%) patients were dry. After multiple imputation, data from 809 (89%) 
patients were available for performing the final logistic regression model, of whom 362 (45%) were dry. 
Gender and initial degree of enuresis were the significant predictors of success after six weeks (Table 2), 
both in the original and the imputed data. In the latter data, men had an OR of 0.665 (95%CI 0.481-0.918) 
compared to women. Mild enuresis an OR of 1.460 (95%CI 1.061-2.009) compared to severe enuresis. 
The Nagelkerke R2 was 0.023 and 0.025 (original and imputed data). The Hosmer and Lemeshow 
goodness-of-fit test showed a significant value of 0.005 and 0.014 (original and imputed data, 
respectively) at the final step of our model, suggesting that the model fits poorly to our data.
Table 2. Results of logistic regression analysis for secondary outcome: success after six weeks 
OR: odds ratio, CI: confidence interval 
Independent variables with a p<0.25 in the univariate analyses included in the multivariable model were: gender, age 
(adolescent or adult), past treatments (taking up to go to toilet at night, alarm therapy, setting own alarm, medication, 
desmopressin, anticholinergics, imipramin), current diaper use, how wet if no use of diapers, how often wet per night, 
diurnal incontinence complaints, urinary tract infection in the past, pain during voiding, family history positive of enuresis, 
degree of enuresis before Adapted DBT, ever been dry (and during how many months)), own prediction (between 1-10) of 
success before Adapted DBT, type of group (normal or plus, with additional psychotherapy)  referred by first or secondary 
care, volume voided at uroflowmetry. Only the remaining variables are presented.
OR CI 95%
Original data
Gender (male vs female) 0.676 0.493 - 0.928
Initial degree enuresis (mild vs severe) 1.443 1.043 - 1.996
Pooled imputed data
Gender (male vs female) 0.665 0.481 - 0.918
Initial degree enuresis (mild vs severe) 1.460 1.061 - 2.009
Enuresis: adapted DBT - predictors for success
7
123
Discussion
Factors that could predict successful treatment response of Adapted DBT in adolescents and adults 
with enuresis after six months are gender, initial degree of enuresis, current diaper use, never having 
used anticholinergics in the past and degree of enuresis six weeks after training. Factors that predict 
the outcome after six weeks are gender and initial degree of enuresis.
We were able to create a prediction model for those parameters that are easily available and relevant 
for predicting a successful treatment. Such parameters are of importance in daily practice as well 
as in the design of prospective (intervention) studies. Most adolescents and adults with enuresis 
already experienced many different therapies for which a strong motivation is essential. Predicting 
which patients will most likely benefit from therapy helps in several ways: informing patients on their 
possible individual benefit, more realistic goals, and selection of patients for specific therapies and 
directing treatment in a cost-effective way.
As far as we are aware, no prediction model for the effect of in-hospital dry bed training in combination 
with alarm therapy for enuresis has been published yet. However, Adapted DBT consists of several 
components, for which prediction models have been described in literature [11-13, 15], which are 
however limited due to lack of external validation. A multivariate analysis in a recent trial in primary 
MNE children treated by desmopressin or enuretic alarm for six months, showed that treatment group, 
monthly income and severe enuresis (>5 wet nights/week) were independent important predictive 
factors for cure after first line treatment [15]. Response categories were complete, good, partial and 
no response. Severe enuresis being a predictive factor for success is in contrast with our results. 
Behaviour therapy (charts, motivational therapy and bladder awareness training without alarm 
therapy) was analysed in a population of 122 (74 completed study) children aged 5-9 years old. 
Thickness of the bladder wall measured by ultrasound was strongly correlated to poorer treatment 
response and higher severity of the complaints [12]. This treatment differed to our Adapted DBT 
by it being on an outpatient basis, only focusing on behavioural therapy, not on alarm therapy. 
Response categories were the same as used by Onol et al. [15], suggested by the ICCS in 2006 [23]. 
Devlin et al. treated 127 patients aged 6-17 (mean 8.8) years with alarm therapy and outpatient 
behavioural therapy (cleanliness training, personal hygiene, daily bladder exercises and charts) [13]. 
Response was categorised in dry and still wet, as ‘children who achieved >50% improvement in 
wetting but not full cure were considered to be failures’. Their prediction model showed that risk of 
failure was 5% at six months and 10% at 12 months if none of the following adverse variables was 
present, increasing by family stress and lack of child’s distress (six months) and lack of child’s distress, 
psychiatric disorder and developmental delay (12 months) [13]. 
 
Butler’s DBT-M also took place on an outpatient basis, in 6.1-14.4 year olds. A predictive factor for 
treatment response was teasing by siblings, as reported by the child. Drop-out rate increased if 
maternal anger over their child’s bedwetting was present [11]. Our Adapted DBT differs from Devlin 
and Butlers therapies by the treatment taking place in-hospital with special consideration to gaining 
self-confidence, and the alarm-therapy being continued for six weeks. Additionally, our population is 
much larger and concerns only adolescents and adults. 
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Recently, new ICCS guidelines have been published [17], proposing three instead of four response 
categories, as this was thought to be relevant for research purposes. The evidence base for this 
change remains unclear. As stated, throughout the years, different categories have been used. We 
argue that patients are only really cured with dryness, and therefore, we chose for two response 
categories: dry or wet. 
We believe that our study has two main limitations. First, the number of missing data was 
considerable, due to the retrospective nature of our study. This could have led to attrition bias in 
our study. We aimed to improve the accuracy of our models by multiple imputing our data on the 
outcome parameters. We chose for presenting both models in the original as well as in the pooled 
imputed data, to give the reader insight in the possible difference. We have shown that neither the 
models nor the fit of them differed, except for the degree of enuresis at six weeks, which was found 
as additional predictor in the 6 month-original-data-model compared to the pooled model. This 
variable added only little to the model with a very small OR. 
The second limitation of our study is that our models showed a low explained variance. We believe 
this might illustrate that our study population may have been more homogeneous than previously 
expected. This can also be explained by the multifactorial origin of enuresis, patients in different age 
groups, with a different medical history concerning enuresis treatments. The low R2 of our model 
shows that many other factors, not included in our study, will be of interest in the prediction of 
success. 
 
Although the urge arises to try to explain why the variables that we found predict success, we cannot 
infer any causal relationships based on (these) prediction models. One of the next steps should be 
to externally validate our prediction model because non-validated models should not yet be used in 
clinical practice, preferably using patients from another hospital [24].  
Conclusions
Factors that could predict successful treatment response of Adapted DBT in adolescents and adults 
with enuresis after six months are gender (‘female’), initial degree of enuresis (‘mild’), current 
diaper use (‘yes’), anticholinergic drug use in the past (‘none’) and degree of enuresis six weeks after 
training. Factors that predict the outcome after six weeks are gender and initial degree of enuresis.
Enuresis: adapted DBT - predictors for success
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Abstract
Introduction
Enuresis and nocturia share etiological factors, but little is known about their association. 
We aimed to study the presence of nocturia in patients formerly treated for enuresis, but experienced 
problems with response. We focus on this and on possible solutions for this field of research. 
Methods
Cross-sectional questionnaire (ICIQ M/FLUTS and LUTSqol) study in 553 patients ≥18 years, treated 
between 2005-2011 by adapted Dry Bed Training. Invitations were sent in three, sequential, steps: 
initial invitation (9% response), subset called (15% response), random subset, n=50, offered reward 
(42% response). Due to these low response rates, we decided to focus on comparing patient 
characteristics according to the invitational phases, instead of comparing the prevalence of nocturia 
between initial success-of-treatment-groups. 
Results
Of the 76 responders, median age was 23 [IQR 20-25], 41 were men. ICIQ and bother scores were 
all low. Nocturia (≥1x) was present in 55% (men) and 72% (women); clinically relevant nocturia (≥2x) 
in 8% (men) and 25% (women). Ten men (30%) and 9 women (28%) had enuresis (≥1/28 nights). In 
the different invitation phases, patient characteristics were not significantly different, although the 
reward-group had slightly lower bother scores and nocturia prevalence.
Conclusions
We faced serious problems in successful patient recruitment in studying long-term follow-up of 
adapted DBT for enuresis. As others have faced this as well, we doubt if long-term follow-up is 
feasible in this patient group. When gathering long-term follow-up in a retrospective study, we 
recommend to include a reward to increase response rates and thus interpretability of the results.
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Introduction
Enuresis (the involuntary loss of urine at night) is common in children (15-20% of five year olds), and 
still exists in up to 2% of young adults [1, 2]. Those patients who remain wet if they grow older, have 
more severe complaints [3]. Nocturia represents the condition in which patients do arise in response 
to bladder stimuli. In adults, two or more nocturnal voidings are increasingly considered to be the 
threshold at which nocturia is more likely to be symptomatically bothersome [4]. 
Enuresis and nocturia share etiological factors such as nocturnal polyuria and a small bladder capacity. 
Still, little is known about the association between enuresis and nocturia. The available information 
is gathered from retrospective studies in former enuresis patients or their parents. The other way 
around; investigating past enuresis in older nocturia patients will lack information about the course 
of the enuresis. Mothers of children with enuresis who experienced enuresis in their own childhood, 
show a higher risk of having nocturia in adulthood [5]. Additionally, 35% of former – mainly non-
monosymptomatic enuresis patients in a tertiary care population had (clinically relevant) nocturia. 
The response rate in this study was 41% [6]. The International Children’s Continence Society states 
that long term follow up of enuresis of two years or more is necessary [7], but it seems to be very 
difficult to gather a high response rate and thus valid answers [8]. 
A detailed study on nocturia comparing groups of (former) enuresis patients could be of help in 
understanding the evolution of enuresis into nocturia. Especially differences in enuresis degree, and 
applied methods for the treatment of enuresis are of interest. Asides, the impact of nocturia on 
health related quality of life is of interest for clinical care of this patient group. 
We aimed to study the presence of nocturia and other LUTS, and their impact on quality of life in 
patients formerly treated for therapy-resistant enuresis by adapted Dry Bed Training (DBT): long term 
follow up studied by cross-sectional questionnaires. Unfortunately, we experienced large difficulties 
regarding appropriate response rates. In this paper, we will focus on these problems and possible 
solutions for this field of research. 
Methods
We performed a cross-sectional questionnaire study in which patients formerly treated by 
Adapted DBT in the Dry Bed and Pelvic Center (Droog Bed en Bekken Centrum – DBBC, Meppel, 
The Netherlands) were included. Results of the initial treatment of this group have been published 
previously [9].
Patient selection
We selected a group of patients treated between 2005 and 2011, and were 18 years or older at the 
moment the questionnaire was sent in July 2014. The study closed in August 2015. Hence, the time 
since treatment varied from 3 to 9 years. This period is chosen because the ICCS defines long term 
follow up being a follow up of two or more years after treatment [10]. 
Patients were selected from the hospital/outpatient department records at Diagnosis Treatment 
130
Code (in Dutch “Diagnose Behandel Combinatie”, DBC) and were contacted by postal mail using 
an explanatory letter. The questionnaires could be filled in digitally or on paper, according to 
the patient’s wishes. For the digital input of the questionnaires, Research Manager® was used. 
Participants were asked to fill out a questionnaire and a Frequency Volume Chart (FVC).
The institutional review board of our hospital approved this study (nr 14.061).
Questionnaires
The questionnaire consisted of three parts: the validated International Consultation on Incontinence 
modular Questionnaires (ICIQ) [11, 12]; the MLUTS or FLUTS, for males and females, respectively, 
and the LUTSqol. MLUTS scores range from 0-20 (voiding symptoms), and 0-24 (incontinence); FLUTS 
scores range from 0-16 (filling), 0-12 (voiding), and 0-20 (incontinence).
The third part of the questionnaire consisted of questions concerning enuresis, developed by 
ourselves for this study. Although a questionnaire for evaluating nocturia, enuresis and quality of 
life exists (NNES-Q), this questionnaire has been validated in an elderly, unselected population [13]. 
Therefore, we believed that it consists of questions, which are not completely appropriate for our 
population. Additionally, NNES-Q has not been validated in Dutch. Consequently, we have chosen to 
compose a questionnaire with additional relevant questions, which are not addressed by the ICIQ’s. 
These questions concerned the amount of wet nights, the severity of wetness, treatments after 
adapted DBT for enuresis, and current medication use.
The response rate for FVCs was expected to be lower than for the questionnaires. Therefore, at 
the first contact, we focused on these validated questionnaires and we sent the FVC’s only to the 
responders of the questionnaires. We planned on contacting patients by telephone in case of a low 
response rate.
Initial power analysis and statistical analysis plan
Our purpose was to compare the prevalence of nocturia between patients who had an initial full 
response with those having had a partial or no response to adapted DBT. Therefore we performed 
a sample size calculation using this primary outcome parameter. Goessaert et al. found 35% of full 
response patients to have nocturia [6]. 
 Index 
population
Responders Non-responders Responders vs 
non-responders
Number, n (%) 553 76 (13.7) 477 (86)  
Gender, males, n (%) 361 (65) 41 (54) 320 (67) 0.025
Age in years, med [IQR] 22 [20-24] 23 [20-25] 22 [20-24] 0.206
Infrequent enuresis pre-treatment 
(≤3 wet nights/ wk), n (%)
176 (32) 28 (37) 148 (31) 0.135
Frequent enuresis pre-treatment 
(≥4 wet nights/ wk), n (%)
321 (58) 36 (47) 285 (60) 0.135
Treatment response after 6 months 0.077
  no treatment response, n (%) 30 (7) 3 (6) 27 (7)
  partial treatment response, n (%) 114 (27) 8 (15) 106 (28)
  full treatment response, n (%) 283 (66) 43 (80) 240 (64)  
Table 1. Descriptives of patients, considering invitation and response.  
Patients aged 18 years and older, and underwent adapted DBT ≥2 yrs ago were invited.  
Analyses are performed by Chi-square, Fisher exact and Kruskall Wallis testing.
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Between 2005 and 2011, 553 patients now aged 18 years and older were treated by adapted DBT 
and could be approached. With an expected response rate of 60%, 182 patients in each group would 
be available. With this amount of patients, we would have been able to demonstrate a difference of 
14 percent in proportion of nocturia between the full and partial/no response group (α 0.05, β 0.2, 
two sided testing), which we considered to be clinically relevant.
Secondary study outcomes concerned current LUTS and micturition pattern, and quality of life, as 
measured with the ICIQ F and M LUTS and the ICIQqol, respectively. For quality of life assessment, a 
discrete 10-point scale was used. For the other items on the questionnaire, a Likert scale was used. 
These ordinal data are expressed in proportions. To compare the two groups, Chi-square testing was 
planned to be performed. 
Adjustments to the study protocol
The response rate to the initial invitation was only 9% (n=48). Calling a subset of 89 patients, of 
which 48 patients were reached, resulted in a response rate of 15% (n=7). Therefore, a third effort 
was made, by resending the invitation to a random subset of 50 patients, which we offered a reward 
if the questionnaire would be completed. We wondered if our initial way of approaching patients 
was too difficult (giving them the choice of filling out the questionnaire digitally or asking for a paper 
questionnaire). Therefore, we chose to approach 25 patients of this subset the way we initially did, 
while the other 25 patients were immediately sent a paper questionnaire, without the opportunity 
of digital administration. As re-inviting all participants could be thought of to be unethical for the 
primary purpose of a study, we changed our focus from the initial primary outcome to potential 
solutions to improve response rates. As we received only one FVC, we decided not to describe these 
FVC data.
 Total Initial 
invitation, 
digital
Initial 
invitation, 
paper
After 
calling
Second 
invitation 
(reward)
P
Number, n (%) 76 (13.7) 39 9 7 21
Gender, males, n (%) 41 (54) 19 (49) 5 (56) 3 (43) 14 (67) 0.541
Age in years, med [IQR] 23 [20-25] 23 [22-25] 23 [22-25] 24 [20-25] 22 [19-24] 0.585
Infrequent enuresis  
pre-treatment  
(≤3 wet nights/ wk), n (%)
28 (37) 15 (38) 3 (33) 2 (29) 8 (38) 0.993
Frequent enuresis  
pre-treatment  
(≥4 wet nights/ wk), n (%)
36 (47) 18 (46) 4 (44) 3 (43) 11 (52) 0.993
Treatment response  
after 6 months 0.117
  no response, n (%) 3 (6) 0 (0) 1 (20) 1 (25) 1 (6)
  partial response, n (%) 8 (15) 4 (14) 2 (40) 0 (0) 2 (13)
  full response, n (%) 43 (80) 25 (86) 2 (40) 3 (75) 13 (81)
Nocturia (≥1x/ night), n (%) 48 (64) 27 (69) 6 (67) 5 (71) 10 (50) 0.501
Nocturia (≥2x/ night), n (%) 12 (16) 6 (15) 2 (22)  2 (29) 2 (10) 0.653
Bother score, males,  
med [IQR] (min-max)
1 [0-2] 
(0-10)
1 [0-1] 
(0-9)
0 [0-5] 
(0-10)
0 [0-1] 
(0-1)
1 [0-2] 
0-7)
0.475
Bother score, females,  
med [IQR] (min-max)
1 [0-3] 
(0-7)
1 [0-4] 
(0-7)
2 [1-2] 
(1-2]
2 [0-4] 
(0-5)
0 [0-1] 
(0-5)
0.506
Table 2. Characteristics of response in different invitation phases.  
Analyses are performed by Chi-square, Fisher exact and Kruskall Wallis testing.
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Instead of comparing the prevalence of nocturia between initial treatment success groups (full 
response vs partial/no response), we decided to compare patient characteristics (age, gender, 
nocturia status, treatment response) according to the phase of responding (initial invitation, 
telephone reminder, reward), to see if invitation methods resulted in a different sample. We 
compared the differences between invitation groups by Chi-square and Kruskall-Wallis testing. 
Results of questionnaires are presented without further statistical analysis, for men and women 
separately (Table 3). Data were processed in SPSS 22.0.
Results
Response
An invitation to fill out the questionnaire was sent to 553 patients (65.3% males). Total response of 
N (%) Median 
[IQR]
Experienced as a problem
(0 no - 10 big problem)
Median (min-max)
Males 41
ICIQ – symptom scores
   Voiding symptoms (0-20) 40 3 [1-4]
   Incontinence symptoms (0-20) 39 2 [1-4]
ICIQ – specific questions
   Nocturia (≥1x) 22 (55) 0 (0-10)
   Nocturia (≥2x) 3 (8)
   Urgency (sometimes/often) 23 ( (58) 1 (0-10)
   Perceived low self-image 7 (18) 0 (0-8)
   Tired due to LUTS (sometimes/often) 7 (18) 0 (0-8)
   Influence on sleep (sometimes/often) 16 (41) 0 (0-10)
   Overall influence of LUTS on daily life 1 (0-10)
Additional questionnaire
   Enuresis (≥1 wet night/28 nights) 10 (30) 0 (0-10)
   Enuresis (≥1 wet night/6 months) 16 (44)
   Frequent enuresis (≥4 wet nights/wk) 2
   Additional treatment after adapted DBT 1, mesology
Females 35
ICIQ – symptom scores
   Filling (0-16) 33  4 [2-5]
   Voiding symptoms (0-12) 33 1 [0-2]
   Incontinence symptoms (0-20) 34 3 [0.75-6.25]
ICIQ – specific questions
   Nocturia (≥1x) 26 (72) 1 (0-10)
   Nocturia (≥2x) 9 (25)
   Urgency (sometimes/often) 26 (74) 2 (0-8)
   Perceived low self-image 11 (32) 0 (0-8)
   Tired due to LUTS (sometimes/often) 13 (39) 0 (0-10)
   Influence on sleep (sometimes/often) 21 (62) 2 (0-8)
   Overall influence of LUTS on daily life 1 (0-7)
Additional questionnaire
   Enuresis (≥1 wet night/28 nights) 9 (28) 0 (0-10)
   Enuresis (≥1 wet night/6 months) 20 (61)
   Frequent enuresis (≥4 wet nights/wk) 1
   Additional treatment after adapted DBT 3, PFP, botox, alarm
Table 3. Results questionnaires, for males and females. 
DBT: Dry Bed Training, ICIQ: International Consultation on Incontinence Questionnaire, PFP: Pelvic Floor Physiotherapy
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the three efforts was 14%. Response rate to the initial sending was 9% (n=48). The response rate to 
the additional calling of a subset of 89 patients of which 48 patients were reached, was 15% (n=7). 
The final subset of patients that was approached with a possibility of a reward gave a response 
of 42% (n=21 out of 50), of which 11 patients (44%) responded to the initial way of approaching - 
offering patients choice between digital and paper questionnaire - and 10 patients (40%) responded 
to the paper questionnaire. 
Table 1 shows the distribution of age, gender, initial degree of enuresis and success group after 
six months for responders and non-responders. Overall, males were less likely to respond to the 
invitation (p=0.025). Responders seemed more likely to have had a full treatment response six 
months after adapted DBT, although this was not statistically significant (p=0.077). Table 2 shows 
these characteristics and current quality of life and nocturia, over the different invitation phases 
(initial sending/calling/reward).  In the three invitation phases, there were no differences considering 
age or gender. The group of participants that responded to the invitation with the reward, seemed 
to have a lower prevalence of nocturia than the participants in the other groups, although this 
difference was not statistically significant.
ICIQ scores, nocturia and enuresis
Of the 76 responders, median age was 23 [IQR 20-25]. This represented 41 men and 35 women. 
ICIQ scores were all low (Table 3). Overall quality of life due to voiding complaints was median 1 
(expressed on a Likert scale from 0-10), both for men and women. Nevertheless, maximum values 
were 7 and 10 respectively. 
Nocturia (≥1 voids per night) was present in 55% of men and 72% of women; clinically relevant 
nocturia (≥2 voids per night) was present in eight percent of men and 25% of women. Enuresis 
(≥1/28 wet nights) was present in 10 (30%) of men and 9 (28%) of women (Table 3).
Discussion
Response
We faced serious problems in successful patient recruitment in studying long-term follow-up of 
treatment for enuresis. Comparable studies have experienced response rates of approximately 
40% [6]. In a former short survey (unpublished data), we encountered a response rate of 47% of 
patients treated in the last ten years. However, from 2007 onward, the annual response rate was 
between 54 and 62%. Therefore, we had expected a higher response rate than we experienced 
in this study. The possibility of digital completion of the questionnaires was presumed to 
increase the response rate, as we approached a young, digitally active, group of patients. 
Several different explanations for the problems in patient recruitment can be assigned: 
In daily life, people increasingly receive invitations to evaluate used services or products. Inevitably, 
this results in a lower willingness to participate in all separate evaluations. A more extensive 
questionnaire will have a negative impact on response rates. Our questionnaire was rather large. 
Additionally, patients had been asked to fill in a very short questionnaire before. The absence of an 
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active treatment relation with the DBBC may also negatively influence response rates in our view. 
Additionally, we evaluated a shameful problem; former patients want to let this topic rest if 
the enuresis is gone, or do not want to talk about it if it is still present. A high proportion of the 
responders had a full treatment response six months after the initial adapted DBT (80%). A full 
treatment response was defined following ICCS definitions as 100% response to treatment, so dry; 
no wet nights [7]. The full treatment response of the invited population as a whole was 66% (Table 
1). This shows that mainly those patients that have been cured were willing to respond. 
ICCS guidelines and Cochrane reviews focus on the lack of research on long-term follow-up and 
consequently propagate to report this information [7, 14]. As others have faced serious response 
problems as well, we doubt if long-term follow-up is feasible in this patient group, especially when 
patients do not have an active treatment relation with their physician anymore.
Different strategies to recruit patients
In this study, we used four different strategies to include patients. Our analyses showed differences 
in outcomes between these groups. Those patients that responded to the invitation with a reward 
differed with respect to the treatment response compared to the telephone group and the initial 
response on paper group. Although not statistically significant, a slightly lower proportion had 
nocturia. Of course, due to the low numbers, it is unclear whether this group or the other groups 
represent the whole population best. The initial responders could be eager to respond because they 
still have LUTS and are hindered by it. The responders to the reward-invitation are mainly those 
not experiencing any bother of their LUTS (median score 0, IQR 0-1). Possibly, their main reason for 
participation is the reward. Overall, we think it to be worthwhile to improve inclusion of patients 
by offering them a reward, as the response rate increased to above 40%, in which case additional 
analyses can be performed to interpret the data. There was no observed difference in response rate 
between offering patients choice between digital and paper questionnaire, and sending a paper 
questionnaire at once. No recommendations can be made for that specific topic.
ICIQ scores, nocturia and enuresis
In this paper, we decided not to present a sensitivity analysis, as the achieved response rate ham-
pers the interpretation of such analyses. Response bias may well be present. The direction of the 
response bias is not clear but will most likely be directed toward a better quality of life and less LUTS, 
as full response to therapy patients were more likely to respond.
 
Conclusion
 
We faced serious problems in successful patient recruitment in studying long-term follow-up of 
adapted DBT for enuresis. As others have faced this as well, we doubt if long-term follow-up is 
feasible in this patient group. Possibly, only a prospective cohort study with a high emphasis on 
patient commitment could produce substantial and reliable long-term information. This is however, 
time consuming and costly. In case of gathering long-term follow-up in a retrospective study, we 
recommend to include a reward to increase response rates and thus interpretability of the results.
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This thesis has focused both on enuresis and nocturia, mutual causal factors like Nocturnal Polyuria 
(NP) and small Maximum Voided Volume (MVV), and on therapy for enuresis. In specific, the 
following topics were investigated: the association between NP and nocturia (part I), the wide 
variety of definitions of NP available for adults and children, and its consequences both for research 
and therapy (part I and II), evaluation of causal patterns of enuresis by frequency volume charts 
(FVCs) (part II) and on a treatment for and long-term evaluation of treatment-resistant adolescent 
and adult enuresis patients (part III). Here, a summary of the different topics of this thesis will be 
presented, combined with flaws and strengths of the specific chapters of this thesis, and future 
research perspectives. 
Enuresis and nocturia - causal factors
Enuresis and nocturia share the causal triad of nocturnal polyuria, bladder storage problems and sleep 
problems. The overlapping causal factors probably show that the conditions are different entities in 
the same spectrum; the presence or absence of arousal to stimuli of the bladder makes that either 
enuresis or nocturia is present [1]. Sleep problems can be bidirectional related to nocturia: due to a 
voiding sensation and getting up to void, sleep is interrupted. On the opposite, people lying awake 
at night will often go for a convenience void [2]. Enuresis patients are superficial sleepers with an 
arousal problem. What the true cause of these arousal problems is remains unclear. Disturbed sleep 
is related to NP, via sleep deprivation, higher nocturnal blood pressure and lower AVP-levels [3].
NP is an overproduction of urine at night. It can be idiopathic due to aging, or can exist due to high 
evening fluid intake, disturbance of circadian pattern of atrial vasopressin (AVP), or a defect in AVP 
action. It can also be due to solute diuresis caused by congestive heart failure, sleep apnea or renal 
insufficiency [4]. In case of NP, after night-time fluid intake has been reduced, desmopressin can be 
prescribed [5-7]. Initially, desmopressin was mainly a treatment modality for enuresis. Currently, 
it is suggested as a treatment option in adults with nocturia as well [5]. Prescription data in the 
Netherlands show that it is much more frequently prescribed in children than in adults (Table 1). 
Additionally, over the years, it is slightly less prescribed (Table 2) [8].  
A systematic review and meta-analysis on the efficacy and safety of desmopressin for adults showed 
that studies were of good quality but many studies did have a high risk of bias due to an active 
run-in period and exclusion of non-responders or patients with adverse effects. Desmopressin 
offers only a modest benefit for nocturia in healthy adults, by increasing the hours of uninterrupted 
sleep (one hour more than placebo), and slightly decreasing nocturnal voids (0.72 fewer voids 
Table 1. Desmopressin use in the Netherlands in 2014 [8].
Table 2. Desmopressin use in the Netherlands over the years [8].
0-4 yrs 5-14 yrs 15-24 yrs 25-44 yrs 45-64 yrs 65-74 yrs ≥75 yrs
Male 14 6162 1457 1152 1292 803 870
Female 21 2461 853 902 1363 563 670
Total 35 8623 2310 2054 2655 1366 1540
2010 2011 2012 2013 2014
Desmopressin users 20771 20508 19754 18786 18584
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compared to placebo) [9]. The main severe side-effects of desmopressin are headache (RR 4.3 
vs placebo in nocturia patients) and hyponatremia (RR 5.1 vs placebo in nocturia patients) [9]. 
Hyponatremia is more often seen in the elderly, and leads to more clinically relevant situations in this 
group. The difference between adults and children in prevalence of hyponatremia as a side-effect 
of desmopressin use, could be explained by these different mechanisms. The pathogenesis in young 
patients is thought to be related to overdosing and insufficient fluid restriction [10]. In patients over 
65 years of age, the pathogenesis is more related to a different renal water and solute handling [11]. 
Current guidelines state that desmopressin can be started when nocturnal polyuria is the main 
causal factor, as shown by the FVC, and non-pharmacologic treatment did not improve symptoms 
[7]. One of the problems however is the lack of a valid definition for NP, which is discussed on the 
following pages.
Reduced functional bladder capacity, or small MVV, is often caused by bladder storage problems, 
which can be due to overactive bladder (OAB), bladder outlet obstruction, neurogenic bladder, a 
high Post Void Residual volume, or developmental disturbances [4, 5, 12]. Other causes include 
dysfunctional voiding [1], cancer of the lower urinary tract, stones and aging [4]. OAB represents 
urge, urge-incontinence, increased frequency, nocturia and/or enuresis [1].
These three causal factors could potentially all be elicited by a distortion of parts of the brainstem, 
as the locus coeruleus, which has a function in sleep arousal, overlaps with the pontine micturition 
center and has connections with the AVP producing hypothalamus [13]. 
Others have investigated the relation between enuresis and nocturia in several ways. It was shown 
in a sample of mothers of children with enuresis, that those mothers who experienced enuresis in 
their own childhood, were at higher risk for having nocturia in adulthood [14]. Thirty-five percent 
of former enuresis patients in a tertiary care population had (clinically relevant) nocturia. This was 
mainly true for NMNE [15]. Nocturia was present in 75% of 25 enuresis patients when treated with 
desmopressin [16]. These studies however, all face problems regarding possible biases – recall bias in 
the study of the mothers, and selection bias in the tertiary care study. Additionally, the information is 
Table 3. Odds ratio’s (OR) according to prevalence of nocturnal polyuria (NP).  
In case of a constant relative risk (RR) of NP of 2.00, but a different prevalence of NP, the OR and RR are only comparable in 
the situation of a low prevalence. In case of a high prevalence of NP, OR and RR cannot be assumed to be similar. An OR can 
thus only be interpreted as an RR in case of a rare disease (Rare disease assumption). In this table, hypothetical numbers 
are used.
Prevalence NP Nocturnal 
Polyuria
No Nocturnal 
Polyuria
Total
5.0%
Nocturia + 20 230 250
Nocturia - 30 720 750
Total 50 950 1000
Prevalence NP Nocturnal 
Polyuria
No Nocturnal 
Polyuria Total25.0%
Nocturia + 100 150 250
Nocturia - 150 600 750
Total 250 750 1000
Prevalence NP Nocturnal 
Polyuria
No Nocturnal 
Polyuria Total60.0%
Nocturia + 240 10 250
Nocturia - 360 390 750
Total 600 400 1000
Odds NP, nocturia + (20/230)
Odds NP, nocturia - (30/720)
Odds ratio NP odds NP nocturia + / odds NP nocturia - 2.09
Risk NP, nocturia + (20/250)
Risk NP, nocturia - (30/750)
Relative risk NP risk NP nocturia + / risk NP nocturia - 2.00
Odds NP, nocturia + (100/150)
Odds NP, nocturia - (150/600)
Odds ratio NP odds NP nocturia + / odds NP nocturia - 2.67
Risk NP, nocturia + (100/250)
Risk NP, nocturia - (150/750)
Relative risk NP risk NP nocturia + / risk NP nocturia - 2.00
Odds NP, nocturia + (240/10)
Odds NP, nocturia - (360/390)
Odds ratio NP odds NP nocturia + / odds NP nocturia - 26.00
Risk NP, nocturia + (240/250)
Risk NP, nocturia - (360/750)
Relative risk NP risk NP nocturia + / risk NP nocturia - 2.00
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gathered retrospectively in former enuresis patients or their parents, resulting in missing information 
on the course of the enuresis. 
Part I: Nocturnal polyuria, definition in and association with nocturia
A good definition of the conditions and the causal factors is important, not only to facilitate discussion 
and research initiatives, but also to decide when to start specific treatment, like e.g. desmopressin for NP. 
A is shown in Chapter 3, NP was found to be defined in 19 ways considering the adult population by 
different authors, studying the possible association between NP and nocturia. All these definitions 
used different strategies to calculate NP, and lack validation procedures. This lack of a validation 
procedure even accounts for the ICS and ICCS definitions, which are consensus-based [17, 18]. 
Nevertheless, the ICS does recommend to use their definition (adults: varying from young: nocturnal 
urine production >20% of total urinary production during 24h to elderly: >35%), which is also most 
frequently used. Clearly, due to all these different definitions, the true incidence and prevalence of NP 
is difficult to assess. Chapter 2 shows that the pooled prevalence, based on different NP definitions, 
is 63.8%. Most frequently, this was assessed by using an FVC. This is also the recommended method 
and has to include both voided volumes and (sleeping) times [18].  
Chapter 2 also focuses on the association between nocturia and NP. It shows that nocturia and 
NP are indeed associated as was previously reported before by Weiss et al. [19]. However, 
the association is less firm than it seemed before: the relative risk of having NP for people 
with nocturia, compared to those without nocturia, (≥2x/night) is 1.41. However, current NP-
definitions differentiate only moderately: the difference in nocturnal voids between people 
with and without NP is only 0.6 voids per night. This is most likely not clinically relevant. 
We also emphasized that odds ratios cannot be interpreted as relative risks when the prevalence of 
a condition is high. This refers to the rare disease assumption of the odds ratio (Table 3, Figure 1). 
It is probably one of the reasons why the association of nocturia and NP was previously thought to 
be much firmer. 
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Figure 1. Relation Odds Ratio’s and Relative Risks according to prevalence.  
In case of a constant relative risk, but a different prevalence, the OR and RR are only comparable in the situation of a low 
prevalence. An OR can thus only be interpreted as an RR in case of a rare disease (Rare disease assumption).
142
Limitations of the systematic review and meta-analyses of part I (Chapter 2 and 3) are as follows: only 
15 studies were available for meta-analyses, reflecting a restriction of this research field. Although 
language barriers did not result in exclusion of any of the studies found in Pubmed or Embase, it is 
possible that we have missed research in languages other than Dutch, English, French or German, 
which could have introduced selection bias. 
 
Part II - Nocturnal polyuria and bladder capacity, definitions in enuresis and assessment methods 
As stated, we have found 19 different definitions for adult NP in the literature. Even more intriguing 
is the fact that the definition is described in different ways by the two continence societies, the ICS 
for adults (varying from young: nocturnal urine production >20% of total urinary production during 
24h to elderly: >35%) and the ICCS for children (ICCS NP-definition: >130% of the maximum EBC for 
age). Applying both definitions in our population of adolescents and adults with enuresis resulted in 
a striking different prevalence of NP (Chapter 4). Treatment choices will be based on presence of NP 
and will consequently inevitably vary between different definitions used.
Data regarding the exact prevalence of NP in patients with enuresis is lacking [20]. Due to enuresis 
episodes, nocturnal urine production measurement is difficult. This is also one of the main 
shortcomings of Chapter 4, in which the ICS and ICCS definition of NP are compared in adolescent 
and adult enuresis patients. To date, it is unclear whether enuretic adolescents, or even enuretic 
adults, have to be assessed according to the ICCS or the ICS definitions. 
Chapter 4 additionally described reference values for FVC and uroflowmetry parameters for enuresis 
patients aged 11 years and older. Small functional bladder capacity (FBC) or maximum voided volume 
(MVV), has been defined for children as <65% of expected bladder capacity (EBC) [17]. EBC (in ml) 
has been defined as (age in years +1)*30, for children aged 4-12 years [21]. Reference values for 
adults have been described as well [22]. MVV clearly showed an association to LUTS severity [22]. 
MVV increases with age during childhood, and decreases with age in adulthood [20, 22].  The first 
voided volume in the morning (first morning void) is not included in this definition. MVV equals the 
EBC if the first morning void is excluded. If the first morning void is included, the MVV is 80-100 ml 
higher than the EBC [20]. We presented both the proportion of patients with small MVV including 
and excluding the first morning void, which obviously resulted in different proportions of small MVV 
in our population.
Chapter 5 describes the use of FVCs and uroflowmetries for the assessment of bladder capacity and 
shows that only in the range of 200-450 ml voided during uroflowmetry, results are comparable 
with the FVC. Therefore, for daily clinical purposes, uroflowmetry could be used to make a rough-cut 
estimation of the MVV, only in this range.
Limitations of part II (Chapter 4 and 5) are mainly due to the retrospective character of the study, the 
corresponding missing data and problems in the lay-out of and information about FVCs used in the 
DBBC. These FVCs did point out how to measure nocturnal urine production. However, sleeping and 
waking times were not routinely recorded in a standardized way. This is one of the omissions of the 
retrospective study design, and has been adjusted in daily clinical practice according to this study. 
Strengths consist of the observation of the difference of NP prevalence when using the two NP-
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definitions, and of the publication of reference values, which were not available yet. 
Future research directives for part I and II – Importance of new definitions 
Both for pediatric NP and for adult NP, new definitions have been proposed: a nocturnal urine 
volume greater than 20 x (age + 9) ml (pediatric) [20], based on a population sample. And for adult 
NP a nocturnal urine production > 90 ml/hr [23]. 
Although we do agree that it is advisable to improve uniform use of definitions throughout the 
medical literature, we do feel that the current ICS definition should not be recommended. One of 
the problems with the current definition could be that it includes the first morning void. Although 
this urine is indeed produced during night-time, the NP-definition is less distinctive with regard to 
nocturia episodes. On the other hand, a NP-definition that does not take the first morning void 
into account, also has severe limitations. Such a definition does not incorporate all urine produced 
during night-time, and will only define NP for patients suffering from nocturia as other patients will 
not collect their urine during night-time. However, such a definition could be of use to differentiate 
between nocturia severity. 
A recent report by the nocturia think tank of the International Consultation on Incontinence – 
Research Society also stated that more practical and clinically meaningful definitions of NP are 
needed [5]. Recently, an ICS/ICCS working group has been formed, focusing on the definitions for 
nocturia and NP. Hopefully, the ICCS and ICS will interactively come to an overall definition, which 
is applicable both for children and adults, both in enuresis and nocturia. This definition should 
mainly cover the production of urine during the night, as this is easier to interpret and shows what 
a nocturnal overproduction of urine actually is. Conditions to which a NP-definition would have to 
rely on are indeed that the definition should be based on urine production per time unit instead of 
on a day/night or night/24-hour ratio or a diurnal urine pattern, especially when the first morning 
void is included [5]. For the interpretation of resulting nocturia or enuresis, this can be combined 
with other measures like the nocturnal bladder capacity index (NBCi) [24]. NBCi is not useful for the 
analysis of explanatory factors of nocturia, because nocturia is mathematically already incorporated 
and consequently always related.
This new, most appropriate NP-definition which will focus on nocturnal urine production alone 
should be thoroughly investigated and validated in different populations (general population, 
primary/ secondary/ tertiary care). For this, raw FVC data from earlier studies could be used. Both 
in- and exclusion of volume of first morning void should be studied. 
Altogether, several study designs of choice can be used to determine and study reference values 
of nocturnal urine production, and come to a new NP-definition. Examples are longitudinal cohort 
studies to assess reference values, and prevalence and incidence rates of NP, or cross-sectional 
studies for the assessment of reference values, defining of a new NP-definition, and prevalence 
of NP when using this definition. Ultimately case-control studies could investigate the distinctive 
nature of the definition in nocturia patients versus controls. The most appropriate method to gain 
information on urine production and on nocturia would be the frequency volume chart on which 
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sleeping times should be recorded, supplemented with a questionnaire, like the IPSS or the ICIQ. 
Considering small MVV: we presented both the proportion of patients with small MVV including and 
excluding the first morning void, which obviously resulted in different proportions of small MVV in 
our population. Apparently, this first void is in general larger than the other voids during the day. 
Potentially, the circadian rhythm and physiology of sleeping, including the decreased sensation of a 
bladder stimulus during sleep, results in a larger volume of this first void. We feel that the volume 
of the first morning void is taken into account in clinical decision-making. It would be sensible to 
present both values in future research – MVV including first morning void and MVV excluding first 
morning void. Possibly, this is another topic for the ICS/ICCS committee. Here as well, studies should 
incorporate FVCs as the method of choice, and the distinctive nature of new definitions could be 
assessed with the same study designs as proposed for the new definition of nocturnal polyuria. 
Circadian rhythm and sleep in enuresis and nocturia
Although not the primary subject of this thesis, one of the additional interesting fields of study in the 
area of enuresis and nocturia is the circadian clock mechanism. The multifactorial etiology of both 
enuresis and nocturia is possibly related to this mechanism. Hypertension, diabetes and depression 
often occur together, in the presence of nocturia. In genetically modulated mice with a dysfunctional 
circadian clock, the diurnal rhythm of micturition, production of urine and functional bladder capacity 
is lost [25]. Micturition cycle disorders like enuresis and nocturia could be genetic and present itself 
throughout the life span [25]. Related to this, a seasonal variation in nocturia symptom severity in 
men with LUTS exists; in winter, there were less nocturia events [26]. Seasonal variation does also 
exist in enuresis, at least for treatment success of alarm therapy, for which winter was shown to 
be associated with failure [27]. And, although melatonin has a circadian rhythm; serum levels are 
high at night and low during the day, and is associated with sleep, it is not with enuresis. Enuresis 
and control patients however had no different melatonin levels [28], and melatonin treatment in 
therapy-resistant enuresis patients did not improve enuresis frequency [29]. 
 
 As stated, the origin of the arousal problem in enuresis patients remains unclear. NP, sleep deprivation, 
nocturnal hypertension and AVP-levels are interrelated [3], and the underlying problem could be 
based in the brainstem [13]. Sleep studies and studies focusing on the neurological basis of arousal 
could be of help to further distinguish these two entities [1]. Additionally, radiographic or nuclear 
studies could be initiated to compare activity in these brain-regions between enuresis patients and 
controls, between enuresis patients and nocturia patients, and between sleep deprivation and no 
sleep deprivation.  
Part III - Therapy-resistant enuresis in adolescents and adults, adapted Dry Bed Training (DBT)
The initial treatment of enuresis is clear and consists of alarm therapy and/or desmopressin 
[7, 12]. Those treatments are known to be helpful during treatment, but have a high relapse 
rate. Recently, imipramine has been advocated as the next therapeutic step for patients who 
are treatment-resistant, although it has adverse effects like cardiac problems, personality 
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changes, insomnia, anorexia and anxiety [30, 31]. Still, after alarm therapy, desmopressin 
and imipramine were applied in adolescent patients, 17% remained therapy resistant [32]. 
Specifically for the group of patients which are 11 years and older and therapy-resistant to alarm 
therapy and desmopressin, adapted DBT has been developed in 2003 by a urologist, continence 
nurse and the patient association. Part III of this thesis focuses on this adapted DBT for therapy-
resistant enuresis in adolescents and adults. In our retrospective analyses, we showed that adapted 
DBT seems to be effective in a large group of therapy resistant patients. Although the exact place of 
adapted DBT remains to be determined, it could be an option for treatment-resistant adolescents 
and adults (Chapter 6). To improve the interpretation of the data with regard to the missing data that 
we encountered, we chose to present sensitivity analyses in this chapter. The worst-case and best-
case scenario showed that the real treatment success would be within wide limits, but at least 43% 
after six months. However, due to the retrospective study design and the lack of a control group, no 
definite recommendations can be made. 
Given the costs, it is interesting to identify those patients that benefit most. This discussion on costs 
is comparable to what could be read in the early papers on DBT as well [33, 34]. Nevertheless, back 
then, DBT was performed as a first-line treatment as well, whereas it now seems more appropriate 
to direct adapted DBT only to therapy-resistant cases. To identify the patients that are susceptible for 
treatment success, we performed prediction modeling to identify patient factors predicting success 
in Chapter 7. We showed that there are several factors that are involved in success of adapted DBT. 
Although the temptation is present to elucidate why these factors are found to be predictive, it 
is good to remember that no causal relationships can be inferred based on prediction models. 
Due to the low explained variance of our model, we expect many other factors to be involved 
as well. Bladder capacity will be one of them. One of the inclusion criteria for the adapted DBT 
was an FBC of 300 ml or more. Therefore, this factor could not be studied. The intensive relation 
with the pedagogic staff could have been a positively influencing factor as well; it is known that 
contact with a therapist is helpful. It enhances the effect of an intervention [35, 36]. Possibly, this 
and explicit agreements are of additional value in patients with behavioral problems like ADHD. 
Additionally, the low explained variance could be due to the homogenous group of patients that 
were treated, and the high proportion of success, resulting in low predictive possibilities. 
Overall limitations of Chapters 6 and 7 are the retrospective design, and the missing data 
encountered. In Chapter 6 we chose for the neat observation that a sensitivity analysis offers, to 
be able to deliberate on reasons for the real results being closer to the worst or best case analysis. 
Besides, we felt that this is easier to interpret for clinicians in general. For the additional regression 
analyses of Chapter 7 however, we needed to improve the reliability of our database. Therefore, we 
performed multiple imputation before running the logistic regression analyses. This way, we were 
able to strengthen our conclusions.
In Chapter 8, we investigated long-term follow up of the adapted DBT. Larger sample sizes and longer 
follow up are advocated by Cochrane reviews and the ICCS [17, 35]. However, a quick review of the 
literature reveals that only a few studies indeed have had a follow up longer than 1 year. One study 
investigating the body worn alarm and a supportive program in 505 monosymptomatic enuresis 
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patients achieved a follow up of 99.2% after two years [37]. Nevertheless, this is a rare example. 
Much more often, response rates for long term follow up studies are around 40%, like the Gent 
group experienced [15]. We experienced even lower response rates (Chapter 8). We performed a 
cross-sectional study to gain knowledge on the long-term follow up of enuresis patients treated by 
adapted DBT, specifically on nocturia and associated quality of life. This appeared to be very difficult, 
and we changed our focus to the question how to improve response rates in this population. 
Offering a reward for a completed questionnaire gave a higher response rate, although this was still 
only moderate (42%). Potential reasons are the overload on questionnaires sent by (commercial) 
entities; increasingly causing a feeling of bother and the lack of feeling that one can be of added 
value. Additionally, patients are not patients anymore; there is no actual treatment-relationship, and 
therefore it seems less interesting for people to join. 
Future research directives for part III
Future research on adapted DBT would preferably be prospective. A prospective randomized trial 
could hardly include placebo treatment, although sham-treatment would be possible. Nevertheless, 
it is difficult to define what the sham-arm should and should not include. Adapted DBT versus 
no treatment will not be ethically justified and feasible, as we sincerely question whether these 
patients would be willing to join such a study. A possible future study could be to investigate the 
effect of adapted DBT of five days and four nights versus a shorter period of time (the sham-arm). 
This will also address the main problem of adapted DBT; which are the high costs that are involved. 
In fact, the current adapted DBT in our center has already been shortened to four days and three 
Figure 2. Origin of patients treated by adapted Dry Bed Training. 
Red squares represent place of residency of treated patients, based on postal code.  
Blue circle represents Dry Bed and Pelvic Center.  
Left: 2003-2008. Right: 2009-2013.
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nights, among other things due to costs. Therefore, we already started a prospective cohort study 
in patients currently treated by this shortened in-hospital training. The fourth night is performed 
at home, with extensive telephone contact in the evening and the next morning. Here, the data-
handling is improved not only due to the prospective character, but also due to the faced difficulties 
and shortcomings of the historical cohort, resulting in improved maintaining of medical charts for 
study purposes. In the future, this cohort can be compared to the historical cohort that is described 
in Chapter 6 and 7.
For prediction modeling, all data that are available for the clinical setting, could be used. In other 
fields of medicine, like oncology, it is widely acknowledged that insight in current treatments can 
only be gained by recording patient data in a thorough way. In our center, we started prospective 
data recording of all consecutive outpatients treated for enuresis in 2015. For this we have defined 
several quality parameters, which will be assessed twice a year, to improve overall patient care.
Other developments in medicine are the number of cases treated that has to overcome a certain 
threshold, to gain skills and knowledge in a particular center (volume-standards). In children, enuresis 
is a highly prevalent condition and thus many healthcare professionals nearby home should perform 
treatment. However, in adolescents and adults, particularly the therapy-resistant cases are not that 
frequently encountered by a general practitioner or even a urologist. Therefore, we advocate that 
there should be only a few centers that satisfy volume-standards, direct this treatment and have 
the skills and knowledge available. In that light, the Dry Bed and Pelvic Center is a unique treatment 
facility. This has been shown by the numbers of patients in this age group that were treated during 
the last decade, from all over the Netherlands (Figure 2).  It is important to keep improving the 
available knowledge and treatment modalities for this difficult to treat, but interesting group of 
patients. 
Summary and additional remarks 
Future directives for research have been described throughout this discussion and focus mainly on 
the causal factors of enuresis and nocturia and their definitions, on transition in urology, on therapy-
resistance and initiatives to improve long-term follow-up. 
During the years of this PhD research, the research group on enuresis from Gent, Belgium, has 
also studied the relation between enuresis and nocturia, and nocturnal polyuria [1, 15, 38]. The 
renal function profile that they have investigated seems to be interesting for future research on 
nocturnal polyuria both in nocturia and enuresis [38]. It differentiates between water and solute 
diuresis and can indeed be of help to determine the best treatment modality. Possibly, this explains 
the non-response in some children with nocturnal polyuria to desmopressin. Additionally, they also 
studied long-term follow up of enuresis patients, and encountered low response rates, like we did. 
Altogether, many thoughts on the subjects have been comparable. Although we first wondered 
if sensitivity analyses should be performed to account for the missing data in their sample [39], 
since we have experienced even lower response rates, we should join forces to come to solutions to 
improve long-term follow up of enuresis patients. 
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In general, many things remain elusive considering enuresis in adolescents and adults. It is not only 
often therapy-resistant, another subset of patients is known to never even have consulted a doctor 
for their complaints [40]. It however is known that those patients who remain wet if they grow older, 
have more severe complaints [41]. Therefore, it is of utmost importance that patients are identified 
and treated, as ‘healthy aging starts the moment you’re born’.
In conclusion: this thesis has shown that, although the association between nocturia and NP is 
apparent and robust, definitions of NP are widespread and differing, both for children and adults. 
Epidemiologic measures like odds ratio and relative risk should be interpreted according to the 
prevalence of disease. It has also shown that, in adolescents and adults with treatment resistant 
enuresis, adapted DBT gives good results, although the exact place of adapted DBT is not clear 
yet. Furthermore, long-term follow up was found to be difficult to assess in this group of patients, 
and could be improved by prospective cohort studies, or introducing a reward for completion of 
questionnaires. The research field of these entities should become more integrated than it currently 
is. The two continence societies could play an important role in this, for a start by discussing their 
non-conform definitions together and to come to uniform points of view, not the least because 
adolescents should not fall between two stools, between pediatric and adult urology.
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Dit proefschrift bespreekt verschillende aspecten van enuresis (bedplassen) en nycturie (wakker 
worden om te plassen), nachtelijke plasproblemen met een vergelijkbare pathofysiologie. 
Hoofdstuk 1 introduceert beide ziektebeelden, inclusief terminologie, etiologie, epidemiologie en 
effect op kwaliteit van leven. Tevens worden huidige behandelingen besproken. Nachtelijke polyurie, 
een kleine blaascapaciteit en slaapproblemen komen bij beide ziektebeelden voor.
Nachtelijke polyurie betreft een overmatige productie van urine gedurende de nacht. De urine-
productie wordt onder andere gereguleerd door atriaal vasopressine (AVP). Hierdoor blijft de 
plasma-osmolariteit en natrium concentratie gehandhaafd. Kleine aanpassingen in de hoeveelheid 
AVP kunnen een groot effect hebben op de hoeveelheid vocht die uitgescheiden wordt. Normaliter 
heeft zowel de secretie van AVP als de productie van urine een 24-uurs ritme; ’s nachts wordt er 
minder urine geproduceerd. Nachtelijke polyurie kan optreden als het 24-uurs ritme van AVP secretie 
verstoord is. Andere oorzaken zijn een overmatige vocht-intake gedurende de avond, hartfalen, slaap 
apneu en nierfalen. AVP secretie wordt daarnaast beïnvloed door veroudering.
Nachtelijke polyurie wordt verschillend gedefinieerd door de twee wetenschappelijke continentie 
verenigingen.  De definitie van de International Continence Society (ICS – volwassenen) en de 
International Children’s Continence Society (ICCS – kinderen) worden respectievelijk bij nycturie en 
bij enuresis toegepast. De ICS definitie is als volgt: een leeftijdsafhankelijke nachtelijke urine output 
groter dan 20-33% van de 24-uurs urine output: de nachtelijke polyurie index. De ICCS definitie 
gaat niet uit van deze ratio, maar van het concept dat de nachtelijke urine productie de verwachte 
blaascapaciteit voor de leeftijd overschrijdt: indien de nachtelijke urineproductie meer dan 130% 
van de verwachte blaascapaciteit is, is er sprake van nachtelijke polyurie. Het is duidelijk dat deze 
twee definities een andere insteek hebben.
Blaascapaciteit betreft de hoeveelheid urine die de blaas kan opslaan. Ook de blaascapaciteit heeft 
een 24-uurs ritme: de eerste plas van de dag is groter dan alle andere. Tot de leeftijd van 12 jaar 
neemt de blaascapaciteit toe, en naarmate volwassenen ouder worden neemt deze weer af. Er zijn 
meerdere manieren om de blaascapaciteit te meten: cystometrie al dan niet onder anesthesie, 
uroflowmetrie of het plasdagboek (Frequency Volume Chart – FVC). Mogelijke oorzaken van een 
verminderde functionele blaascapaciteit zijn opslagproblemen zoals onder andere outlet obstructie, 
overactieve blaas, een groot residu of een neurogene blaas. 
Slaapproblemen zijn vermoedelijk verschillend bij enuresis en nycturie. Bij enuresis is er voornamelijk 
een ontwaakprobleem. Bij nycturie is het lastig te objectiveren wat het primaire probleem is; een 
slaapstoornis waardoor een persoon gaat plassen, of juist een plasprobleem waardoor de slaap 
wordt onderbroken. 
 
Het doel van dit proefschrift is het bestuderen van verscheidene aspecten van deze twee 
ziektebeelden. Hierbij wordt ingezoomd op een aantal zaken: de associatie met nachtelijke polyurie, 
huidige definities en ten slotte aangepaste droog bed training bij behandel resistente adolescente 
en volwassen enuresis patiënten. 
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Deel I - Nycturie en nachtelijke polyurie
Dit deel omvat een systematische review en meta-analyse naar de associatie tussen nycturie en 
nachtelijke polyurie, met een beoordeling van de interne en externe validiteit, informativiteit en het 
effect van de publicatie van het ICS standaardisatie rapport over terminologie. 
Hoofdstuk 2 toont aan dat nycturie en nachtelijke polyurie inderdaad geassocieerd zijn, zoals eerder 
reeds werd beschreven. Deze relatie is echter minder stevig dan tevoren werd aangenomen. Mensen 
met nycturie (≥2x/nacht) hebben, in vergelijking met diegenen zonder klinisch relevante nycturie, 
een relatief risico van 1,41 op nachtelijke polyurie. De eerder vermoede steviger associatie komt 
waarschijnlijk doordat eerder de hoge prevalentie van nachtelijke polyurie niet is meegenomen in de 
berekeningen.  De hoge odds ratio (4,99 in Hoofdstuk 2) komt overeen met een lager relatief risico 
in verband met de hoge gepoolde prevalentie van 63,8%; er is dus geen sprake van een zeldzame 
ziekte (Tabel 3 en Figuur 1 Hoofdstuk 9), waardoor de odds ratio niet als een relatief risico kan 
worden geïnterpreteerd.  Wanneer de relatie andersom wordt bekeken blijkt dat, indien er sprake is 
van nachtelijke polyurie, dit samengaat met slechts 0,6 plassen per nacht meer dan indien er geen 
sprake is van nachtelijke polyurie. Dit verschil is vermoedelijk niet klinisch relevant. 
In de medische literatuur voor volwassenen blijken in ieder geval 19 verschillende definities voor 
nachtelijke polyurie in omloop. In Hoofdstuk 3 wordt beschreven dat veel van deze definities 
verschillende methoden gebruiken om nachtelijke polyurie te berekenen. Daarnaast ontbreken 
validatie procedures, zelfs voor de ICS en ICCS definities. De publicatie van het ICS terminologie 
standaardisatie rapport in 2002 bleek een positief effect te hebben op het rapporteren van gebruikte 
definities. De ICS definitie wordt het meest gebruikt. Het belang van eenduidige, goede definities 
is helder: het duiden van de precieze prevalentie en incidentie van nachtelijke polyurie is op dit 
moment lastig vanwege de verschillende maatstaven waarmee gemeten wordt. 
Deel II – Enuresis, nachtelijke polyurie en functionele blaas capaciteit: focus op definities
Naast alle definities die gevonden werden voor volwassen nachtelijke polyurie, is het intrigerend 
om op te merken dat ook de ICS en de ICCS definitie van nachtelijke polyurie verschillend zijn. Ze 
zijn gebaseerd op verschillende concepten. Het is onduidelijk of adolescente en jongvolwassen 
patiënten met enuresis geëvalueerd moeten worden volgens de ICS of juist volgens de ICCS definitie. 
Dit is interessant, aangezien de prevalentie van nachtelijke polyurie zeer verschillend bleek te zijn 
wanneer de ene of de andere definitie werd toegepast (Hoofdstuk 4). Indien patiënten op de dag 
dat ze 18 jaar worden volgens de volwassen definitie moeten worden geëvalueerd, zullen veel van 
hen van de ene op de andere dag nachtelijke polyurie (lijken te) hebben. Dit is van belang omdat 
behandelkeuzes hierop gebaseerd kunnen en zullen zijn. 
Samenvattend is het essentieel dat de twee wetenschappelijke verenigingen samen tot een nieuwe 
definitie komen. Inmiddels is zowel voor kinderen als voor volwassenen een nieuwe definitie 
van nachtelijke polyurie voorgesteld. Deze voorgestelde definities gaan beiden uit van alleen de 
nachtelijke urine productie. Er is een commissie samengesteld uit ICS en ICCS-gelederen, die zich 
buigt over deze kwestie. De nieuwe nachtelijke polyurie definitie is pas optimaal indien deze goed 
gevalideerd wordt in verschillende populaties. Plasdagboek data van eerdere studies kunnen hier 
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goed voor worden gebruikt, waardoor de tijdspanne tot het bereiken van deze valide definitie 
verkort kan worden. 
In Hoofdstuk 4 worden daarnaast referentiewaarden voor plasdagboek en uroflowmetrie parameters 
beschreven voor adolescente en volwassen enuresis patiënten. Bij gebruik van de ICCS definitie 
om het maximaal geplast volume te berekenen, wordt de eerste ochtendplas buiten beschouwing 
gelaten. Wij kozen ervoor om het maximaal geplast volume op twee wijzen te presenteren: met en 
zonder meenemen van de eerste ochtendplas. 
Hoofdstuk 5 betreft een post-hoc analyse naar twee meetmethoden voor blaascapaciteit. Het 
maximaal geplast volume van het plasdagboek (zonder eerste ochtendplas) werd vergeleken met 
het geplaste volume bij uroflowmetrie. Deze analyse suggereert dat, wanneer een patiënt bij 
uroflowmetrie een volume plast van 200-450 ml, dit resultaat vergelijkbaar is met het maximaal 
geplast volume van het plasdagboek. Alleen in dit bereik kan uroflowmetrie gebruikt worden om een 
grove schatting te maken van het maximaal geplaste volume. 
Deel III – Adolescenten en volwassenen met enuresis: aangepaste droog bed training
De aanvankelijke behandeling van enuresis is duidelijk en bestaat uit alarm therapie en/of 
desmopressine, afhankelijk van de aanwezigheid van een kleine blaascapaciteit of nachtelijke 
polyurie. Het is bekend dat beide opties goed werken tijdens de behandeling, maar een hoog 
terugval percentage hebben wanneer de behandeling wordt gestopt. In 2003 werd speciaal voor 
de groep patiënten van elf jaar en ouder die therapie resistent waren voor alarm therapie en 
desmopressine, een aangepaste vorm van droog bed training (DBT) ontwikkeld in het Droog Bed 
en Bekken Centrum te Meppel. Deel III van dit proefschrift richt zich op deze aangepaste DBT, welke 
plaats vindt gedurende vijf dagen en vier nachten in leeftijdsgroepen van zes patiënten. De training 
omvat een enuresis-anamnese, uitleg over de ziekte, gebruik van een dagboek, een plaswekker en 
een eigen gewone wekker, groepscontact en activiteiten gedurende de dag om het zelfvertrouwen 
van de deelnemers te vergroten. De nacht wordt zowel ’s avonds als ’s ochtends met de deelnemers 
besproken. De eerste nacht worden deelnemers elk uur gewekt om te voelen of ze moeten plassen 
en om een glas water te drinken. De daaropvolgende nachten slapen ze met de plaswekker en 
met een eigen wekker die ’s nachts op een geïndividualiseerd tijdstip wordt gezet. Behandeling 
is multidisciplinair: de training wordt uitgevoerd door pedagogisch medewerkers. Uroloog en 
continentie verpleegkundigen zijn tevens betrokken. Follow up wordt telefonisch verricht; de eerste 
zes weken gebeurt dit wekelijks, waarna de frequentie wordt afgebouwd tot zes maanden na de 
training. De plaswekker wordt gecontinueerd na de klinische training en wordt gestopt als patiënten 
twee weken droog zijn.
Hoofdstuk 6 en 7 betreft een retrospectief cohort onderzoek, waarbij in Hoofdstuk 6 de behandeling 
en de resultaten van deze behandeling worden besproken. In verband met ontbrekende data 
werd een sensitiviteitsanalyse uitgevoerd. Na 6 weken bleek 46% van de patiënten een volledige 
behandelrespons te hebben: zij waren ’s nachts droog. Het werkelijke succes percentage zal liggen 
tussen de twee scenario’s van de sensitiviteitsanalyse: 31% en 64%. Het behandelsucces na 6 
maanden was 68% in de beschikbare data en lag volgens de sensitiviteitsanalyse tussen 43% en 80%. 
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Vanwege de kosten is het interessant om na te gaan welke patiënten het meeste profijt hebben van 
de aangepaste DBT. Derhalve focust Hoofdstuk 7 op een predictiemodel waarin patiënt-factoren 
worden betrokken die succes voorspellen. Vanwege de ontbrekende data werd multipele imputatie 
toegepast voordat een logistische regressie analyse werd verricht. Er bleken meerdere factoren te 
kunnen worden geïdentificeerd. Externe validatie dient echter plaats te vinden voordat dit model 
gebruikt kan worden. Een nadeel van dit model is de lage verklaarde variantie, waardoor andere 
factoren mede van belang zullen zijn voor succes. 
De ICCS beveelt aan om patiënten tot twee jaar na behandeling te volgen. Dit lijkt gezien de 
hoge terugval percentages na conventionele behandelingen als plaswekker en desmopressine 
ook verstandig, zodat het uiteindelijke effect van de behandeling ingeschat kan worden. In 
Hoofdstuk 8 wordt een cross-sectionele vragenlijst studie gepresenteerd, waarbij zeer lage respons 
percentages werden verkregen. Vragenlijst studies lijken in zijn algemeenheid gepaard te gaan met 
een tegenvallende respons. De vraag dringt zich op op welke manier de uiteindelijk beschikbare 
data geanalyseerd en de resultaten geïnterpreteerd moeten worden. We hebben de focus van 
dit hoofdstuk vanwege deze tegenvallende respons aangepast naar de vraag op welke manier we 
de respons konden verbeteren. Hoewel er meer vragenlijsten werden ingevuld bij het aanbieden 
van een beloning, bleef de respons mager (42%). Mogelijke verklaringen voor de tegenvallende 
respons zijn de hoeveelheid vragenlijsten die dagelijks per e-mail binnenkomen, het feit dat enuresis 
een aandoening is die gepaard gaat met schaamte, evenals het feit dat patiënten geen actuele 
behandelrelatie meer hadden.
Hoewel aangepaste DBT succesvol lijkt te zijn in de voorheen therapieresistente groep enuresis 
patiënten, is voorzichtigheid bij het trekken van conclusies op zijn plaats vanwege het retrospectieve 
karakter van de studie, het ontbreken van een controle groep en de matige respons op de 
vragenlijststudie naar plasklachten langere tijd na behandeling. 
Toekomstig onderzoek zou daarom gericht moeten zijn op het prospectief vergelijken van de 
aangepaste DBT met bijvoorbeeld een sham-arm, of een verkorte versie van de training. Dit is ook 
uit kostenoverwegingen interessant. Ook een historische vergelijking behoort tot de mogelijkheden. 
De huidige training omvat 4 dagen en 3 nachten. De vijfde nacht wordt thuis geslapen. ’s Avonds en 
’s ochtends is er telefonisch contact met de pedagogisch medewerkers. Alle patiënten die worden 
gezien op het Droog Bed en Bekken Centrum, worden prospectief geëvalueerd. Dit prospectieve 
cohort is gestart om de kwaliteit van zowel proces als behandeling te verbeteren; kwaliteits-prestatie 
indicatoren zijn vastgesteld, welke halfjaarlijks geëvalueerd worden. Dit cohort kan in de toekomst 
vergeleken worden met het historische cohort uit Hoofdstuk 6 en 7. 
Tenslotte biedt dit proefschrift plaats voor de discussie over volume-normen in de klinische praktijk. 
Enuresis is een veelvoorkomend probleem bij kinderen waardoor zorg dicht bij huis beschikbaar 
moet zijn. Echter, enuresis komt ook voor bij 0,5 tot 2% van de adolescente en volwassen populatie. 
Deze patiënten zijn vaak therapie resistent en hebben ernstiger enuresis. Voor deze groep patiënten 
lijkt centralisatie verstandig: het aanwijzen van enkele centra voor behandeling, waardoor kennis en 
kunde gezekerd zijn.
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Concluderend toont dit proefschrift dat, hoewel de associatie tussen nycturie en nachtelijke polyurie 
bestaat, deze minder sterk is dan tevoren werd aangenomen. Bij het omzetten van een odds ratio 
naar een relatief risico is het van belang om de prevalentie van ziekte mee te nemen. Daarnaast 
blijkt nachtelijke polyurie vele gezichten te hebben: in de volwassen literatuur in ieder geval op 19 
verschillende wijzen gedefinieerd, en door de volwassen en kinder-wetenschappelijke continentie 
verenigingen ook verschillend gedefinieerd. Hierdoor is de werkelijke prevalentie van nachtelijke 
polyurie lastig in te schatten. 
Aangepaste droog bed training geeft goede resultaten bij adolescenten en volwassenen met voorheen 
behandel-resistente enuresis, hoewel de precieze plaats van deze training in het behandelspectrum 
nog niet duidelijk is. Het was lastig om informatie te verkrijgen over de resultaten op langere termijn. 
Dit kan verbeterd worden door prospectieve observationele cohort studies of door een beloning aan 
te bieden bij het invullen van vragenlijsten. 
Kennis over deze twee nachtelijke plasproblemen lijkt gebaat te zijn bij de integratie van de twee 
onderzoeksgebieden. De twee continentie verenigingen kunnen hier een belangrijke rol bij spelen, 
bijvoorbeeld door tot gezamenlijke definities en standpunten te komen. Hierbij is niet alleen het 
wetenschappelijk onderzoek gebaat, maar vooral ook de patiënt, wanneer die van kind volwassene 
wordt.
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Dankwoord
Na een paar jaar driftig SPSSen, schrijven, submitten, artikelen terugkrijgen en opnieuw submitten - al 
dan niet als revisie of naar een ander tijdschrift-, en puzzelen met indesign is hij af: mijn proefschrift! 
Met veel plezier ben ik ermee bezig geweest, mede dankzij de hulp van velen. Ik wil dan ook de 
volgende mensen graag bedanken voor hun hulp tijdens mijn promotie: 
Geachte Prof. dr. Feitz, beste Wout, drie jaar geleden kwam ik via Martijn Steffens bij u langs. Er 
lag een nog niet geheel vastomlijnd plan voor een promotie, en er was nog geen financiering. U 
heeft me geholpen het plan te stroomlijnen en alle afzonderlijke hoofdstukken tot een geheel te 
maken. Ziehier het resultaat. De driemaandelijkse overleggen met Marco Blanker, Martijn Steffens 
en u waren immer zinnig, vruchtbaar en voorzien van goed voedsel, of we nu in Nijmegen, Arnhem 
of Zwolle vergaderden. Ik wil u heel hartelijk bedanken voor uw hulp bij mijn promotie.
Geachte dr. Steffens, beste Martijn. Ik wil je bedanken voor je nooit aflatende enthousiasme en 
vertrouwen in de goede uitkomst van dit proefschrift. Jouw optimisme is ongekend en je drijvende 
kracht achter de onderzoeksaanvraag bij het I&W, en achter de SOUZ vind ik bewonderenswaardig. 
Dank voor alle hulp, zowel tijdens mijn promotie als rondom mijn (sollicitatie tot de) opleiding tot 
uroloog!
Geachte dr. Blanker, beste Marco. Dank voor je intensieve hulp tijdens mijn promotie: vanaf onze 
eerste samenwerking met de systematische review, de onderzoeksaanvraag bij het I&W, tot aan 
het voltooien van mijn proefschrift: ik hoefde je maar te mailen of er kwam mail terug. De manier 
waarop jij kliniek en wetenschap combineert vind ik erg inspirerend. Door jou kwam ik bij de 
epidemiologie summer school van het NIHES in Rotterdam, waarna ik het jaar daarna met de master 
clinical epidemiology ben begonnen. Dank voor dit goede idee, daarvoor had ik nooit gedacht dat ik 
statistiek en epidemiologie zo boeiend zou vinden! 
De leden van de manuscriptcommissie, prof. dr. W.J.J. Assendelft, dr. ir. N. Roeleveld en prof. dr. J.M. 
Nijman wil ik graag bedanken voor de beoordeling van dit proefschrift. 
Natuurlijk wil ik alle patiënten bedanken die mee hebben gedaan. Zonder hen was dit proefschrift 
niet mogelijk geweest. 
Geachte dokter van Capelle, beste Jan-Willem. Begonnen in Zwolle als ANIOS in 2012 heb ik eerst de 
resultaten van jouw urethraplastieken op een rij gezet. Zoals je zelf zei had je ooit nog als plan om 
te promoveren op de data uit het Droog Bed en Bekken Centrum. Het werd net wat anders, en ik 
wil je dan ook bedanken voor je innovatieve idee (samen met Zwaan Mulder) ruim 10 jaar geleden 
en je begeleidende rol tijdens mijn promotie. Ik heb erg veel van je geleerd over de functionele, 
reconstructieve en de kinder-urologie!
Beste Zwaan Mulder, continentieverpleegkundige en drijvende kracht achter het Droog Bed en 
Bekken Centrum vanaf het eerste uur. Altijd weer gezellig als ik bij je kwam buurten, zowel als we 
werkten als wanneer we kletsten over het wel en wee thuis. Ik hoop dat we elkaar, ondanks de 
beëindiging van mijn promotie en jouw pensionering, nog af en toe zullen zien!
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Beste Hanny Cobussen-Boekhorst, dr. en mede-eerste auteur! Ik vond onze samenwerking heel 
bijzonder. Je hebt me veel geleerd over enuresis en continentiezorg in de klinische praktijk. Ook de 
gezamenlijke congressen waren wat mij betreft een succes. Na jouw promotie op 28 januari j.l. is 
het nu mijn beurt om ‘ons’ hoofdstuk te verdedigen. Ik hoop dat we nog vaker zullen samenwerken 
in de toekomst!
Geachte dr. Kollen, beste Boudewijn. Als co-auteur van enkele van mijn stukken wil ik je bedanken 
voor je hulp bij de statistisch moeilijkere stukken van mijn promotie. Gedurende de jaren leerde ik 
bij, maar zonder jou had ik de ordinale of logistische regressie analyse vast niet tot een goed einde 
gebracht!
Beste dr. Kortmann, beste Barbara. Dank voor je hulp bij de totstandkoming van het gezamenlijke 
artikel van Hanny en mij. Ik hoop in de toekomst nog eens samen te werken!
Geachte prof. dr. Bosch, dank voor de samenwerking bij het schrijven van de systematische review 
en meta-analyse over nachtelijke polyurie en nycturie. 
Dear prof. dr. Drake, dear Marcus. Thank you for the collaboration during the writing process of the 
first two chapters of this thesis. I enjoyed our encounters during the EAU in Madrid and the ICS in 
Montreal. Maybe we should reconsider studying camel bladders after all!
Dear prof. dr. Weiss. I would like to thank you as well for the cooperation with the systematic review 
and meta-analysis on nocturnal polyuria and nocturia. 
Beste Astrid Brinker, je hielp me tijdens je wetenschappelijke stage vanuit Groningen met de invoer 
van de database. Inmiddels zijn er twee gezamenlijke artikelen gepubliceerd. Dank voor je hulp en 
succes met je carrière. 
Voor de hulp bij de data-invoer wil ik ook Anneke Stegeman bedanken. Wat een tempo kan jij maken! 
Beste eerste promovenda vanuit Zwolle, Saskia van der Meer. Als tweede promovenda uit Zwolle 
ben ik vereerd dat jij me voor bent gegaan. Wat is het altijd gezellig als we elkaar zien! Dank dat je 
me in contact hebt gebracht met Marco en voor je nooit aflatende steun. Hopelijk werken we over 
een tijdje weer eens samen!
Beste urologen uit Zwolle: jullie hebben me heel veel geleerd over de urologie en over mezelf. Dank 
voor de mogelijkheid om niet alleen als ANIOS bij jullie te kunnen werken, maar ook te kunnen 
promoveren. Over een paar jaar kom ik graag terug als AIOS!
Als enige promovendus bij de urologie in Zwolle kwam ik als spreekwoordelijke vreemde eend in de 
bijt terecht op het Diabetes Centrum van prof. dr. Henk Bilo. Ik wil u, maar ook dr. Nanno Kleefstra 
heel erg bedanken voor het feit dat ik bij jullie een plekje kreeg tussen andere onderzoekers, waar 
ik kon sparren en kon kletsen. Mede-onderzoekers Peter, Steven, Laura, Dennis, Leonie, Hans, Gijs, 
Angelien, Yvonne: hoewel we niet naar dezelfde congressen gingen, onze onderlinge muzieksmaak 
soms wat kan verschillen en jullie na al die jaren nog steeds denken dat urologie alleen om het 
mannelijk geslacht gaat: gezellig was het!
En dan: Joep Dille, ook vanaf het eerste moment betrokken, vanuit de Isala academie en vanuit 
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het Innovatie en Wetenschapsfonds van de Isala. Dank voor jouw persoonlijke betrokkenheid 
en je altijd aanwezige interesse. Je weet hoe blij ik ben dat het gelukt is om full-time promotie-
onderzoek te mogen doen. Dit was niet mogelijk geweest zonder jouw hulp en zonder de 
vouchers van het I&W. Ik ben het I&W dan ook ongelooflijk erkentelijk; heel veel dank. 
Naast het I&W wil ik ook de SOUZ, ZWIK en het Radboud bedanken voor de financiering van mijn 
promotie-traject. 
Ook David en Anke van de Isala academie: dank voor alle steun.
Beste Vera, ook jou wil ik bedanken voor je betrokkenheid bij mijn promotie. De tweewekelijkse 
wetenschapsbijeenkomsten urologie zijn waardevol voor me geweest. 
Beste mensen van het Droog Bed en Bekken Centrum in Meppel; Esther, Joke, Anneminke, Astrid, 
Ini, Wilma, Nicole, Hennie, Gea, Janine, Anne, dames van het archief. Dank voor al jullie hulp met 
administratieve zaken, toetsing van de studies en het inzicht wat jullie me gegeven hebben in de 
aangepaste droog bed training. Het was erg leuk om met jullie mee te lopen en te zien hoe jullie deze 
intensieve training gestalte geven. 
Janita en Gertine, vol enthousiasme zijn jullie begonnen aan een project om de continentiezorg 
in Zwolle en Meppel te stroomlijnen en te verbeteren. Ik voel me vereerd dat ik jullie hierbij mag 
helpen en hoop op een goede uitkomst van onze projectaanvraag. 
Lieve Mirte en Thijs. Ik promoveerde in Zwolle, woonde in Enschede en deed een Master in Rotterdam. 
Wat is het dan geweldig om vrienden te hebben als jullie! Ook nu jullie gezin is uitgebreid met Lukas, 
David en Linde kan ik nog steeds bij jullie terecht. Ik voel me altijd weer ongelooflijk welkom. Jullie 
weten het allang, maar nu een keer niet met een bloemetje maar op schrift: dankjulliewel!
Laila en Lisanne: mede-promovendi en (bijna)-specialisten in opleiding: wat een toeval dat ik jullie bij 
die eerste summer school in Rotterdam tegen het lijf liep, en hoe geweldig dat we al bier drinkend 
en museum bezoekend nooit zonder gespreksonderwerpen zitten. 
Lieve pap en mam. Jullie staan altijd voor me klaar. Dank voor de rust en ruimte die jullie me geven 
om me te ontwikkelen op mijn manier. Lieve Nynke en Dorine, zusjes, wat vind ik het fijn dat jullie 
vandaag naast mij staan als paranimfen. 
Lieve lieve Jan, wat hebben we het fijn samen; gek doen, lachen, serieus kletsen, onszelf kunnen 
zijn. Je laat me zo goed zien dat er meer in het leven is dan werk. Dankjewel voor je hulp bij alles, 
van excel-vraagbaak, postcode-plaatjesmaker, kok tot spiegel. Net samen een huis gekocht, wat een 
geluk!
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